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VI 
Summary 
Kidins220 (Kinase D-Interacting Substrate, 220kDa) is a transmembrane scaffold 
protein and has been implicated in several malignancies. However, its role in 
pancreatic cancer remains unknown. The present study aims to investigate the 
role of Kidins220 in pancreatic cancer. A QPCR analysis showed that Kidins220 
mRNA expression was reduced in pancreatic tumour tissues compared with 
adjacent normal pancreatic tissues. Reduced expression was also observed in the 
advanced tumours compared with tumours of an early stage. Furthermore, 
immunohistochemistry (IHC) staining presented reduced protein expression of 
Kidins220 in pancreatic tumour tissues compared with adjacent normal tissues 
and normal pancreatic tissues. Its reduced expression was also seen in invasive 
cancer originating in intraductal papillary mucinous neoplasm (IPMN) compared 
with normal pancreatic tissue. Moreover, primary tumours with distance 
metastasis exhibited a decreased level of Kidins220 protein expression compared 
to those without metastasis. Knockdown of Kidins220 promoted proliferation, 
migration and invasion of pancreatic cancer cells. Panc-1 cells with Kidins220 
knockdown also exhibited an enhanced metastatic capability in vivo in peritoneal 
metastatic mouse model. An enhanced epithelial–mesenchymal transition (EMT) 
was observed in the pancreatic cancer cell lines with the knockdown of Kidins220 
following an elevated expression and activation of EGFR and consequent 
activation of its downstream signalling pathways including extracellular signal-
regulated kinase (ERK) and Protein kinase B (AKT) pathways. Taken together, a 
reduced expression of Kidins220 is observed in pancreatic cancer which is 
associated with disease progression, distant metastases and poor prognosis. The 
loss of Kidins220 in pancreatic cancer may contribute to the disease progression 
through an upregulation of EGFR signalling. It suggests that Kidins220 is a putative 
negative regulator for development and progression of pancreatic cancer. Further 
study will shed light on the interaction between Kidins220 and EGFR, and potential 
of this molecule in targeted therapy, for example EGFR or other HER family 
members for pancreatic cancer. 
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Chapter 1 
General Introduction 
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1.1 Pancreatic cancer 
Pancreatic cancer is the fifth leading cause of cancer death in the UK with around 
8,800 pancreatic cancer patients died from this disease in 2014 (Cancer Research 
UK). The five-year survival rate for all stages of pancreatic ductal adenocarcinoma 
(PDAC), the most common pancreatic malignancy, is just 8%. This falls to 3% in 
advanced pancreatic cancer patients (American Cancer Society) (Chiaravalli et al., 
2017). Early diagnosis for pancreatic cancer is challenging, as patients often 
present no obvious symptoms until the cancer is advanced. Accordingly, most 
patients have inoperable tumours, metastases and consequently a high mortality 
rate. The majority of patients die within one year after diagnosis. The predicted 
increased incidence of pancreatic cancer in the United States, coupled with a low 
survival rate, projects pancreatic cancer as the second leading cause of cancer 
deaths by 2030 (Rahib et al., 2014). 
To date, the combination of cytotoxic therapy including FOLFIRINOX or 
gemcitabine plus nab-paclitaxel (Nanoparticle albumin-bound paclitaxel) has been 
used as the standard of care for those advanced pancreatic cancer patients with 
good performance status (Borazanci and Von Hoff, 2014). However, the remaining 
challenge is to find more efficient methods for early diagnosis and novel 
treatments (Pereira, 2012).  
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1.1.1 The biology of the pancreas 
1.1.1.1 Pancreatic anatomy 
The pancreas is an important organ of the digestive system. It is a retroperitoneal 
organ located in the upper abdomen directly behind the stomach. In most adults, 
it is about 15cm long and 5cm wide. In general, the pancreas is divided into four 
regions; head, neck, body, and tail. The head is surrounded by the duodenum. The 
neck is about 2.5 cm wide and lies between the head and the body and is anterior 
to the superior mesenteric artery and vein. The body is the largest part of the 
pancreas that is located behind the stomach. The tail abuts the spleen.  
The pancreas has two secretory functions including endocrine hormones 
(endocrine) and digestion (exocrine). The exocrine anatomy consists of secretory 
acinar cells in lobules, linked by tubules and larger ducts coalescing into a main 
duct. Dispersed throughout the pancreatic tissue are the islets of Langerhans, 
which perform the endocrine function of the gland and comprise 1-2% of the 
pancreas.  
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Figure1.1: The anatomy of pancreas. Source Pancreatic Duct Anatomy. Available 
at http://www.flspinalcord.us/pancreatic-duct-anatomy/#s. 
 
1.1.1.2 Pancreatic Functions 
The islets of Langerhans endocrine function is to make and secrete insulin, 
glucagon, somatostatin and pancreatic polypeptide into the bloodstream, with the 
function of regulating blood glucose, energy metabolism and storage. The 
exocrine function produces enzymes that help to digest food. Pancreatic amylase 
breaks down carbohydrates or starches into glucose. Proteases break down 
protein into amino acid, and lipase breaks down fats. These exocrine digestive 
enzymes are confined in the secretory structure while in the pancreas, and remain 
as inactive precursors, such as trypsinogen until reaching the gastrointestinal tract. 
To reach the gastrointestinal tract, the digestive enzymes travel through the 
pancreatic ducts and eventually reach the duodenum at the major papilla, also 
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known as the Ampulla of Vater (Figure 1.1). Bile from the gallbladder also enters 
the duodenum at the major papilla. Bile emulsifies fat droplets to aid digestion 
action of lipase. Proteases such as trypsinogen are activated by enterokinase 
produced in the intestinal mucosa, with subsequent activated trypsin performing 
autocatalytic function in a cascade of activation. When the pancreas is healthy, it 
contributes to a healthy digestive system, however, when pancreatic function is 
impaired, digestion, metabolism, and blood sugar control can become unbalanced. 
The consequent symptoms may include steatorrhea, weight loss, malnutrition, 
poor blood sugar control, and diabetes. Alcohol consumption, high-fat diet, 
obesity, and smoking can contribute to pancreatic dysfunction.  
 
1.1.2 Incidence and genetics of pancreatic cancer  
1.1.2.1 Incidence and mortality 
According to incidence estimated in the GLOBOCAN 2012, pancreatic cancer is the 
eleventh most common malignancy worldwide, with 338,000 new cases in 2012 
(available from: http://globocan.iarc.fr.). Globally, its causes more than 331,000 
deaths per year, making it the seventh leading cause of cancer-related death 
(Ferlay et al., 2015) (Ilic and Ilic, 2016). The incidence and mortality for both 
genders has increased in the past few years, however, it is more common in men 
(Ilic and Ilic, 2016). In 2012, the worldwide incidence of pancreatic cancer was 4.9 
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per 100,000 in men and 3.6 per 100,000 in women (available from: 
http://globocan.iarc.fr.). Men also have a higher age standardised mortality rate 
for pancreatic cancer. 
Gender differences are also apparent with geographic variation with the 
highest incidence of pancreatic cancer in Armenia and the Czech Republic in men, 
and Hungary and Denmark in women. In contrast, the lowest incidence of 
pancreatic cancer was Pakistan and Guinea in men, and Guinea and Tanzania in 
women (Figure 1.2). 
In terms of mortality, Latvia and Hungary have the highest age standardised 
mortality rates for pancreatic cancer in men, whereas the highest mortality for 
women was in Hungary and Malta. The lowest rate was recorded in Bahrain and 
Belize for men, and Georgia and Belize for women (Figure 1.3). 
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Figure 1.2: Pancreatic cancer incidence in men (A) and women (B), GLOBOCAN 
2012 estimates. 1Country with the lowest incidence rates; 2Country with the 
highest incidence rates. GLOBOCAN 2012 estimates. Source: Epidemiology of 
pancreatic cancer (Ilic and Ilic, 2016). 
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Figure 1.3: Pancreatic cancer mortality in men (A) and women (B), GLOBOCAN 
2012 estimates. 1Country with the lowest mortality rates; 2Country with the 
highest mortality rates. GLOBOCAN 2012 estimates. Source: Epidemiology of 
pancreatic cancer (Ilic and Ilic, 2016). 
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1.1.2.2 Geographic virafication 
In addition to gender, the incidence of pancreatic cancer is varied in different 
countries and populations. More than half of new cases (55.5%) were registered 
in more developed countries and less than half (41.0%) of all new cases of 
pancreatic cancer were recorded in Asia in 2012. Moreover, the highest rates were 
seen in Northern America and Western Europe, around 7.4 per 100,000 people 
and 7.3 per 100,000 people, respectively, and the lowest incidence rate was seen 
in Middle Africa and South-Central Asia, being 1.0 per 100,000 people (Figure 1.4). 
 
Figure1.4: The incidence and mortality of pancreatic cancer in both sexes. 
GLOBOCAN 2012 estimates. Source: Epidemiology of pancreatic cancer (Ilic and 
Ilic, 2016). 
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1.1.2.3 The genetics of pancreatic cancer 
Approximately 5-10% of pancreatic cancers are inherited (McWilliams et al., 2005). 
People with a family history of pancreatic cancer in more than one first degree 
relative will have nearly double the risk of developing pancreatic cancer compared 
to those without a family history (Schenk et al., 2001). 
Several inherited syndromes contribute to an increased risk of pancreatic 
cancer, such as Peutz-Jeghers syndrome and Lynch syndrome. Similarly, the risk is 
also increased in patients with hereditary pancreatic disorders, e.g. hereditary 
pancreatitis (Lowenfels et al., 2001). 
Peutz-Jeghers syndrome is an autosomal dominant disorder, and the clinical 
syndrome includes hamartomatous polyps in the gastrointestinal tract and 
pigmented macules of the lips, buccal mucosa, and digits. It has been reported 
that patients with this syndrome would have an 11-32% lifetime risk for 
developing pancreatic cancer (Giardiello et al., 2000, Korsse et al., 2013). The 
mutation of the STK11 gene exists in more than 80% of Peutz-Jeghers cases. 
Considering this higher risk for Peutz-Jeghers patients, screening tests for the 
detection of early pancreatic neoplasia has been proposed (Canto et al., 2006, Sato 
et al., 2001, Wolfgang et al., 2013).  
 Lynch Syndrome, also known as hereditary non-polyposis colorectal cancer 
(HNPCC), is an autosomal dominant disease caused by germline mutations in 
genes responsible for DNA mismatch repair. Patients with Lynch Syndrome have 
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shown an increased risk of pancreatic cancer (Rustgi, 2007). An 8.6-fold increased 
risk of pancreatic cancer was seen in a study of 147 families with this syndrome 
compared with the general population (Kastrinos et al., 2009). In these families, 
patients with pancreatic cancer always demonstrated microsatellite instability 
(MSI+) and a distinct poorly differentiated medullary histopathology, together with 
MSI+ colorectal cancers (Alexander et al., 2001, Wilentz et al., 2000). 
 Hereditary pancreatitis is a rare autosomal dominant genetic disorder caused 
by mutations in the cationic trypsinogen gene (PRSS1). The risk of having 
pancreatic cancer is almost 58-fold higher compared with the risk in the general 
population. The lifetime risk (by age 70) of pancreatic cancer is 30–40% in patients 
with hereditary pancreatitis (Lowenfels et al., 1997, Lowenfels et al., 2001). This 
risk can be even higher in patients with smoking history (Lowenfels et al., 2001). 
 
1.1.3 Other risk factors  
Increasing age is an important factor associated with the incidence of pancreatic 
cancer in both genders (Bosetti et al., 2012). Most patients diagnosed with 
pancreatic cancer are aged between 60-80 years. It is rare before the age of 40, 
and more than half of patients diagnosed with pancreatic adenocarcinoma are 
over 70 years old (Ilic and Ilic, 2016). 
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The causal relationship between pancreatic cancer and tobacco smoking has 
been confirmed by The International Agency for Research on Cancer (Ezzati et al., 
2005).Tobacco smoking doubles the risk of pancreatic cancer, and the risk is 
accumulated with the years of smoking and the number of cigarettes smoked per 
day. Parkin et al. estimated that around 26.2% of pancreatic cancers in men and 
31.0% in women were associated with tobacco smoking in the United Kingdom in 
2011 (Parkin et al., 2011). Lodice et al., (2008) performed a meta-analysis based 
on 82 studies that included the epidemiologic information about smoking and 
pancreatic cancer. The result showed that people who smoke cigarettes would 
have a 75% increased risk for pancreatic cancer in comparison with non-smokers, 
with the risk persisting for at least 10 years after smoking cessation (Iodice et al., 
2008). The results from the European Prospective Investigation into Cancer and 
Nutrition (EPIC) also showed that the increased risk of pancreatic cancer can be 
detected in both active cigarette smokers and people exposed to environmental 
tobacco smoke (ETS), and that risk is decreased in people who quit smoking for 5 
or more years (Vrieling et al., 2010)  
The positive correlation between obesity and the risk of pancreatic cancer has 
been highlighted as a landmark in 2003 (Calle et al., 2003). The American Cancer 
Society also report that increased mortality from pancreatic cancer is associated 
with obesity. Those with a BMI ≥ 30 have a higher risk for pancreatic cancer 
compared with people with normal body mass index (Calle et al., 2003). Recent 
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meta-analysis presented the association between general and abdominal obesity 
and the elevated risk of pancreatic cancer (Berrington de Gonzalez et al., 2003). In 
the UK, it was estimated that around 12.8% of pancreatic cancers in men and 11.5% 
in women are related to obesity (Parkin et al., 2011). 
Both type I and type II diabetes have been associated with increased risk of 
pancreatic cancer (Maisonneuve and Lowenfels, 2015). The United States National 
Cancer Institute estimates that patients with diabetes have around a 1-1.8 fold 
increased risk of pancreatic cancer, and this trend is more obvious in Hispanic men 
and Asians compared with Caucasian and black populations (Li et al., 2011). In Italy, 
it was estimated that 9.7% of pancreatic cancers might be caused by diabetes 
(Rosato et al., 2015). Moreover, the risk of pancreatic cancer attributed to 
diabetes can be reduced by the uptake of anti-hyperglycaemics or insulin (Li et al., 
2011, Bosetti et al., 2014). 
 
1.1.4 The diagnosis of pancreatic cancer  
Since pancreatic cancer is mainly asymptomatic at an early stage and symptoms 
that do occur are often nonspecific, diagnosis is usually at an advanced stage. 
(Boulaiz et al., 2017). Yachida et al. report that around 21 years elapse from the 
onset of the tumour until metastasis (Yachida et al., 2010). Thus, there is a 
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potentially long latent phase in which early diagnosis could be made, and early 
diagnosis may improve the survival rate for pancreatic cancer patients.  
The most common symptoms of pancreatic cancer include abdominal pain, 
jaundice, and weight loss. Pain is a symptom in about 70% of pancreatic cancer 
cases. It may be caused by tumour invasion of the celiac or mesenteric plexus. Pain 
in the upper back (not the lower lumbar region) can occur if the cancer spreads to 
the nerves around the pancreas. Jaundice occurs in about 50% of pancreatic 
cancer cases. It may occur when pancreatic cancer is of an early stage if the tumour 
is within the head of the pancreas adjacent to the common bile duct and can press 
on the duct leading to obstructive jaundice while the tumour is still fairly small. 
However, cancers located in the body or tail of the pancreas have little impact on 
the duct until they are larger or have spread through the pancreas, and thus are 
more likely to have metastasised by the time jaundice is apparent. Jaundice can 
also occur when pancreatic cancer spreads to the liver.  
Diabetes can develop if a tumour interferes with the endocrine function of the 
pancreas. People with diabetes often feel thirsty, pass more urine than normal, 
lose weight and feel weak and lacking in energy. Diabetes is particularly associated 
with pancreatic cancer in older people.  
Pancreatic premalignant lesions have been identified, such as pancreatic 
intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm 
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(IPMN), which may be of use in screening populations with high risk of pancreatic 
cancer (Poruk et al., 2013, Brosens et al., 2015).  
Populations with the relevant hereditary and non-hereditary diseases can be 
chosen for conducting screening. Age >55 years, smoking, obesity, diabetes, 
dietary factors, and chronic pancreatitis are the common non-hereditary risk 
factors. Familial pancreatic cancer (FPC), Peutz-Jeghers syndrome, and familial 
adenomatous polyposis (FAP) are included in hereditary factors (Urayama, 2015, 
Del Chiaro et al., 2014, Midha et al., 2016). The International Cancer of the 
Pancreas Screening (CAPS) consortium agreed that those with familial and 
hereditary conditions at high risk of pancreatic cancer would be suitable for 
endoscopic ultrasonography (EUS) or magnetic resonance imaging (MRI) based 
screening (Canto et al., 2012). This is in keeping with the findings of other 
screening studies from the U.S (Kimmey et al., 2002), Germany (Langer et al., 
2009), and Holland (Poley et al., 2009).  
As well as genetic mutation testing, adjunct laboratory blood tests for 
pancreatic cancer biomarkers would add to the efficacy of a screening program. 
Carbohydrate antigen 19-9 (CA 19-9), is the most widely used biomarker for 
pancreatic cancer; included in clinical practice for monitoring after a diagnosis of 
pancreatic cancer. However, due to its relatively low sensitivity and specificity 
(Goonetilleke and Siriwardena, 2007) it is not an ideal biomarker for the screening 
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and early detection of pancreatic cancer, but it is useful for determining the 
progression and monitoring the response to therapy (Poruk et al., 2013).  
Many imaging techniques play a significant role in identifying neoplasms in 
patients who are highly suspected having pancreatic cancer, which include trans-
abdominal ultrasound (US), computerized tomography (CT), magnetic resonance 
imaging (MRI), endoscopic ultrasound (EUS) and positron emission tomography 
(PET) (Poley et al., 2009, Boulaiz et al., 2017). US is a suitable screening test on the 
grounds of low price, wide availability and innocuity (Collins and Bloomston, 2009). 
EUS is however more accurate than US and in 2011, the EUS technique was 
improved by conducting a computer-aided method for distinguishing the EUS 
image of pancreatic cancer and extracting and classifying its textural features 
(Boulaiz et al., 2017). A further advantage is that EUS allows a hollow needle to be 
passed down the endoscope for biopsy. EUS-guided fine needle aspiration (EUS-
FNA) has been developed to improve the characterization of the lesions detected 
by EUS, and it is particularly useful for the diagnosis of pancreatic tumours and 
helping to test therapeutic regimens. It has a sensitivity of 54-96%, a specificity of 
96-98%, and accuracy of 83-95% for the diagnosis of pancreatic cancer (Kamata et 
al., 2016).  
CT scanning can clearly present the pancreas and is also used to guide a biopsy 
needle to sample a suspect pancreatic tumour. It is also suitable for identifying 
small tumours and helps to decide whether the tumour can be surgically removed. 
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CT scans can be used to assess tumour invasion and invasive spread to other 
organs, and to what extent blood vessels are involved. When CT scanning is 
indeterminate, or for patients with contraindication, MRI may be useful for the 
diagnosis of pancreatic cancer especially when pancreatic and bile ducts are 
blocked, narrowed, or dilated (Duell et al., 2012).  
Imaging and biopsy are used to determine the stage of the pancreatic cancer. 
This is based on the size of tumour and whether the disease has spread to the 
nearby structures, mainly blood vessels and organs. Stages I & II include localised 
tumours with or without local lymph node involvement. At stage III, the tumour 
may be invading tissues locally including other organs and important arteries or 
veins. This means they cannot be removed surgically. This stage is also called 
‘locally advanced’. Stage IV indicates that cancer cells have spread to other organs, 
most commonly the liver or the peritoneum of the abdominal cavity. Other 
common sites include lung and bone. Staging helps to guide which treatment and 
approach to take and also been related to outcomes. Survival rates are higher for 
the stage I&II diseases. Staging and TNM classification of pancreatic cancer is listed 
in Table 1.1 (Edge and Compton, 2010). 
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Table 1.1: TNM staging of pancreatic cancer. Source: AJCC Cancer Staging Manual, 
Eight Edition (Amin et al., 2017).  
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1.1.5 The treatment of pancreatic cancer 
1.1.5.1 Surgery 
At diagnosis, surgery with an intention to cure is only possible for around 10-20% 
of patients. The evaluation before surgery of pancreatic cancer includes the 
assessment of the relationship between the tumour and the adjacent major 
vessels such as the portal vein (PV), superior mesenteric vein (SMV), superior 
mesenteric artery (SMA), celiac axis (CA) and hepatic artery (HA), together with 
the presence of metastases (Ansari et al., 2016). The surgical procedure is a 
pancreaticoduodenectomy, also named Whipple's procedure (Figure 1.5), which 
was established by Allen Oldfather Whipple. The operation is conducted by 
removal of the distal half of the stomach, gallbladder, distal portion of the 
common bile duct, head of the pancreas, duodenum, proximal jejunum and lymph 
nodes. Pancreaticojejunostomy, choledochojejunostomy, and gastrojejunostomy 
are then required for reconstruction of the digestive tract. A portion of the 
pancreas remains, as a total pancreatectomy often leads to brittle diabetes. An 
important modification of the Whipple's procedure is the pylorus preserving 
pancreaticoduodenectomy (PPPD) which preserves the whole stomach and is 
suitable for localised pancreatic cancer in pancreatic head part. However, no 
significance was found in age, sex distribution, tumour localization, and staging   
when comparing PPPD with standard Whipple’s operation in a prospective 
randomized multicentre study (Michalski et al., 2007, Tran et al., 2004).   
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Figure 1.5: Anatomy and anastomoses after a Whipple's procedure. Source: The 
role of surgery for pancreatic cancer: a 12-year review of patient outcome (Badger 
et al., 2010). 
 
1.1.5.2 Chemotherapy  
Over the years, chemotherapy for the treatment of pancreatic cancer has only 
provided modest progress in improving patient survival. The single agent 
gemcitabine had been a standard-of-care first-line treatment for advanced 
pancreatic cancer for more than 2 decades, as it was indicated to be superior to 5-
Fluorouracil (5-FU) in patients with a Karnofsky performance status (KPS) ≥ 50. 
Gemcitabine made an improvement of 5-weeks’ survival duration and improved 
quality of life for advanced pancreatic cancer patients compared to 5-FU. Burris et 
al., (1997) conducted a randomized controlled trial of 126 patients with advanced 
pancreatic cancer using either gemcitabine (1,000mg/m2weekly for 7 weeks 
followed by 1 week off, then on days 1, 8, and 15 of a 28-day cycle), or 5-FU 
600mg/m2 weekly. The result showed that patients who took gemcitabine 
presented not only a clinical benefit, but also a better median overall survival and 
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overall one-year survival rate (Burris et al., 1997). Thus, gemcitabine was approved 
by the Food and Drug Administration (FDA) as the first-line treatment for 
advanced pancreatic cancer. 
Several studies have been conducted by adding other drugs to gemcitabine, 
but the results are unsatisfactory. The combination of gemcitabine, cisplatin, 
epirubicin and 5-FU (PEFG regimen) was considered promising due to an extra 
progression-free survival (PFS) of 4 months in 60% of the combination group 
compared with a control group. However, this result is difficult to be generalised 
because of the small sample of patients (Reni et al., 2005).  
Overexpression of epidermal growth factor receptor (EGFR), a 
transmembrane tyrosine kinase receptor, is present in up to 90% of pancreatic 
cancer samples (Fjallskog et al., 2003, Tobita et al., 2003), and indicates that small 
molecule inhibitors targeting the EGFR tyrosine kinase domain, could prove to be 
promising therapeutic agents. In a phase III trial involving 569 patients with locally 
advanced or metastatic pancreatic adenocarcinoma, the combination therapy of 
gemcitabine with erlotinib (an inhibitor of EGFR tyrosine kinase) presented a 
statistically significant improvement in survival compared to gemcitabine 
treatment alone (Moore et al., 2007). It has been approved by the FDA for the 
treatment of advanced pancreatic adenocarcinoma. 
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Currently, two phase III studies of combination therapies have shown a 
significant benefit for overall survival of patients and the proposed regimens were 
approved by FDA as standard treatment regimens for patients with advanced 
pancreatic cancer. The FOLFIRINOX (the 5-FU, leucovorin, irinotecan, combination) 
chemotherapy regimen is able to improve the survival of patients with advanced 
pancreatic cancer compared with gemcitabine alone (Conroy et al., 2011). 
Conroy et al., (2011) performed a randomized phase II/III trial including 342 
patients with previously untreated metastatic pancreatic cancer using FOLFIRINOX 
or gemcitabine. The result showed that patients treated with FOLFIRINOX had a 
significantly improved median overall survival of 11.1 months compared with 6.8 
months taking gemcitabine (Conroy et al., 2011). In 2015, Ferrone et al. found that 
patients with borderline resectable pancreatic cancer presented a significant 
decrease in tumour size, lymph node positivity, operative morbidity, and peri-
neural invasion by treated with neoadjuvant FOLFIRINOX (Ferrone et al., 2015). 
Currently, FOLFIRINOX has been considered as one of the first-line regimens for 
patients with metastatic pancreatic cancer who have a good performance status. 
The second trial examined a combination of gemcitabine and nab-paclitaxel. When 
comparing gemcitabine and gemcitabine-nab-paclitaxel in the Metastatic 
Pancreatic Adenocarcinoma Clinical Trial (MPACT), the median overall survival 
(mOS) was 8.5 months in the combination group versus 6.7 months in the control 
arm (HR, 0.72; 95% CI, 0.62–0.83; P < 0.001). However, combination therapy does 
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appear to have significant side effects, such as neutropaenia (38%), fatigue (54%), 
peripheral neuropathy and alopecia (50%)(Vishnu and Roy, 2011). 
 
1.2 Molecular and cellular mechanisms in pancreatic cancer  
Molecular alterations lead to the development and progression of pancreatic 
cancer. The occurrence and development of pancreatic cancer is affected by 
numerous factors and events including genetic and epigenetic alterations, as well 
as deregulated signalling pathways (Khan et al., 2017). A better understanding of 
the molecular mechanisms involved in pancreatic tumorigenesis may help to 
identify novel biomarkers for the early diagnosis of pancreatic cancer, and 
therapeutic targets. In recent years, some critical molecules have been implicated 
in the progression of pancreatic cancer (Bhardwaj et al., 2016, Zubair et al., 2016, 
Whatcott et al., 2015). The formation and metastasis of pancreatic cancer 
undergoes a multistep process from pancreatic intraepithelial neoplasia (PanIN) 
lesions to invasive carcinomas (Figure 1.6) (Hidalgo, 2010, Makohon-Moore and 
Iacobuzio-Donahue, 2016). According to the cellular and nuclear atypia, PanIN is 
further classified into low grade lesions (PanIN-1A/B) to high grade lesions (PanIN-
3) (Hruban et al., 2000). During this process from PanIN1 to PanIN3, several 
genetic changes such as gain or loss of tumour promoting/suppressor genes and 
microRNAs (miRNAs) are accumulated and finally lead to an invasive phenotype 
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(Weissmueller et al., 2014, Makohon-Moore and Iacobuzio-Donahue, 2016, 
Yonemori et al., 2017, Khan et al., 2013).  
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Figure 1.6: Histopathological and molecular changes in the progression of 
pancreatic adenocarcinoma. The development of pancreatic cancer includes 
normal epithelium, low-grade pancreatic intraepithelial neoplasia (PanINs), high-
grade PanIN, and invasive carcinoma. During this process, numerous genetic 
alterations such as KRAS, CDKN2, TP53, SMAD4/DPC4 and BRCA2 are involved. 
Resource: Molecular drivers of pancreatic cancer pathogenesis: Looking inward to 
move forward by Khan MA Int J Mol Sci (Khan et al., 2017). 
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1.2.1 K-ras mutation  
The mutation of Kirsten rat sarcoma oncogene homolog (K-ras) has been found in 
30% of early panIN1 lesions, however, K-ras mutation is present in 95% of 
advanced pancreatic cancers (Pylayeva-Gupta et al., 2011, Eser et al., 2014). This 
evidence is also supported by mouse models whereby the activation of a mutant 
K-ras allele resulted in the mice developing PanIN lesions, and when in 
combination with the deletion of a tumour suppressor allele resulted in 
progression to invasive PDAC (Aguirre et al., 2003).  
Point mutation of K-ras mainly occurs in codon 12 with the substitution of 
glycine with asparate, valine or arginine, and its mutation results in GTP-bound 
protein accumulation leading to an active conformation (Jonckheere et al., 2017). 
The mutation of K-ras leads to a constitutive activation of its downstream 
oncogenic signalling, which is required for initiation, progression and maintenance 
of pancreatic cancer (Pylayeva-Gupta et al., 2011, di Magliano and Logsdon, 2013). 
The most direct regulators attribute to the activation of Mitogen-Activated Protein 
Kinase (MAPK), Phosphoinositide 3-Kinase (PI3K) and Ral Guanidine exchange 
factor (RalGEF) signalling pathways (Jonckheere et al., 2017). The activation of 
MAPK pathway is associated with a poor prognosis in pancreatic cancer (Handra-
Luca et al., 2012). K-ras induced Extracellular signal-Regulated Kinase (ERK) 
signalling pathway promotes migration and invasion of pancreatic cancer cells 
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leading to a poorer survival (Neuzillet et al., 2013, Endo et al., 2009, Zhao et al., 
2010).  
 
1.2.2 P16 
P16, also known as Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a critical 
regulator involved in cell cycle, targeting CDK4 and CDK6 and abolishing their 
interaction with cyclinD1 (Asghar et al., 2015). Deregulated progression of cell 
cycle caused by loss of function of p16 includes mis-sense mutation, promoter 
methylation, and small deletion or loss of heterozygosity (Scaini et al., 2009). P16 
alterations are also related to the aggressiveness of pancreatic cancer. Ohtsubo et 
al., (2003) found that pancreatic cancer patients with larger tumours present a 
decreased expression level of p16 (Ohtsubo et al., 2003). Furthermore, pancreatic 
cancer patients who have a p16 mutation or hypermethylation show larger 
tumours and shorter survival period compared with pancreatic carcinoma with an 
unaffected p16 gene (Ohtsubo et al., 2003). There is also a significant correlation 
in histological grade of pancreatic malignancy with loss of p16, and metastasis is 
more likely in cases without p16 expression (Hu et al., 1997).  
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1.2.3 P53 
The p53 tumour suppressor gene, located on chromosomal arm 17p, is inactivated 
in 50% to 75% of pancreatic carcinomas. It has been reported that the inactivation 
is due to intra-genic mutation, accompanied with a loss of the second allele of p53, 
which impairs the cell cycle and cell apoptosis (Redston et al., 1994, Morton et al., 
2010). The altered p53 gene coupling with other genetic abnormalities, has been 
shown in some studies. Xiang et al., (2016) found that p53 together with cavin-1, 
is correlated with poorer survival for patients with resectable pancreatic ductal 
adenocarcinoma. Moreover, the mutation of p53 increased the invasion and 
metastasis of pancreatic cancer cells in vitro and in vivo through up regulation of 
cavin-1 and enhanced cavin-1/caveolin-1 signalling (Xiang et al., 2016). The altered 
p53 gene is also related to progression of pancreatic cancer when present in PanIN 
lesions. Weissmueller et al., (2014) showed that the invasive phenotype of 
pancreatic cancer cells requires the sustained expression of mutant p53 
(Weissmueller et al., 2014). 
 
1.2.4 SMAD4/DPC4 
SMAD4, locating on chromosomal arm 18q, is an important transcriptional 
regulator involved in transforming growth factor-beta (TGFβ) signalling by 
transducing extracellular signals of TGFβ to the nucleus and regulating cell 
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functions (Hruban et al., 2001). The major role of SMAD4 is to inhibit cell 
proliferation by inducing an arrest of cell cycle at the G1 phase. It has been 
indicated that inactivation of SMAD4 due to allelic deletion or intra-genic mutation 
mainly occurs in the late stages of PDAC development (Chen et al., 2014). 
Furthermore, reduced expression of SMAD4 is considered an independent 
prognostic factor regarding tumour progression, Epithelial-Mesenchymal 
Transition (EMT) and therapy failure (Lopez-Gomez et al., 2015). 
 
1.2.5 BRCA1 and BRCA2 
BRCA1 and BRCA2 have a wide range of biological functions, such as transcription 
regulation and DNA repair. It has been reported that individuals who have BRCA1 
and BRCA2 mutations gain 2.2 and 3.5 fold higher risk respectively for the 
development of pancreatic cancer (Greer and Whitcomb, 2007, Iqbal et al., 2012, 
Thompson et al., 2002). Goggins and co-workers found that biallelic inactivation 
of the BRCA2 gene occurs only at a late stage in the development of pancreatic 
cancer. This finding was supported by another observation that the loss of wild-
type allele of BRCA2 only existed in high-grade PanIN (PanIN-3) lesions rather than 
in the low-grade PanIN (PanIN-1) lesions (Goggins et al., 1996). A binding partner 
of BRCA2 named PALB2 was also found be abnormal in familial pancreatic cancer 
(Jones et al., 2009). PALB2 mutation, together with germline mutations of BRCA2, 
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is associated with eventual onset of pancreatic cancer due to increased 
accumulation of damaged DNA by changing the DNA repair pathway (Rustgi, 2014).  
 
1.2.6 Epidermal growth factor receptor (EGFR) 
The epithelial growth factor receptor, also known as Human Epidermal Growth 
Factor 1 (HER-1), or v-erb-b2 erythroblastic leukaemia viral oncogene homolog 1 
(ERBB-1), is a tyrosine kinase receptor. Amplification and mutation of this gene has 
been identified in several cancer types, such as non-small-cell lung cancer (NSCLC), 
metastatic colorectal cancer, glioblastoma, head and neck cancer, and breast 
cancer (Normanno et al., 2006). The up regulation of EGFR promotes proliferation, 
differentiation and metastasis of pancreatic cancer through downstream pro-
oncogenic signalling pathways, including the RAS-RAF-MEK-ERK MAPK and AKT-
PI3K-mTOR pathways (Oliveira-Cunha et al., 2011).  
 
1.2.6.1 EGFR Structure and expression 
EGFR is located at chromosome 7 short arm q22, spanning 110 kb of DNA 
containing 28 exons (Davies et al., 1980, Kondo and Shimizu, 1983). Generally 
normal cells express 4 × 104 to 1 × 105 EGF receptors, however, tumour cells can 
express more than 2 × 106 receptors per cell (Herbst and Shin, 2002). The EGFR 
protein is synthesized as a 1210 residue precursor that is cleaved at the N-terminal 
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to result in the mature 1186 residue transmembrane EGFR (Ullrich et al., 1984). 
From N-terminal to C-terminal, the EGFR consists of an extracellular domain, a 
hydrophobic transmembrane region, and a tyrosine kinase-containing cytoplasmic 
region (Roskoski, 2014). EGFR belongs to the ERBB family, which also include HER-
2/ERBB2, HER-3/ERBB3, and HER4/ERBB4. All the ERBB family members share the 
same structures and can form 28 different combinations coupling with each other 
through homo- and heterodimers (Lemmon and Schlessinger, 2010).  
 
1.2.6.2 EGFR signalling 
EGFR activation is generated through the binding of ligands to the extracellular 
domains of monomeric EGFR. Various ligands are involved in the activation of 
EGFR and the common ones include Epidermal Growth Factor (EGF) and 
Transforming Growth Factor alpha (TGF-α). Both EGF and TGF-α are expressed as 
integral membrane proteins and are able to release soluble mature ligand through 
a cleavage by metalloproteinases.  
The ligand binding to receptor results in dynamic conformational changes, 
homodimer and heterodimer formation, as well as tyrosine kinase activation 
(Yarden and Sliwkowski, 2001, Oliveira-Cunha et al., 2011). In the C-terminal tail 
and the kinase domain, EGFR dimerisation leads to an auto-phosphorylation of the 
tyrosine residues. These residues act as binding sites for subsequent recruitment 
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and docking of various signalling modules containing the Src homology 2 (SH2) 
domain, involving kinases, adaptor proteins, ubiquitin ligases, and transcriptional 
factors (Yarden and Pines, 2012). Activation of these signalling molecules by 
binding to EGFR results in activation of downstream signalling pathways, including 
the RAS/RAF/ MEK/ ERK, PI3K/ AKT/ mammalian target of rapamycin, and Janus 
kinase (JAK)/ signal transducer and activator of transcription (STAT) pathways. 
Finally, these signalling pathways induce a variety of cell responses such as the 
activation of cell proliferation, promotion of angiogenesis, cell survival and 
apoptosis inhibition (Figure 1.7) (Yamaoka et al., 2017). 
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Figure 1.7: Signal transduction pathways controlled by the activation of 
epidermal growth factor receptor. EGFR is activated by its growth factor ligands, 
and the dimerisation of EGFR activates its intrinsic intracellular protein-tyrosine 
kinase activity. The occurrence of EGFR auto-phosphorylation through several 
tyrosine residues triggers the activation of downstream signalling cascades 
including the RAS/extracellular signal regulated kinase (ERK) pathway, the 
phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway and the Janus 
kinase/Signal transducer and activator of transcription (JAK/ STAT) pathway. The 
activation of these signalling pathways are involved in the regulation of cell growth, 
cell cycle, and cell survival. Source: The Role of Cyclooxygenase-2, Epidermal 
Growth Factor Receptor and Aromatase in Malignant Mesothelioma. 
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1.2.6.3 Mutations and amplification of EGFR in cancer 
EGFR mutations have been detected in the extracellular region, the kinase domain, 
and the C-terminal tail (Pines et al., 2010). These mutations of different sites have 
been shown in different types of cancer. Ectodomain mutation is present in most 
glioblastomas, whereas NSCLCs exhibit a preference of harbouring kinase domain 
mutation (Pines et al., 2010, Lee et al., 2006). Rare EGFR gene mutation has also 
been identified in colorectal cancers (Moroni et al., 2005). The EGFR variant EGFR 
VIII generated from the loss of amino acids 6-273 (encoded by exons 2-7) occurs 
in approximately 20% of glioblastoma (Lee et al., 2006, Gan et al., 2013). 
Additionally, mutations in the EGFR kinase domain clustered around the ATP-
binding pocket of the enzyme have been observed in NSCLC (Sharma et al., 2007).  
EGFR gene amplification has been found in various human tumours, including 
lung, head and neck, oesophageal, and colorectal cancers (Yarden and Pines, 2012). 
In NSCLC, 40%-80% patients harboured EGFR overexpression due to changes in 
gene copy number and epigenetic transcriptional activation (Merrick et al., 2006). 
Amplification of the EGFR gene has also been detected in colorectal cancer (CRC). 
Several studies using fluorescence in situ hybridization have demonstrated that 
approximately 40% of CRC tumours harbour increased EGFR gene copy number 
(Barber et al., 2004, Jiang et al., 2013). Increased expression of EGFR and its ligand 
have been detected in up to 90% of human pancreatic cancers (Lemoine et al., 
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1992), but the correlation of EGFR expression and pancreatic tumour grade, size, 
or lymph node status is unknown (Bloomston et al., 2006).  
 
1.2.6.4 Targeting EGFR therapy 
Considering the role of the EGFR signalling pathways in cancer development, 
several therapeutic agents such as monoclonal antibodies (mAbs) and small-
molecule tyrosine kinase inhibitors (TKIs), have been used to target EGFR for the 
treatment of human cancers (Table 1.2). mAbs compete with endogenous ligands 
by binding to the extracellular domain of EGFR and block the subsequent EGFR 
tyrosine kinase activation (Burgess et al., 2003). Currently, Cetuximab and 
Panitumumab are the two most progressive mAbs applied in clinical treatment 
which target the extracellular domain of the EGFR. Cetuximab (Erbitux), an IgG1 
human mouse chimeric monoclonal antibody, has been used for the treatment of 
metastatic CRC and Squamous Cell Carcinoma of the Head and Neck (SCCHN) 
(Yamaoka et al., 2017). Panitumumab (Vectibix) is a human mAb specific to EGFR, 
approved by the FDA for the treatment of metastatic CRC (Yamaoka et al., 2017).  
TKIs are ATP mimetics that bind to the receptor’s kinase pocket, which 
excludes ATP and prevents signal transduction (Ciardiello and Tortora, 2008). To 
date, both Gefitinib (Iressa) and erlotinib have been approved by the FDA for the 
treatment of advanced or metastatic NSCLC. A combination of erlotinib with 
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gemcitabine has been approved for the treatment of locally advanced or 
metastatic pancreatic cancer (Modjtahedi and Essapen, 2009). 
Table 1.2: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
and anti-EGFR monoclonal antibodies approved for cancer treatment.  
 
 
Source: Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and 
Its Resistance Mechanisms by Yamaoka T. Int J Mol Sci (Yamaoka et al., 2017). 
 
1.2.7 Epithelial-mesenchymal transition (EMT)  
EMTs is a cell biological program initially identified as playing a vital role in 
embryonic development (Kalluri, 2009). EMT is indispensable when a non-motile 
epithelial cell acquires invasive capacities during the process of losing polarized 
cellular organization, cell-cell junction breakdown, cell matrix adhesion 
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remodelling, and changes towards a mesenchymal state (Mitra et al., 2015, Martin 
and Jiang, 2009).   
The association between tumorigenesis and EMT is established through 
enhanced invasiveness and metastasis and the acquisition of therapy resistance 
(Singh and Settleman, 2010, Radisky and LaBarge, 2008). The activation of the EMT 
program triggers cancer cells to disseminate from the primary tumour, invade 
adjacent tissues, migrate through the bloodstream or lymphatic system and 
ultimately generate secondary cancer sites. (Ocana et al., 2012, Tsai et al., 2012) 
(Figure 1.8). However, some metastatic tumours from prostatic cancer, breast 
carcinoma, colorectal cancer, ovarian cancer may represent some epithelial 
phenotype and certain histological features of the tissues from where they are 
derived. Thus, a mesenchymal-epithelial transition (MET) in the metastatic sites 
was postulated to be happening when the disseminated tumour cells undergo this 
reverse transition at the site of metastases and is involved in the formation of the 
secondary tumour (Yao et al., 2011). 
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Figure1.8: The progression of carcinoma undergoes EMT and MET. The formation 
of adenoma can be caused by the local proliferation of normal epithelia lined by a 
basement membrane, and its further transformation caused by epigenetic 
changes and genetic alterations give rise to a carcinoma in situ. Further alterations 
can lead to EMT and the carcinoma cells disseminating. The cells extravasate into 
lymph or blood vessels and are transported to distant organs, where they form a 
new carcinoma through a MET at secondary sites. Source: Epithelial-mesenchymal 
transitions in tumour progression by Thiery, J.P. Nat. Rev. Cancer 2, 442-454 
(Thiery, 2002). 
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1.2.7.1 EMT and tumour progression 
The transition from an epithelial cell into a mesenchymal cell requires the 
alteration of cell morphology and cell-matrix adhesion. Also, the acquisition of 
migration abilities is pivotal in this process. The earliest occurrence of EMT might 
start from loss of cell polarity, and subsequently a dissolution of tight junctions 
(McCaffrey et al., 2012, Martin-Belmonte et al., 2007, Li et al., 2014, Huang et al., 
2012). Thus, loss of E-cadherin (epithelial marker) and acquisition of vimentin 
(mesenchymal marker) are considered an important event during the EMT process 
(Prieto-Garcia et al., 2017). The biological function of E-cadherin is to keep the 
mobility of tumour cells during dissemination and maintain cell-cell interaction 
and cytoskeleton stabilisation. Thus, the breakdown of adherens junctions caused 
by the down-regulation of E-cadherin expression, leads to loss of cell polarity and 
acquisition of a mesenchymal phenotype with migratory abilities (Wijnhoven et 
al., 2000, Ghahhari and Babashah, 2015). It has been reported that several factors, 
such as TGF-β or Fibroblast Growth Factor (FGF) are involved in this complex 
process. Also, several tyrosine kinase receptor (RTKs), WNT/β-catenin, NOTCH and 
HEDGE-HOG signalling pathways, transcription factors (TFs), miRNAs, and 
epigenetic and post-translational modifications are implicated in the activation of 
EMT (Prieto-Garcia et al., 2017).  
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1.2.7.2 EMT regulation in cancer 
Apart from the role of EMT in normal embryonic development, evidence has also 
accumulated identifying its role in tissue fibrosis and cancer metastasis (Kalluri and 
Neilson, 2003). In March 2008, during an EMT meeting at Cold Spring Harbor 
Laboratory, researchers suggested that EMT was to be classified into three general 
subtypes according to different functional consequences. Type 1 EMT can give rise 
to mesenchymal cells that have the potential to generate secondary epithelial cells 
via mesenchymal-epithelial transition (MET). This process is related to embryonic 
gastrulation and neuroepithelium generating motile neural crest cells. Type 2 EMT 
involves secondary epithelial or endothelial cells transitioning to resident tissue 
fibroblasts, which are induced in response to persistent inflammation in mature 
tissues. Type 3 EMT occurs when epithelial carcinoma cells undergo genetic and 
epigenetic changes, and transit to metastatic tumour cells. Carcinoma cells that 
undergo type 3 EMT may acquire the ability to migrate through the blood stream 
and generate secondary nodules, thus lead to the formation of distant metastatic 
lesions (Kalluri and Weinberg, 2009). In pancreatic cancer, EMT associated with 
cancer development underlying invasion, dissemination, and metastasis, has been 
widely investigated (Hugo et al., 2007). During EMT, several biomarkers have been 
used to demonstrate the transition from epithelial cells to mesenchymal cells 
(Table 1.3). The most commonly used epithelial markers are E-cadherin, integrins, 
and cytokeratin, whereas the mesenchymal markers are N-cadherin, vimentin or 
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fibronectin (Thiery et al., 2009). However, not all cells acquire mesenchymal traits 
in EMT. Cells in early EMT may only include loss of E-cadherin without gaining N-
cadherin. This observation reflects different biological results of the intermediate 
stages and might result in different molecules during migration and invasion 
compared with those that gain N-cadherin (Chu et al., 2006, Halbleib and Nelson, 
2006). According to this phenomenon, it has been suggested that not only these 
epithelial or mesenchymal markers and traits are altered during EMT, but also 
other molecules being essential for the biological processes associated with EMT 
such as invasion, survival and proliferation should be considered as altered too 
(Zhou et al., 2017). 
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Table 1.3: EMT markers.  
 
 Acquired markers Attenuated markers 
Cell –surface proteins N-cadherin E-cadherin 
Cytoskeletal markers 
Vimentin 
β-Catenin 
 
Cytokeratin 
Transcriptional factors 
Snail slug 
zeb1 twist 
 
ECM proteins 
α1 (I) collagen 
α1 (III) collagen 
α1 (IV) collagen 
Laminin1 
miRNAs 
miR 10b 
miR-21 
Mir-200 family 
Source: Biomarkers for epithelial-mesenchymal transitions (Zeisberg and Neilson, 
2009). 
Downregulation or inactivation of the E-cadherin gene (CDH1) has been 
described during tumour cell progression, and this may be caused by up regulation 
of CDH1 transcriptional repressors, known as EMT transcriptional factors (TFs). 
The EMT-inducing transcription factor (EMT-TFs) not only plays a role in regulation 
of cell progression, invasion, and migration, but is also involved in protecting cells 
from senescence and apoptosis. Also, a role for EMT-TFs in resistance to 
chemotherapy and radiotherapy has been identified (Nieto, 2011, Ansieau et al., 
2008, Mejlvang et al., 2007). As TFs, snail, slug, zeb, and twist have been identified 
in promoting EMT (De Craene and Berx, 2013). Snail, slug and zeb are reported as 
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direct repressors of E-cadherin since they bind to conserved E-box sequences in 
the promoter of E-cadherin and repress its transcription (Prieto-Garcia et al., 2017). 
Furthermore, loss of E-cadherin can also trigger certain epithelial cells switching 
to a mesenchymal state (Onder et al., 2008). The reexpression of E-cadherin and 
downregulation of zeb, snail, slug, or twist, are usually referred as important 
hallmarks of MET (Yao et al., 2011).  
It has been indicated that TGF-β, a secreted factor from stroma, is implicated 
in inducing EMT through activation of SMAD2 signalling or other non-canonical 
signalling pathways such as PI3K/AKT or MAPK/ERK pathways (Massague, 2012). 
TGF-β can also interact with other growth factors such as the epidermal growth 
factor (EGF) to affect the malignant transformation of cancer stem cells as well as 
the activation of cancer-associated stromal fibrosis (Zhou et al., 2017). 
In addition to the regulation of this transcriptional program, a number of small 
non- coding RNAs or miRNAs have been reported as playing a vital role in the EMT 
process (De Craene and Berx, 2013). Depending on the different cell contexts, 
miRNAs can either promote or repress EMT. The most intensively studied miRNAs 
include the miR-200 family which consists of miR-200a, miR-200b, miR-429 on 
human chromosome 1, miR-200c and miR-141 on human chromosome 12 (Korpal 
et al., 2008). miRNAs can target different EMT-related signalling pathways and 
contribute to cancer development. Parikh et al., (2014) identified that in ovarian 
cancer, miR-181a can induce TGF-β-mediated EMT through the suppression of 
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Smad 7 (Parikh et al., 2014). In breast cancer, promotion of EMT and metastasis 
can be caused by ectopic overexpression of miR-374a through targeting several 
negative regulators of the Wnt/beta-catenin signalling cascade both in vivo and in 
vitro (Cai et al., 2013). Taken together, miRNAs are supposed to modulate EMT 
networking by coordinating TFs or reinforcing the EMT signalling network.  
 
1.3 Kidins220/ARMS 
Scaffold proteins have evolved mechanisms for efficiently interacting with certain 
signalling pathways and maintaining cellular structure. This is achieved through 
the regulation of the cytoskeleton, cell adhesion, and migration, allowing cells to 
survive and grow in a variable environment. Dysregulation of certain scaffold 
proteins has been implicated in malignancies, including cancer development and 
metastasis. In mammals, an example of such multi-functional transmembrane 
scaffold proteins is Kinase D-interacting substrate of 220kDa/ Ankyrin repeat-rich 
membrane spanning (Kidins220/ARMS). Kidins220 is a highly convserved integral 
membrane protein, which was initially identified as a substrate for protein kinase 
D (PKD), a serine/threonine kinase responsible for regulation of several cell 
processes (Iglesias et al., 2000). Despite recent studies demonstrating the role of 
Kidins220/ARMS in neurotrophin response, it is increasing apparent that 
Kidins220 is involved in the regulation of many cellular functions. Kidins220 
dysregulation occurs in several human diseases including neurodegeneration and 
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cancer, and thus there is increasing effort to pharmacologically target this protein. 
Here, we review our current understanding of Kidins220 and discuss further 
discuss possible links of Kidins220/ARMS to malignancies.  
 
1.3.1 Kidins220/ARMS 
Initially discovered in the nervous system, Kidins220, responding to variable 
environment cues, coordinates neuronal survival, differentiation, and plasticity 
(Lipsky and Marini, 2007, Gomez-Palacio-Schjetnan and Escobar, 2013, Benoit et 
al., 2001). In the nervous system, Kidins220 is one of the downstream substrates 
for tropomyosin-related kinase (Trk) signalling (Scholz-Starke and Cesca, 2016). In 
mammal neural tissues, Kidins220 has a high binding affinity for neurotrophins and 
localizes to the tips of neurites abundant and enriched with expression of ephrin 
receptors and neurotrophins (Aravind et al., 2004). In the nervous system, 
Kidins220 acts as a platform for protein-protein interactions, where its multiple 
domains recruit downstream receptor substrates, resulting in the activation of 
signalling pathways which lead to neuronal differentiation, survival, cytoskeleton 
remodelling, synaptic plasticity and dendrite and synapse development (Neubrand 
et al., 2012). The development of the vascular system involves Kidins220 
interacting with vascular endothelial growth factor receptors (VEGFR). Knockout 
of Kidins220 resulted in the impairment of the VEGF signalling pathway, whilst an 
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in vivo study revealed that mice lacking Kidins220 developed cardiovascular 
abnormalities (Cesca et al., 2011). 
 
1.3.2 Kidins220 structure, expression, and localization  
The Kidins220 gene encodes a protein of 1715 amino acids. Kidins220 protein 
comprises 11 ankyrin-repeats within the N-terminal region, a proline-rich stretch, 
a Sterile alpha motif (SAM) domain (Kong et al.), kinase light chain (KLC)-
interacting motif (KIM), and a PSD-95, Dlg, ZO-1 (PDZ)-binding motif at its C-
terminal. It contains four transmembrane segments in the central part of the 
molecule and N- and C-terminal tails both exposed to the cytoplasm. Kidins220 is 
the target of a molecule called protein kinase D, which first gained attention due 
to its broad regulation of neuronal properties. Biochemical processes led to the 
purification and identification of multiple Kidins220 domains which act as 
regulators in a variety of cell signalling pathways. 
Originating from monocytes, immature dendritic cells in peripheral blood 
have been shown to express high levels of Kidins220. Therefore, currently the 
cytoskeleton remodelling driven via Kidins220, is best characterised in immature 
dendritic cells (Riol-Blanco et al., 2004). Upon migration onto extracellular 
matrices highly polarised immature dendritic cells change stage, from monopolar 
to symmetrical bipolar. During this process, Kidins220 is highly expressed at the 
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dendritic cells polarised membrane edges, where F-actin localises (Riol-Blanco et 
al., 2004). Further immunocytochemistry analysis has revealed that Kidins220 
expression was concentrated around proteins which are associated with the raft 
compartment (Riol-Blanco et al., 2004). Lipid rafts are microdomains of the cell 
plasma membrane and contain distinctive protein and lipid constituents, which 
are involved in the regulation of signalling transduction. Chemically induced 
disruption of lipid rafts resulted in the loss of Kidins220 from the enriched 
polarised edges, indicating a regulatory role of Kidins220 in cell morphology 
changes and motility (Riol-Blanco et al., 2004, Cabrera-Poch et al., 2004).  
Kidins220 is expressed in developing muscle and has also been observed at 
the neuromuscular junction (Luo et al., 2005). In rat embryonic muscle, Kidins220 
transcript was gradually reduced in the process of muscle development. A 
prominent protein band of ∼220 kDa was detected in muscle throughout 
development using an antibody that specifically recognized the COOH-terminal 
fragment of Kidins220. Luo et al (2005) proposed a possible model in which 
Kidins220 bridges a link between α-syntrophin and Eph4, thus contributing in the 
regulation of synapse formation and plasticity. Further evidence has shown that 
this interaction occurs through α-syntrophin induction of Kidins220 clustering at 
the neuromuscular junction. This Kidins220-mediated localization subsequently 
results in the activation of Eph4 which in turn stimulates postsynaptic signal 
cascades (Luo et al., 2005). By interacting with a variety of proteins, Kidins220 
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regulates neuronal activities. For instance, kinesin light chain 1 (KLC1) is a binding 
partner for Kidins220. Within PC-12 cells, it was demonstrated that after never 
growth factor (NGF)-stimulation, intracellular trafficking of Kidins220, from trans-
Golgi network to the plasma membrane, relied on KLC1-based transport 
mechanisms (Bracale et al., 2007). 
 
1.3.3 Interacting partners 
Kidins220 binds with a variety of interacting partners and is involved in some 
neuronal activities (Figure 1.9). Kidins220 acts as a downstream substrate of 
protein kinase D (PKD), where enhanced PKD activity stimulates phosphorylation 
of Kidins220 at serine 919 in PC-12 cells (Iglesias et al., 2000). The most significant 
role identified for Kidins220 is to act as a downstream substrate of Trk receptors. 
Kidins220 is currently the only known membrane-associated protein which 
interacts with both Trk and p75 neurotrophin receptors, often forming a ternary 
complex (Chang et al., 2004). Kong et al., (2001) identified that hippocampal 
neurons stimulated by neurotrophin, exhibited rapid phosphorylation of Kidins220, 
implicating Kidins220 as a downstream target of neurotrophin (Kong et al., 2001). 
Further work by Arévalo et al., (2006), revealed that rapid tyrosine 
phosphorylation of Kidins220 was induced in primary neurons after treatment 
with neurotrophin. Upon an activation of neurotrophin signalling, phosphorylation 
of Kidins220 at Tyr1096 leads to a recruitment of CrKl, an upstream component of 
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the C3G-Rap1-MAP kinase cascade, which in turn activates mitogen-activated 
protein kinase (MAP kinase) pathways. This sustained MAP kinase activation was 
affected in PC-12 cells by a mutation within Tyr1096 (Arevalo et al., 2006). 
Interestingly it appears that the mutation or interference of Kidins220/ARMS only 
reduces neurotrophin-elicited signalling in the ERK pathway, suggesting an 
important role played by Kidins220 in mediating neurotrophin-induced signal 
transduction via this MAP kinase pathway (Arevalo et al., 2004). Kidins220 was 
also phosphorylated in NG108-15 cells on exposure to ephrin B, suggesting it has 
actions downstream of ephrin receptors as well (Kong et al., 2001).  
Based on yeast two-hybrid screening, Kidins220 activity within muscle has 
been linked to the binding of α-syntrophin, via the PDZ domain. Kidins220 displays 
clustering in response to increased expression levels of α-syntrophin which further 
augments EphA4 signalling (Luo et al., 2005). In brain-derived neurotrophic factor 
(BDNF) induced nuclear factor-κB (NF-κB) signalling, neurotrophin presented a 
preference for targeting tropomyosin receptor kinase B (TrkB) (Sniderhan et al., 
2008). Sniderhan et al., (2008) demonstrated that silencing Kidins220 or targeting 
the Kidins220-TrkB interaction abolished NF-κB signalling elicited by BDNF. Further 
elucidation of the BDNF induced Kidins220-TrkB interaction, suggested that NF-κB 
signalling was facilitated by the activation of MAP kinase and IκB kinase (IKK) 
leading to the phosphorylation of RelA (Sniderhan et al., 2008). 
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Septin 5, which has been implicated in cytoskeleton reorganisation, has also 
been identified as an interacting partner of Kidins220 and may serve as a 
regulatory element for intracellular signalling activities (Park et al., 2010). The 
results of a yeast two-hybrid screen and co-immunoprecipitation revealed that 
these two proteins are co-localized in hippocampal neurons. In PC-12 cells, 
Kidins220 and Septin5 expressed in the tips of growing neurites was induced by 
NGF. Andreazzoli and colleagues (2012) performed a screening for brain cDNA 
products from a phage display library and demonstrated an interaction between 
the PDZ-domain of Kidins220 and Pdzrn3, a protein comprising of PDZ-domain and 
RING-finger. The co-localization of Kidins220 and Pdzrn3 has been observed in 
PC12 cells at the growing neurites induced by nerve growth factor (Andreazzoli et 
al., 2012).  
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Figure 1.9: The structure of Kidins220 and its binding interaction partners. 
Schematic structure of Kidins220/ARMS scaffold protein. An archetypal 
Kidins220/ARMs scaffold protein contains multiple protein binding domains and 
post-translational modified sites, through which Kidins220/ARMS coordinates 
signal transduction of various pathways, such as Trk and MAPK. The scaffolding 
role of Kidins220 appears to be directed based on the different binding partners 
within the protein. SAM, sterile alpha motif; MAP, microtubule-associated protein; 
KIM, kinase light chain (KLC)-interacting motif; PDZ, (PSD-95, Dlg, ZO-1)-binding 
motif); Trks, tropomyosin receptor kinase; NGFR, nerve growth factor receptor; 
VEGFR vascular endothelial growth factor receptors. 
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1.3.4 Kidins220, neurite outgrowth, survival, and death 
The ankyrin repeats in Kidins220 bind and activate the RhoGEF, Trio. Trio is a 
RhoGEF for Rac1, RhoG, and RhoA and plays an important role in the regulation of 
neurite outgrowth. In NGF-differentiated PC-12 cells, Neubrand and colleagues 
found that Kidins220 and Trio were colocalized in specific sites with F-actin and 
Rac1 (Neubrand et al., 2010). They identified that overexpression of an ankyrin 
repeat fragment of Kidins220 in PC-12 cells, inhibited NGF-dependent neurite 
outgrowth regulated by Trio, and a similar mechanism was also verified in 
hippocampal neurons (Neubrand et al., 2010). Bracale and colleagues conducted 
a yeast two-hybrid screen and identified KLC1, the subunit of kinesin1, as an 
interacting partner of Kidins220. In NGF-induced PC-12 cells, Kidins220 co-
localising with kinesin1 was impacted by the overexpression of KIM, a KLC-
interacting motif in Kidins220, ultimately interfering with neurite outgrowth 
(Bracale et al., 2007). Based on the preferential binding of NGF and TrkA 
neurotrophin receptor, Lopez-Benito et al., (2016) identified a novel signalling 
pathway, mediated by NGF which includes TrkA, Kidins220, synembryn-B and Rac1, 
implicated in neuronal secretion in PC-12 cells (Lopez-Benito et al., 2016). Rac1 is 
the downstream target of Kidins220 and synembryn-B, which themselves directly 
interact. NGF-mediated secretion is blocked by the overexpression of Kidins220 
and synembryn-B, however basal secretion appeared unaffected (Neubrand et al., 
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2010). The secretion defects caused by high levels of Kidins220 could be rescued 
with the expression of dominant-negative Rac1 (Lopez-Benito et al., 2016). 
 
1.3.5 Kidins220 in neuronal polarity, synaptic plasticity, and neurotransmission  
The diverse function of neurons depends on the highly polarised morphology 
regulated by axon and dendrites. Kidins220 interacts with tubulin (SCG10, and 
SCLIP) and microtubule-associated proteins (MAPs) to regulate neuronal polarity. 
As members of MAPs, the phosphorylation of MAP1b and stathmins were 
impaired following the downregulation of Kidins220. Furthermore, 
downregulation of Kidins220 also led to aberrant dendritic arbors and extensions 
of the longer axon (Higuero et al., 2010). α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) produce a mature glutamatergic 
synapse by targeting the cell surface during neuronal development (Hall and 
Ghosh, 2008). As a subunit of AMPAR, GluA1 can be up-regulated when Kidins220 
is down-regulated. Thus, in the process of neuronal mutation and synapse 
formation, the decreased expression of Kidins220 results in enhanced GLuA1 
expression and thus the establishment of a strong synaptic connection (Neubrand 
et al., 2012). In mature neuronal cultures, there is also evidence of interplay 
between Kidins220 and NMDA receptors. Upon overstimulation of the NMDA 
receptors, such as during excitotoxicity, or when neurons are depolarised, Ca2+ 
activity-dependent Ca2+ influx, through NMDA receptors, leads to a decrease in 
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Kidins220 levels through both transcriptional downregulation and protein 
cleavage by calpain (Lopez-Benito et al., 2016). As Kidins220 knockdown causes a 
decrease in the amount of phosphorylated MAPK, a reduction in the expression of 
Kidins220 might contribute to neuronal death through a decrease in MAPK 
signalling (Neubrand et al., 2012). In hippocampal neurons, the decreased 
expression of Kidins220 prohibited GABAergic neurotransmission, whereas the 
overexpression of Kidins220 reverses this effect. Furthermore, the GABAergic 
neurotransmission regulated by Kidins220 is through a presynaptic mechanism 
(Sutachan et al., 2010). Within hippocampal neurons with overexpression of 
Kidins220, increased long-term potentiation was impaired when calpain was 
prohibited (Wu et al., 2010). Sutachan et al., (2010) found that Kidins220 was 
implicated in regulating inhibitory neurotransmission (Sutachan et al., 2010). 
 
1.3.6 Kidins220 and vascular development  
Cesca et al., (2012) addressed the potential role of Kidins220 in vascular 
development due to its targeting of and interaction with VEGFRs. Mice with a 
Kidins220 knockdown phenotype presented with cardiovascular abnormalities. 
These abnormalities may be caused by impaired VEGF signalling pathways induced 
by lack of kidins220 (Cesca et al., 2012). Interestingly, Kidins220 interacts with 
VEGFR2 and VEGFR3 but not Nrp1, although both VEGFR2 and VEGFR3 are co-
receptors of Nrp1 in endothelial cells. VEGF signalling is one of the key pathways 
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in the process of angiogenesis especially mediated by VEGF/VEGFR2, and 
Kidins220 is demonstrated to interact with VEGFR2 constitutively (Guo et al., 
2010). However, mice with more severe vascular abnormalities can be detected in 
the VEGF knockdown models, VEGRFs, Nrp1 than Kidins220−/− itself (Cesca et al., 
2012), suggesting that Kidins220 regulation of angiogenesis may be limited.  
 
1.3.7 Kidins220 and immunomodulation 
Apart from the role of Kidins220 in modulating neuronal activities, it also 
contributes to immunomodulation alongside B cells and T cells. Kidins220 is 
expressed at the uropod of T lymphocytes and has been shown to be co-
immunoprecipitated with ICAM-3 and caveolin-1 (Jean-Mairet et al., 2011). 
Notably, in primary T lymphocytes, the co-localisation of Kidins220 and ICAM-3 is 
increased with the induction of morphological polarisation. In contrast, Kidins220 
displays different distribution upon change in cell polarity and co-localisation 
when ICAM-3 becomes disrupted. The identification of Kidins220 in the regulation 
of T-cell motility was indicated in a Kidins220 knockdown model of human 
polarised T-cell lines in which basal and stromal cell-derived factor-1α induced 
migration was increased, following knockdown of Kidins220 (Jean-Mairet et al., 
2011). Based on mass spectrometry, Deswal et al., (2013) demonstrated the 
interaction between Kidins220 and B-Raf in T lymphocytes. In 
immunoprecipitation and proximity ligation assays, sustained ERK signalling relied 
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on Kidins220 induced by the T cell receptor (TCR) (Deswal et al., 2013). 
Furthermore, Fiala et al. reported that Kidins220 interacted with stimulated B cell 
antigen receptor (BCR), in an enhanced Src kinase–independent manner. In B cell-
specific Kidins220 knockdown (B-KO) mouse model, Kidins220 couples the BCR to 
PLCγ2, Ca2+, and ERK signalling and reduces the activation of B cells regulated by 
BCR in vitro and in vivo. The role of Kidins220 involved in the PLCγ2 pathway was 
supported by the six-fold reduction of λ light chain positive B cells (Fiala et al., 
2015). Taken together, Kidins220 involves functional performance of both B cell 
and T cell by coordinating specific signal transduction.  
 
1.3.8 Kidins220 in tumours 
Several observations support the importance of Kidins220 in cancer pathogenesis 
in addition to its function in neuronal activity. A growing body of evidence points 
to the deregulation of Kidins220 at a cellular level affecting cell proliferation, 
invasion, migration, and apoptosis, playing an important role in tumour formation 
and metastasis (Table 1.4). Overexpression of the Kidins220 gene was initially 
reported in melanoma and associated with shorter overall survival. As a cutaneous 
malignancy, melanoma originates from the neural crest ontogenetically, and 
increased expression of Kidins220 was detected in melanoma cell lines (Liao et al., 
2007, Liao et al., 2011b). Immunohistochemical staining on different surgical 
specimens subsequently revealed significantly increased expression of Kidins220 
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in primary and metastatic melanoma tissues compared with benign tumour 
tissues (Liao et al., 2007). 
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Table 1.4: The alteration of Kidins220 in tumorigenesis and related signalling pathways.  
 
Tumour type Alteration Effect Signalling pathways references 
Cutaneous melanoma Increased 
expression 
Melanoma formation, 
migration, and 
invasion 
MEK/ERK signalling pathway (Liao et al., 
2007) 
(Liao et al., 
2011a) 
Neuroblastoma Increased 
expression 
Proliferation 
NGF-regulated 
signalling 
Transition from N-type 
to S-type 
P21/Cyclin D1 (Jung et al., 
2014) 
(Rogers and 
Schor, 2013a) 
Castration-resistant prostate 
cancer  (CRPC) 
Increased 
expression 
Angiogenesis VEGF/VEGFR and 
PI13K/AKT signalling pathways 
(Wang et al., 
2016) 
Ph-like acute lymphoblastic 
leukaemia (ALL) 
Gene fusion with 
PAX5 
Proliferation and 
survival 
ERK signalling pathway (Sakamoto et 
al., 2017) 
Paediatric high-grade glioma Intragenic copy 
number breakpoint 
n.d. n.d. (Carvalho et 
al., 2014) 
Note: n.d., not determined. 
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Kidins220 lies upstream of the BRAF gene that encodes proteins as part of the 
RAS/MAPK signalling pathway, controlling several important cell functions. 
Overexpression of Kidins220, resulting in sustained activation of MEK/ERK 
signalling, rather than BRAF mutation, has been identified as leading to acral 
lentiginous melanoma tumorigenesis. On the other hand, high levels of Kidins220 
also enhances ultraviolet radiation B (UVB) (290-320 nm) induced apoptosis in 
melanoma cells via targeting the activated ERK signalling pathway (Liao et al., 
2007). The inhibition of melanoma cell migration and invasion associated with 
Kidins220 knockdown indicated that Kidins220 can promote tumour 
migration/invasion through MEK/ERK signalling (Liao et al., 2007, Liao et al., 
2011b). Taken together, Kidins220 expression is regarded as a predictor of 
melanoma patient outcomes, and a target for therapies inhibiting 
Kidins220/MEK/ERK/MAPK signalling pathways.  
The regulatory role of Kidins220 in cancer development can be tumour 
specific. For example, Kidins220 possesses different regulatory mechanisms of the 
MAPK signalling pathway in neuroblastoma tumours. Rogers and Schor first 
reported that neuroblastoma tumours overexpress Kidins220, and that its forced 
overexpression promotes NGF-stimulated MAPK signalling activity, but not BDNF 
driven activation of MAPK signalling. Unlike melanoma, Kidins220 knockdown did 
not affect the survival of neuroblastoma cells under oxidative stress within 24 
hours. Furthermore, loss of Kidins220 did not affect migration of neuroblastoma 
cells (Rogers and Schor, 2013b). During development, neuroblastoma undergoes 
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a morphology transition between Schwannian stromal (S-type) cells and 
neuroblastic (N-type) cells. S-type cells are highly adhesive to extracellular matrix 
(ECM) and non-invasive, whereas N-type are less adhesive and highly invasive.  
DCX and STMN2 markers for neuronal lineage appear to be reduced in Kidins220-
deficient N-type cells, whereas S-type cells containing low levels of Kidins220 (but 
not Kidins220 depletion) expressed considerable levels of both DCX and STMN2. It 
suggests an essential role of Kidins220 in regulating morphology alteration in 
neural crest tumour cells (Rogers and Schor, 2013a). Jung et al., (2014) generated 
Kidins220-knockdown neuroblastoma cell lines to determine whether Kidins220 is 
involved in cell proliferation. They found that the wild type cells were 1.8 fold 
higher in number than the matching knockdown cells on the fourth day of culture. 
Further analysis revealed that the decreased growth rate of Kidins220-knockdown 
neuroblastoma cells were due to the arrest of cell cycle at the G1 phase, which 
was accompanied with decreased expression of both Cyclin D1 and CDK4, and also 
an up regulation of p21, suggesting that Kidins220 can coordinate cell cycle 
through a regulation of p21-cyclinD1/CDK4 (Jung et al., 2014).  
As previously mentioned, Kidins220 is a direct target of miR-4638-5P. MiR-
4638-5P has been related to the growth of castration resistance prostate cancer 
(CRPC) in vivo and in vitro.  Wang and colleagues discovered a significant 
downregulation of miR-4638-5P in CRPC. Kidins220 was detected with higher 
expression levels in both CRPC cell lines and tissues compared with androgen-
dependent prostate cancer (ADPC). Western blot analysis showed that only 
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Kidins220 expression was significantly reduced in PC3 and DU145 cells in the 
presence of miR-4638-5P. The knockdown of Kidins220 leads to reduced 
proliferation and growth of CRPC cells in vitro and in vivo. Furthermore, miR-4638-
5P and Kidins220 regulate prostate cancer (PCa) associated angiogenesis. 
Kidins220 knockdown or overexpression of miR-4638-5P result in similar inhibition 
of endothelial cell growth and the formation of vasculogenic mimicry. Further 
molecular analysis indicates that pCDH-miR-4638-5p sponge, a competitive miRNA 
inhibitor, caused an increase in expression of VEGF, PI3K, and AKT in androgen-
independent PCa cells, whereas all three molecules were reduced in Kidins220 
knockdown PCa cells, suggesting that both miR-4638-5P and Kidins220 may be 
involved in androgen-independent PCa-associated angiogenesis. Interestingly, a 
reduced level of cell growth and angiogenesis was also seen in AKT-knockdown 
cells which is in accordance with the result from Kidins220-knockdown cells. Taken 
together, loss of miR-4638-5 may result in the activation of Kidins220 and promote 
neoangiogenesis and androgen-independent PCa growth through the regulation 
of VEGF/VEGFR2 and PI3K/AKT signalling pathways (Wang et al., 2016). 
As mentioned before, Kidins220 is the substrate of PKD. At the trans-Golgi 
network, the family members of PKD were found to regulate secretory transport 
(Yeaman et al., 2004). PKD1 plays an important role in stimulating the secretion of 
neurotensin, a gut peptide, which modulates gastrointestinal functions such as 
secretion and growth, as well as being involved in the proliferation of neurotensin 
receptor-positive cancers (Li et al., 2004, Carraway and Plona, 2006, Evers, 2006). 
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In human carcinoid BON cells, a novel endocrine cell line that is derived from a 
human pancreatic carcinoid tumour, Kidins220 and PKD2 regulate the secretion of 
neurotensin (Evers et al., 1991, Li et al., 2008). Of further interest is the 
observation that in BON cells, Kidins220, PKD1 and PKD2 present the same 
localization pattern as neurotensin vesicles. Overexpression of PKD1 nullifies 
Kidins220 expression and neurotensin secretion in BON cells (Li et al., 2008). Thus, 
the PKD/Kidins220 signalling pathway provides evidence for their critical role in 
the regulation of neurotensin hormone secretion. Since neurotensin is involved in 
secretion and inflammation in both normal and tumour cell growth, the 
PKD/Kidins220 pathway and neurotensin-containing vesicles are considered as a 
novel drug target for clinical applications (Li et al., 2008, Castagliuolo et al., 1999). 
Apart from its role in solid tumours, a recent study also demonstrated a gene 
fusion of PAX5 and Kidins220, which leads to leukaemogenesis by inhibiting B 
lymphocyte differentiation. Kidins220-mediated activation of ERK pathway may 
contribute to the increased cell proliferation and the survival of leukemic cells 
(Sakamoto et al., 2016). Controversially, Kidins220 plays a different role in glioma, 
which was demonstrated in a profiling study of its function as a tumour suppressor 
in paediatric high-grade glioma (Carvalho et al., 2014). 
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1.3.9 Summary 
Kidins220 is involved in the regulation of diverse cellular activities, especially in 
neural differentiation and cytoskeleton remodelling (Bracale et al., 2007). Its 
different domains mediate the function of Kidins220 as well as act as a platform 
for protein-protein interactions, intracellular signalling and protein transportation. 
Dysregulation of Kidins220 has been evident in several malignancies. Kidins220 
binds to Trio, tubulin, SCG10 and SCLIP to modulate actin and microtubule 
cytoskeleton, which is critical in coordination with cellular processes, such as cell 
migration, cell polarity, and cell cycle progression (Fife et al., 2014). Tumour cell 
migration and invasion requires the remodelling of the cell cytoskeleton. The 
reorganization of the actin cytoskeleton that enables dynamic cell elongation and 
directional motility is also found in EMT, a critical process involved in tumour 
development (Thiery et al., 2009). Further investigation will shed light on the role 
played by Kidins220 in the dynamic arrangement of cytoskeleton and EMT, and its 
implication in tumorigenesis and cancer progression. 
Kidins220 regulates cell survival and death through MAPK signalling after the 
binding of neurotrophins and Trk receptors (Neubrand et al., 2012). Since the 
dysregulation of MAPK signalling is linked to tumorigenesis in several types of 
cancer, and the inhibition of MAPK signalling pathways is critical for the progress 
of anticancer agents, it is necessary to gain insight into the corresponding 
involvement of Kidins220 (Fang and Richardson, 2005, Mirzoeva et al., 2009). 
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Targeting its specific multiple domains such as the proline-rich domain and 
transmembrane segments may provide the possibility of more precise targeting. 
In addition to its involvement in VEGF/VEGFR regulated angiogenesis, 
Kidins220 has been shown as a target gene of miR-4638-5p, and its overexpression 
has been seen in androgen independent PCa and tumour associated angiogenesis 
(Wang et al., 2016). However, its potential for targeted tumour associated 
angiogenesis therapy in these malignancies requires further investigation. 
 
1.4 Hypothesis and aims 
To date, the role of Kidins220 in pancreatic cancer still remains unknown. 
According to the profound role played by this molecule in the regulation of cellular 
functions and signal transduction, and also aberration of its expression observed 
in other malignancies, we performed an initial assessment of its expression in 
pancreatic cancer by analysing publically available gene expression array data. A 
reduced expression was seen in pancreatic adenocarcinomas compared with 
adjacent non-cancerous pancreatic tissues which is presented in Chapter 3. 
Therefore, we proposed that Kidins220 is involved in the development and disease 
progression of pancreatic cancer.  
 
 
  
65 
The aims of the present study are:  
1) To determine the expression of Kidins220 in pancreatic cancer and its 
implication in development and disease progression; 
2) To examine its impact on the functions of pancreatic cancer cells, which may 
contribute to its role in the disease; 
3)To dissect the underlying molecular mechanism. 
Objective 1: Kidins220 expression in pancreatic cancer and its clinical relevance. 
The expression of Kidin220 transcripts in a cohort of pancreatic cancer tissue 
samples will be determined using real time quantitative PCR (QPCR). Kidin220 
protein expression and distribution will be evaluated using immunohistochemical 
staining (IHC) of Kidins220 in a pancreatic tumour tissue microarray. The 
association with histopathological and clinical characteristics will be evaluated 
accordingly. Additional analyses will be performed on relevant public gene 
expression array data to further validate our findings. 
Objective 2: Kidins220 and function of pancreatic cancer cells.  
The impact of Kidins220 on cellular function in pancreatic cancer cells will be 
determined using in vitro cell line models. A knockdown model using lentiviral 
shRNAs will be employed. Cellular functions such as proliferation, migration and 
invasion will be determined using corresponding in vitro assays. 
Objective 3: Molecular mechanisms.  
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Underlying molecular mechanism for altered cellular functions and EMT will be 
investigated by determing expression and activation of candidate molecules, for 
example EMT markers including snail, slug and twist etc. In a parallell study of 
Kidins220 in gastric cancer from the host laboratory, involvement of EGFR was 
observed in Kidins220 knockdown gastric cancer cell lines from an analysis of 
protein activation using a protein array. Therefore, we may focus on the influence 
of Kidins220 on EGFR and its signalling in pancreatic cancer and the corresponding 
implication in the disease progression.  
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Chapter 2 
Methodology  
68 
2.1 Materials 
2.1.1 Cell lines 
The current study used three pancreatic cancer cell lines; Panc-1, Mia paca-2 and 
ASPC-1. All these cell lines were purchased from the American Type Culture 
Collection (ATCC, Rockville, MD, USA). All cell lines were verified at the source for 
identity and were at low passage on acquisition. Full details of these cell lines are 
listed in Table 2.1.  
Table 2.1: Details of pancreatic cancer cells used in this study. 
 
 Panc-1 Mia paca-2 ASPC-1 
Species Human Human Human 
Tissue Pancreas/duct Pancreas 
Pancreas; 
derived from 
metastatic site: 
ascites 
Gender Male Male Female 
Age 56 65 62 
Morphology Epithelial Epithelial           - 
Growth mode Adherent Adherent Adherent 
Disease 
Epithelial 
carcinoma 
Carcinoma Adenocarcinoma 
Country UK UK UK 
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2.1.2 General compounds 
Chemicals and reagents used throughout the study, together with their suppliers 
are outlined in table 2.2. 
Table 2.2: Chemicals and reagents. 
 
Material/Reagent Supplier 
10% Foetal calf serum (FCS) Sigma-Aldrich, Pooled, Dorset, UK 
A/G protein agarose beads Santa-Cruz Biotechnology, UK 
Acetic acid Fisher Scientific, Leicestershire, UK 
Acrylamide mix (30%) Sigma-Aldrich, Poole, Dorset, UK 
Agarose Melford Laboratories Ltd, Suffolk, UK 
Ammonium persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK  
Amphotericin B Sigma-Aldrich, Poole, Dorset, UK 
Ampicillin Sigma-Aldrich, Poole, Dorset, UK 
Bio-Rad DC™ Protein Assay Bio-Rad Laboratories, Hercules, CA, USA 
Boric acid 
Duchefa Biochemie, Haarlem, 
Netherlands 
Bovine serum albumin (BSA) Sigma-Aldrich, Poole, Dorset, UK 
Bromophenol Blue Sigma-Aldrich, Poole, Dorset, UK 
Calcium chloride (CaCl2) Sigma-Aldrich, Poole, Dorset, UK 
Chloroform Sigma-Aldrich, Poole, Dorset, UK 
Commasine Blue Sigma-Aldrich, Poole, Dorset, UK 
Crystal violet Sigma-Aldrich, Poole, Dorset, UK  
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Poole, Dorset, UK 
Dimethylsulphoxide (DMSO) Sigma-Aldrich, Poole, Dorset, UK 
Disodium phosphate (Na2HPO4) BDH Chemicals Ltd, Poole, Dorset, UK 
Dithiothreitol Sigma-Aldrich, Poole, Dorset, UK 
Dulbecco’s Modified Eagles’ 
Medium/Nutrient mixture F12  
Sigma-Aldrich, Poole, Dorset, UK 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich, Pooled, Dorset, UK 
Ethanol Fisher Scientific, Leicestershire, UK 
Formalin Sigma-Aldrich, Poole, Dorset, UK 
GoTaq® Green Master Mix Promega 
G418 Sigma-Aldrich, Poole, Dorset, UK 
Hydrochloric acid (HCl) Sigma-Aldrich, Poole, Dorset, UK 
Isopropanol Sigma-Aldrich, Poole, Dorset, UK 
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Matrigel® Corning Incorporated, Flintshire, UK 
Methanol Fisher Scientific, Loughborough, UK 
Na2HPO4 BDH Chemicals Ltd., Poole, Dorset, UK 
NaN3 Sigma-Aldrich, Poole, Dorset, UK 
PVDF membrane 
EMD Millipore Corporation, Billerica, MA, 
USA 
Penicillin Sigma-Aldrich, Poole, Dorset, UK 
Ponceau S Stain Sigma-Aldrich, Poole, Dorset, UK 
Precision qScript™ RT PCR kit Primerdesign Ltd, Southampton, UK 
Potassium chloride (KCl) 
Fisons Scientific Equipment, 
Loughborough, UK 
GoTaq Green master mix  Promega, Madison, USA 
RPMI Sigma-Aldrich, Poole, Dorset, UK 
Sodium dodecyl sulphate (SDS) Melford Laboratories Ltd, Suffolk, UK 
Sodium chloride (NaCl) Sigma-Aldrich, Poole, Dorset, UK 
Sodium fluoride Sigma-Aldrich, Poole, Dorset, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, Poole, Dorset, UK 
Sodium nitrate Sigma-Aldrich, Poole, Dorset, UK 
Sodium orthovanadate (NA2VO4) Sigma-Aldrich, Poole, Dorset, UK 
Sodium pyrophosphate Sigma-Aldrich, Poole, Dorset, UK 
Streptomycin Sigma-Aldrich, Poole, Dorset, UK 
Sucrose 
Fisons Scientific Equipment, 
Loughborough, UK 
SYBR®Safe DNA gel stain  Invitrogen, Paisley, UK 
Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich, Poole, Dorset, UK 
TRI Reagent Sigma-Aldrich, Poole, Dorset, UK 
Tris-Cl Melford Laboratories Ltd, Suffolk, UK 
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK 
Trypsin Sigma-Aldrich, Poole, Dorset, UK 
Tween 20 Melford Laboratories Ltd, Suffolk, UK 
Vectastain Universal ABC kit 
Vector Laboratories Inc, Burlingame, CA, 
USA 
Zinc chloride (ZnCl) Sigma-Aldrich, Poole, Dorset, UK 
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2.1.3 General plastic consumables, hardware and software 
General plastic consumables, hardware and software, together with their 
suppliers are outlined in table 2.3. 
Table 2.3: Instruments, culture vessels and software. 
 
 
2.1.4 Primers 
All primers used in this study were designed using the Beacon Design Programme 
(Biosoft International, Palo Alto, California, USA) and were synthesised by either 
Invitrogen (Paisley, UK) or Sigma (Poole, Dorset, UK). Details of the primers used 
Hardware/Software Supplier 
0.4 μm filtration unit  Sigma-Aldrich, Poole, Dorset, UK 
25cm2 and 75cm2 culture flasks Cell Star, Germany 
Image J  Public Domain  
Lecia DM IRB microscope Lecia GmbH, Bristol, UK  
Microsoft Excel Microsoft In., Redmond, WA, USA 
Neubauer  haemocytometer 
counting chamber  
Mod-Fuchs Rosenthal, Hawksley, UK 
Protein spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
RNA spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
UV light chamber  Germix 
Class II laminar flow cabinet  Wolflabs,York, UK 
EVOS Auto imaging system  
Thermo Fisher Scientific, Waltham, MA 
USA 
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for conventional RT-PCR and real time quantitative PCR (QPCR) are provided in 
Table 2.4. 
Table 2.4: Primers for conventional RT-PCR, QPCR and ribozyme synthesis. 
 
Primer name Primer sequence (5’-3’) 
Product 
size (bp) 
GAPDHF8 GGCTGCTTTTAACTCTGGTA  
GAPDHR8 GACTGTGGTCATGAGTCCTT 475 
Kidins220F2 AGACGTTCCATGCTCAGA  
Kidins220R2 CTCGAGCCACAAGAACTG 539 
Kidins220ZR2 ACTGAACCTGACCGTACATGCCTTCTTCGGTAAGTG 136 
Kidins220 
Rib1F 
 
CTGCAGACCCGGGGCCCCCTTCTAACTGGCTGATGAGT
CCGTGAGGA 
 
Kidins220 
Rib1R 
ACTAGTGCCTATAGAGAATACATTGCTCAGATGTTTCGT
CCTCACGGACT 
 
EGFRF1 AGAGTCTCAAAGCCATGTTAT  
EGFRZR1 ACTGAACCTGACCGTACACCATCCTAAGCATGACTCC 120 
E-cadF22 CAGGAGCCAGACACATTTAT  
E-cadR22 TCTAAGGTGGTCACTTGGTC 515 
VimentinF1 GATGCTTCAGAGAGAGGAAG  
VimentinZR1 ACTGAACCTGACCGTACACTCTTCGTGGAGTTTCTTCA 145 
SnailF11 CGCTCTTTCCTCGTCAG  
SnailR11 GTTGCAGTATTTGCAGTTGA 474 
SlugF11 CTCTCCTCTTTCCGGATACT  
SlugR11 AGCAGTTTTTGCACTGGTAT 521 
TwistF11 AGCAACAGCGAGGAAGAG  
TwistR11 GAGGACCTGGTAGAGGAAGT 318 
T7F TAATACGACTCACTATAGGG  
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BGHR TAGAAGGCAGTCGAGG  
RbBMR 
 
TTCGTCCTCACGGACTCATCAG  
RbTPF CTGATGAGTCCGTGAGGACGAA  
Note: Z Sequence ‘ACTGAACCTGACCGTACA’ is highlighted in green and italic font 
 
2.1.5 Antibodies 
2.1.5.1 Primary antibodies 
Full details of primary antibodies used in the current study are supplied in Table 
2.5. 
 
2.1.5.2 Secondary antibodies 
The secondary antibodies used for western blotting were horseradish peroxidise 
(HRP) conjugated anti-goat IgG, goat anti-rabbit IgG, and rabbit anti-mouse IgG 
antibodies, all these antibodies are purchased from Sigma (Poole, Dorset, UK). 
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Table 2.5: Primary and secondary antibodies used in this study. 
 
 
  
Antibodies 
Molecular 
weight (kDs) 
Supplier Product code 
Rabbit anti-
Kidins220 
220 
Santa Cruz 
Biotechnology 
sc-48738 
Mouse anti- β-actin 42 
Santa Cruz 
Biotechnology 
sc-47778 
Mouse anti-
tyrosine（PY99） 
- 
Santa Cruz 
Biotechnology 
sc-7020 
Mouse anti-EGFR 170 
Santa Cruz 
Biotechnology 
sc-71034 
Mouse anti-p-ERK 42 
Santa Cruz 
Biotechnology 
sc-7383 
Mouse anti-ERK 42 
Santa Cruz 
Biotechnology 
sc-514302 
Mouse anti-p-
AKT1/2/3 
62/56/60 
Santa Cruz 
Biotechnology 
sc-81433 
Mouse anti- AKT 56 
Santa Cruz 
Biotechnology 
sc-5298 
Goat anti-E-
cadherin 
135 
Santa Cruz 
Biotechnology 
sc-1500 
Mouse anti-
vimentin 
57 
Santa Cruz 
Biotechnology 
sc-66002 
Mouse anti-snail 29 Abcam ab167609 
Rabbit anti-mouse 
(whole molecule) 
IgG peroxidise 
conjugate 
Dependent 
on primary 
Sigma-Aldrich A5278 
Goat anti-rabbit 
(whole molecule) 
IgG peroxidise 
conjugate 
Dependent 
on primary 
Sigma-Aldrich A0545 
Rabbit anti-goat 
(whole molecule) 
IgG peroxidise 
conjugate 
Dependent 
on primary 
Sigma-Aldrich A5420 
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2.2 Preparation of reagents, buffers and standard solutions 
2.2.1 Solutions used in cell culture 
Preparation of Complete Cell Culture Medium 
Panc-1, Mia paca-2 and ASPC-1 pancreatic cancer cells were cultured in Dulbecco’s 
Modified Eagle’s medium supplemented with 50ml of heat inactivated foetal calf 
serum (FCS) (Sigma-Aldrich, Pooled, Dorset, UK) and 5ml of an antibiotic cocktail 
comprising penicillin, streptomycin and amphotericin B (Sigma-Aldrich, Pooled, 
Dorset, UK). The prepared medium was stored at 4°C for up to one month. 
 
Preparation of 0.05M EDTA 
A stock solution was prepared by dissolving 40g NaCl, 1g KCl, 5.72g Na2HPO4 (BDH 
Chemical Ltd., Poole, England, UK), 1g KH2PO4 (BDH Chemical Ltd., Poole, England, 
UK) and 1.4g EDTA (Sigma-Aldrich, Pooled, Dorset, UK) in 5 litres of dH2O. The pH 
was adjusted to 7.4 using Sodium hydroxide (NaOH) and was autoclaved before 
use.  
 
Trypsin (25mg/ml) 
A 25mg/ml stock solution was prepared by dissolving 500mg trypsin in 20ml 0.05M 
EDTA. The solution was filtered through a 0.2μm mini-start filter (Sigma-Aldrich, 
Pooled, Dorset, UK) and stored at -20°C. The working solution was prepared by 
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further dissolving 250μl of the stock trypsin/EDTA solution in 10ml of 0.05M EDTA 
to detach cells, and was stored at 4°C until use.   
 
Phosphate-buffered saline (PBS) 
To prepare 1L of 1 x PBS, (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM 
KH2PO4) was prepared by dissolving 8g NaCl, 0.2g KCl, 1.44g Na2HPO4 and 0.24g 
KH2PO4 in 800ml of dH2O. The pH was adjusted to 7.4 with HCl and dH2O added to 
make up the volume to 1 Litre. The solution was then autoclaved and aliquoted 
before being stored at room temperature.  
 
100X Antibiotics 
100X Antibiotic Antimycotic Solution was purchased from Sigma-Aldrich (Poole, 
Dorset, UK). 5ml of the solution was added into a 500ml DMEM to obtain a final 
1X concentration. 
 
2.2.2 Solutions used in molecular biology 
Tris-Boric-Acid (TBE) electrophoresis buffer 
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TBE buffer 10X concentrate (T4415) was purchased from Sigma-Aldrich (Poole, 
Dorset, UK), and diluted with distilled water into 1X stock and stored at room 
temperature for further use. 
 
Diethylpyrocarbonate (DEPC) water 
A stock solution of DEPC water was prepared by dissolving 500μl of diethyl 
pyrocarbonate (DEPC) (Sigma-Aldrich, Poole, Dorset, UK) in 9,500μl distilled water 
and autoclaved before use. 
 
Loading buffer (used for DNA electrophoresis) 
Loading buffer was prepared by dissolving 25mg bromophenol blue (Sigma-Aldrich, 
Poole, Dorset, UK) and 4g sucrose (Fisons Scientific Equipment, Loughborough, UK) 
were dissolved in 10ml of H2O. The buffer was stored at 4°C until use.  
 
2.2.3 Solutions for Western blot 
Lysis Buffer 
Lysis buffer was prepared by dissolving NaCl 150mM (8.76g), Tris 50mM (6.05g), 
sodium azide 0.02% (200mg), sodium deoxycholate 0.5% (5g), Triton X-100 1.5% 
(15ml), Aprotinin 1μg/ml (1mg), Na3VO4 5mM (919.5mg) and Leupeptin 1μg/ml 
(1mg) in 1 litre of dH2O, and was stored at 4°C until use. 
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Tris Buffered Saline (TBS) 
1L of Tris Buffered Saline 10X solution (T5912) (Sigma-Aldrich, Poole, Dorset, UK)  
was diluted in 9L of distilled water. The pH was adjusted to 7.4 using HCl and 
stored at room temperature until use.   
 
10% ammonium persulphate (APS) 
The solution was prepared by dissolving 1g APS in 10ml dH2O and then stored at 
4°C for future use. 
 
Running buffer  
1L of Tris-Glycine-SDS Buffer 10X concentrate (T7777) (Sigma-Aldrich, Poole, 
Dorset, UK) was diluted in 9L of distilled water and stored at room temperature 
for further use. 
 
Transfer buffer 
1L of Tris-Glycine Buffer 10X concentrate (T4904) (Sigma-Aldrich, Poole, Dorset, 
UK) was diluted in 9L of distilled water containing 2L methanol (Fisher Scientific, 
Loughborough, UK) and stored at room temperature for further use. 
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2.3 Cell culture, maintenance and storage 
2.3.1 Preparation of growth medium and cell maintenance 
• Panc-1, Mia paca-2, and ASPC-1 pancreatic cancer cell lines were cultured 
in Dulbecco’s Modified Eagle’s Medium/Nutrient F-12 Ham (DMEM-F12, 
Sigma-Aldrich, Poole, Dorset, UK). This medium contains 2mM L-glutamine 
and 4.5mM NaHCO3 and supplemented with 10% heat inactivated Foetal 
Bovine Serum (Sigma-Aldrich, Poole, Dorset, England, UK) and antibiotics 
in PH 7.3.  
• All the cell lines were cultured in 25 cm2 and 75 cm2 flasks (Greiner Bio-
One Ltd, Gloucestershier, UK) depending on the required application with 
a loose cap in an incubator at 37oC, 95% humidification and 5% CO2.  
• Cell lines transfected with lentiviral shRNA or scramble control were 
initially cultured in DMEM with 500μg/ml G418. The selected transfectants 
were then cultured in medium supplemented with 100μg/ml G418 to 
maintain the acquired phenotype. The transfected cell lines were verified 
for subsequent studies. 
• Confluency and viability of Cells were visually assessed with an inverted 
phase contrast microscope. The confluency of cells was estimated based 
on the percentage of cells covering the surface of the tissue culture flasks. 
Cells were left to grow until they reached sub-confluency (80-95%) for 
experiments. All handing of cells was carried out using a Class II laminar 
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flow cabinet with autoclaved and sterile equipment. Cells were passaged 
when they reached 80%-90% confluency. 
 
2.3.2 Cell detachment and cell counting 
• The tissue culture flask was taken out from the incubator and the waste 
medium was aspirated using a glass pipette. Following this, the flask was 
briefly washed with sterile 5ml EDTA BSS buffer to remove remaining 
serum which would inhibit the action of trypsin.  
• Approximately 1-2ml of trypsin/EDTA solution (Trypsin 0.01% (w/v) and 
EDTA 0.05% (w/v) in BSS buffer) was added to the tissue culture flask. The 
adherent cells were detached after the flask was returned to the incubator 
for 5-10 minutes at 37°C. Flasks were inspected visually under the light 
microscope to make sure the cells were detached completely.   
• Once detached, 5ml DMEM containing 10% FCS was added to the flask to 
neutralise the trypsin and the detached cells were washed from the surface 
of the flask. The cell mixture was then transferred to a 30ml universal 
container (Greiner Bio-One Ltd, Gloucestershire, UK) and centrifuged at 
1,800rpm for 10 minutes. 
• The supernatant was aspirated and the cell pellet was re-suspended in 
medium for re-culturing or used in experimental work immediately. 
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• Cell counting was carried out using a Neubauer haemocytometer counting 
chamber under a light microscope using the x10 objective lens. 
• The haemocytometer calculated the number of cells in a predetermined 
volume of fluid to obtain the quantity of cells per millilitre. The 
haemocytometer chamber was divided into 9 squares with dimensions of 
1mm x 1mm x 0.2mm. For consistency of cell density and error reduction, 
four corners of 9 squared areas were counted. The number of cells was 
calculated by using the following equation: 
• Cell number/ml= (the sum of the number of cells in four corners/ 8) x 
(1x104) 
 
2.3.3 Storage of cells in liquid nitrogen and cell resuscitation 
Cells were detached with trypsin from the flask as described in section 2.3.2. After 
centrifugation, the cells were re-suspended in medium with 10% dimethyl 
sulfoxide (DMSO) at a density of 1x106 cells/ml. 
• One millilitre of this cell suspension was transferred into 1ml pre-labelled 
CRYO.STM tubes (Greiner Bio-One, Germany) wrapped in protective tissue 
paper and then frozen down to -80°C. For a longer-term storage, the cells 
were transferred and stored at -196°C in a liquid nitrogen tank.  
• In order to resuscitate the frozen cells, the CRYO.STM tube was taken from 
the liquid nitrogen and thawed in a 37°C water bath rapidly. The cell 
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suspension was then transferred into a 30ml universal container 
containing 5ml of pre-warmed medium and then centrifuged at 1,800rpm 
for 5 minutes. The medium was removed by aspiration. The cells were then 
resuspended in 5ml media. The cells were incubated at 37°C, 95% 
humidification, and 5% CO2 for further experiment. 
 
2.4 Methods for RNA detection 
2.4.1 Total RNA isolation 
There are three main types of Ribonucleic acid (RNA) within the cytoplasm of all 
living eukaryotic cells known as ribosomal RNA (rRNA), transfer RNA (tRNA), and 
messenger RNA (mRNA). Cellular mRNA was used in this study based on its 
important role of carrying genetic information and encoding corresponding 
protein products. At the transcript level, the presence of specific mRNA thus acting 
as an indication of which proteins are likely being produced by the cell. 
RNA isolation was performed using the Tri Reagent kit (Sigma-Aldrich, Poole, 
Dorset, UK) as outlined below. 
• After cells were cultured in a monolayer to a confluence of approximately 
90% (5-10x105 cells), the medium was removed and replaced with RNA 
reagent (1ml per 5-10x105 cells) to produce cell lysate.  
• The homogenous lysate was then transferred into a sterile microfuge tube, 
and left at room temperature for 5 min. 
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• 0.2ml (per 1ml of RNA reagent) chloroform (Sigma-Aldrich, Poole, Dorset, 
UK) was added to the homogenate and the tube capped and shaken 
vigorously for 15 seconds. 
• The resulting homogenate was then centrifuged at 12,000rpm for 15 
minutes at 4°C (Boece, Wolf laboratories, York, UK). The centrifugation 
resulted in the separation of the lysate into three phases in the acidic 
environment; a red organic phase containing protein, an interphase 
containing DNA and a colourless upper aqueous phase containing RNA. 
• The upper aqueous phase containing RNA was carefully transferred to a 
fresh microfuge tube. Following this, 500 µl of 2-propanol (per 1ml TRI 
Reagent®) was added to the sample, shaken and incubated on ice for 10 
minutes before centrifugation, for pelleting precipitated RNA, at 12,000 x 
g for 10 minutes at 4°C. Subsequently, an RNA pellet was seen at the 
bottom of the microfuge tube. 
• The supernatant was discarded and the RNA pellet was washed with 1ml 
75% ethanol (made with DEPC water) twice with vortexing and centrifuging 
at 7,500rpm for 5 minutes at 4°C. 
• The RNA pellet was briefly dried at 55°C for 5-10 min in a Techne, 
Hybridiser HB-1D drying oven (Wolf laboratories, York, UK), in order to 
remove any remaining ethanol.  
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• Finally, the RNA pellet was dissolved in 50-100μl (depending on RNA pellet 
size) of DEPC water by vortexing.  DEPC is used as a histidine specific 
alkylating agent to inhibit the hydrolysis of RNA by RNAases.  
 
2.4.2 RNA Quantification  
• Once RNA isolation was completed, the concentration and purity of the 
resulting single stranded RNA was quantified by measuring its absorbance 
at a wavelength of 260nm using a UV 1101 Biotech spectrophotometer 
(WPA, Cambridge, UK). The RNA samples were measured with Starna glass 
cuvette (Optiglass limited, Essex, UK).  A260nm/ A280nm ratio was used 
to estimate the purity of RNA sample by measuring the different 
absorbance between the RNA sample and DEPC water (as a blank control).   
• The concentration of RNA samples was then standardised using DEPC 
water for reverse transcription (RT) or stored at -80°C for future use. 
 
2.4.3 Reverse Transcription of RNA for production of cDNA 
To determine the transcript expression, an mRNA template was used to generate 
complementary DNA (cDNA) using reverse transcription (RT). Transcripts of a 
particular gene were then determined using RT-PCR and QPCR.  
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• RT was performed by converting 500 ng of RNA into cDNA using the 
GoScriptTM Reverse Transcription System kit (Promega, Corporation, 
Madison, WI, USA) Based on the instruction provided by the manufacture, 
each reaction was set up in 200μl PCR tubes as follows: 
 
Component Volume Each reaction 
GoScriptTM 5X Reaction Buffer 4μl 
MgCl2 1.2μl 
PCR Nucleotide Mix 1μl 
Recombinant RNasin Ribonuclease Inhibitor 0.5μl 
GoScriptTM Reverse Transcriptase 1μl 
RNA template (0.5μg/μl) 1μl 
Nuclease-Free Water 7.3µl 
• The reaction was carried out in a 2720 Thermal Cycler (Applied Biosystems, 
Paisley, UK). The reaction condition is listed as following: 
 
Time Temperature 
5 minutes 25°C 
60 minutes 42°C 
15 minutes 70°C 
• After the reaction completed, the cDNA was diluted by 1:4 with PCR water 
as a template for PCR or store at -20°C for future use. 
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2.4.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was first devised by Kary Mullis in 1983. It is a 
simple technique that is used to detect and amplify a single target DNA, and 
produce thousands or millions of copies of the DNA sequence (Bartlett and Stirling, 
2003). In this reaction, two short DNA sequences (oligonucleotides- i.e. forward 
and reverse primers), which bind to the template DNA by base pairing, are 
required and are complementary to a defined sequence on each of the two stands 
of the DNA. These primers are aligned with the 3’ ends facing each other.  
The components of a PCR reaction include a DNA template containing the 
target DNA that is to be amplified, a heat resistant DNA polymerase such as Taq 
polymerase which synthesises DNA from nucleotides, short DNA fragments called 
primers which contain complementary sequences to the 3’ ends of the sense and 
anti-sense strand of the target DNA and which act as a starting point for DNA 
formation by the DNA polymerase, deoxynucleotide triphosphates (dNTPs) from 
which the polymerase can synthesise new DNA strands and a thermal cycler, which 
provides repeated cycles of heating and cooling to provide the required 
temperatures for each step of the reaction. The DNA produced by PCR acts as a 
further template for replication resulting in a chain reaction and the exponential 
amplification of DNA.  
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• In the current study, target genes were amplified using the GoTaq Green 
master mix (Promega, Madison, USA). The reaction in aliquots of 16μl was 
set up in PCR tubes as follows: 
 
Component Volume 
cDNA template 2μl 
Forward primer (working concentration of 
1μM) 
1μl 
Reverse primer (working concentration of 
1μM) 
1μl 
2X GoTaq Green master mix  
 
8μl 
PCR H20 4μl 
• A test sample containing PCR water instead of cDNA template was run 
alongside to detect any contamination of the reaction.  
• The PCR samples were briefly mixed and placed in a 2720 Thermo Cycler 
The condition of reaction was set as follows: 
 
Step Temperature Time Cycles 
Initialisation 94°C 5min 1 
Denaturation 94°C 20sec 
32 cycles Annealing 55°C 20 sec 
Extension 72°C 30 sec 
Final extension 72°C 10min 1 
Final hold 4°C ∞ 1 
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2.4.5 Agarose gel electrophoresis and DNA visualisation 
Agarose gel electrophoresis is the most common method to separate and analyse 
DNA fragments. It works by using electrical current to separate negatively charged 
DNA to a positive electrode through an agarose gel matrix, with the speed of 
migration depending on the size of DNA fragments. Agarose gels containing either 
0.8% (1-10kb DNA fragments) or 1-2% (smaller fragments less than 1kb) agarose 
were prepared for running DNA samples. 
• The required amount of agarose powder (Melford Chemicals, Suffolk, UK) 
was added to 100ml (1X) TBE buffer and heated in a microwave oven until 
the agarose was completely dissolved. After cooling down for 5 minutes, 
the solution was stained with SYBR®Safe DNA gel stain (Invitrogen, Paisley, 
UK) and poured into electrophoresis cassettes (Scie-Plas Ltd, Cambridge, 
UK). Well forming combs were gently inserted and the gel was left to set 
at room temperature for 30-40 minutes until completely solidified. 
• Once the gel had set, the well forming combs were removed after 1xTBE 
was poured over and exceed 5mm of the gel surface. 8μL DNA ladder 
(GenScript®, Piscataway, USA) was loaded into the first lane of the gel and 
then 8-10μL of DNA samples were loaded into additional wells of the gel 
by placing the gel loading tips just over the well. 
• The gel was run with an Electrophoresis power supply (Gibco BRL, Life 
Technologies Inc.) at 120V, 100mA and 50W for approximately 30-50 
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minutes.  When the visible dye line had moved the desired distance 
required for the product size, the electrodes were disconnected. 
• The gel was then removed, and the DNA fragments visualised using 
Syngene U: Genius3 fluorescence UV transilluminator (Synoptics Ltd, 
Cambridge, UK). Images were saved electronically and printed using a 
thermal printer. 
 
2.4.6 Real time quantitative PCR (QPCR) 
Real-time (or quantitative) PCR is a sensitive technique for gene analysis. It 
measures PCR amplification in real-time as the reaction proceeds instead of at the 
end of the reaction in comparison with conventional PCR. This method works by 
detecting a fluorescent reporter probe which is increased during PCR amplification 
(PCR product is proportional to the level of fluorescence detected). The 
fluorescence level is continuously recorded by a sensitive camera attached to the 
system. 
In this study, the Ampliflour™ Uniprimer™ Universal system (Intergen 
company®, New York, USA) was used to quantify transcript copy number. The 
ampliflour probe consists of a 3’ region specific to the Z-sequence 
(ACTGAACCTGACCGTACA) present on the target specific primers and a 5’ hairpin 
structure labelled with a fluorophore (FAM). When in this hairpin structure, the 
fluorophore is linked to an acceptor moiety (DABSYL) which acts to quench the 
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fluorescence emitted by the fluorophore, preventing any signal from being 
detected. 
During PCR, the probe becomes incorporated and acts as a template for DNA 
polymerisation in which DNA polymerase uses its 5’-3’ exonuclease activity to 
degrade and unfold the hairpin structure, thereby disrupting the energy transfer 
between flourophore and quencher, allowing sufficient fluorescence to be 
emitted and hence detected. The fluorescent signal emitted during each PCR cycle 
can then be directly correlated to the amount of DNA that has been amplified. This 
process is illustrated in Figure 2.1. 
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Figure 2.1: Real time quantitative PCR using the fluorescent labelled Uniprimer. 
Diagram shows function of the u-probe during DNA amplification using QPCR. 
 
• Each reaction to be amplified was set up as follows: 
 
Component Volume 
2x iQ™ Supermix 5μL 
Forward primer (10pmol/μL) 0.3μL 
Reverse primer (1pmol/μL) 0.3μL 
Amplifluor™ probe (10pmol/μL) 0.3μL 
cDNA 1μL 
PCR H20 3μL 
Total volume per reaction 10μL 
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• Each sample was loaded into a 96 well plate (Applied Biosystems™, Life 
Technologies Ltd, Paisley, UK), covered with MicroAmp® Optical Adhesive 
film (ThermoFisher Scientific, Life Technologies Ltd, Paisley, UK) and run 
alongside a podoplanin (PDPL) standard of a known transcript number 
(ranging from 108 to 101). PDPL is a lymphangiogenesis marker, which is 
employed as a reference control gene for a standard curve to ensure any 
differences observed were not due to technical errors and allowed 
normalization of results. It is also used to calculate relative copy numbers 
of target genes. The 96 well plate was placed in an iCycler Thermal Cycler 
which uses a light source to excite the fluorescent molecules in the wells 
and an image intensifier and a 350,000-pixel charge-coupled device (CCD) 
detector to image all 96 wells every second and detect fluorescent light at 
the annealing stage. The conditions used for QPCR are shown as follows: 
 
Step 
Temperature 
(°C) 
Time 
(minutes:seconds) 
Number of 
cycles 
Initial 
denaturation 
94 05:00  
Denaturation 94 00:10 
 
80-90 cycles 
Annealing 55 00:35 
Extension 72 00:20 
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• The fluorescent signal is deteded at the annealing stage by a camera 
where its geometric increase directly correlates with the exponential 
increase of product. This is then used to determine a threshold for 
quantification of genes amplified in each reaction. Copy number of a 
target transcript is determined using the cycle number of a reaction when 
its fluorescence signal reaches the threshold.  
• The degree of fluorescence emitted by a range of standards with a known 
copy number of a reference gene (PDPL)  are used to compare the 
amount of fluorescence emitted by each sample, allowing for the 
transcript copy number of a target gene in each sample to be accurately 
calculated.  
• Furthermore, the transcript copy number of each sample was normalised 
against the detection of β-actin or GAPDH copy numbers. The procedure 
was repeated at least three times, and representative data is 
demonstrated.  
• How transcript levels are quantified is shown in Figure 2.2. 
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Figure 2.2: (A) Detection of transcript levels from a range of standard samples 
(108 to 101 copy number) using the iCyclerIQ thermal cycler. (B) Subsequent 
generation of a standard curve from these samples. 
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2.5 Methods for protein detection 
2.5.1 Extraction of protein and preparation of cell lysates 
• When cells reached sufficient confluence, the medium was removed and 
the cell monolayer was washed twice with PBS buffer. 5ml PBS was then 
added to the flask and the cells were scraped with a sterile cell scraper 
from the flask surface and transferred to a universal tube. 
• The cell suspension was centrifuged at 1,800rpm for 10 minutes to obtain 
a cell pellet. After removal of the supernatant with a vacuum aspirator, 
200-300μl (depending on pellet size) of lysis buffer was added to the 
universal tube and the cell suspension was transferred to a 1.5ml 
microfuge tube. 
• In order to extract protein from cell lysate, the sample was incubated at 
4°C for 1 hour with continuous rotation on a Labinoco rotating wheel (Wolf 
laboratories, York, UK) (25rpm and 4°C) 
• After 1 hour, the resulting lysate was centrifuged at 13,000 rpm for 15 
minutes. The supernatant containing proteins was then transferred to a 
fresh tube. The pellet containing insoluble and any unwanted cell debris 
was discarded.  
• The protein sample was then either quantified for western blot or stored 
at -20°C until further use.  
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2.5.2 Protein quantification and preparation of protein samples  
In order to standardise the concentration of protein samples before they were 
analysed using sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) 
and western blotting, the protein samples were quantified using the Bio-Rad DC 
Protein Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK). The kit utilised a 
colorimetric assay based on the reaction of protein with an alkaline copper 
tartrate solution (Reagent A) and Folin reagent (Reagent B), which is used for the 
determination of protein concentration following detergent solubilisation. The 
protein reacts with copper in the alkaline medium resulting in the subsequent 
reduction of the Folin reagent and the production of a characteristic blue colour 
(with an absorbance between 405-750nm). Bovine serum albumin (BSA) was used 
as a standard for this protein quantification.   
• In a 96 well plate, 50mg/ml BSA standard (Sigma-Aldrich, Poole, Dorset, UK) 
was diluted in lysis buffer to produce a concentration gradient from 
0.78mg/ml to 50 mg/ml. These were used to generate a standard curve for 
determining concentration of the protein samples.   
• 5μl of either protein samples or standards were added into each well on a 
96-well plate and 25μl of Reagent A’ (prepared by adding 20μl of reagent 
S to every 1ml of reagent A) was added to each well followed by 200μl of 
Reagent B.  
  
97 
• After the sample was mixed, the plate was left at room temperature for 
30-45 minutes for the colorimetric reaction to occur. The absorbance for 
each well was then measured at a wave length of 630nm using the ELx800 
plate reading spectrophotometer (Bio-Tek, Wolf Laboratories, York, UK).  
• The standard curve was set up using the absorbance of the standards. 
Protein concentration of the test samples was determined according to the 
standard curve. Appropriate amounts of lysis buffer was used to 
standardise the protein samples to a final concentration of 1-2mg/ml 
depending on the lowest concentration of the same collection.  
• This sample was finally diluted 1:1 with 2x Lamelli sample buffer 
concentrate (Sigma-Aldrich, Poole, Dorset, UK) and then denatured by 
boiling at 100°C for 5-10 minutes. The boiled samples were either used 
immediately for SDS-PAGE or stored at -20°C until further use. 
 
2.5.3 Protein extraction for KinexusTM antibody microarrays 
• Before protein extraction, each cell type was cultured in two T75 flasks 
until approximately 80% confluence.  Cells were left for serum starvation 
for 24 hours before collection.  
• Upon protein extraction, cells were washed twice with PBS and scraped 
from the flask using 5ml sterile PBS. The cell suspension from two flasks 
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was combined and centrifuged at 2,500 rpm for 10 minutes to pellet the 
cells.  
• The cell pellet was then lysed in 600μl lysis buffer and was subsequently 
placed on a Labinoco rotating wheel (Wolf laboratories, York, UK) (25rpm 
and 4°C) for 40-60 minutes for sufficient extraction.  
• After 15 minutes centrifugation at 13,000rpm, the protein lysate was used 
for protein quantification.  
• 300μl lysis (4mg/ml) was prepared and stored at -20°C before being sent 
for KinexusTM antibody microarray analysis (Kinexus Bioinformatics, 
Vancouver, British Columbia, Canada). 
 
2.5.4 Immunoprecipitation preparation 
Immunoprecipitation is an invaluable technique used to analyse intracellular 
phosphorylation events occurring upon an extracellular stimulation. The process 
of immunoprecipitation involves cell lysis, followed by an incubation with a 
specific antibody against target protein or proteins (for example, PY99 is an 
antibody targeting proteins with phosphorylated tyrosine) presenting within the 
tested protein samples. The resultant antigen-antibody complexes are then 
precipitated using agarose beads conjugated with Staphylococcal protein A and 
protein G followed by SDS-PAGE and immunoprobing. A brief description of the 
Immunoprecipitation method used in this study is outlined as follows: 
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• An Antibody targeting a protein of interest was added to the cell lysate 
samples before being incubated at 4oC for 1 hour with continuous rotation. 
• Following the incubation, 20μl of conjugated A/G protein agarose beads 
(Santa Cruz Biotechnology, UK) were added to each sample. The samples 
were then incubated at 4oC with continuous rotation overnight which 
allowed for antibody-protein complexes binding to the beads. 
• The samples were then centrifugation at 8,000rpm for 5 minutes, allowing 
removal of any unbound protein or excess antibodies present in the 
supernatant. The protein pellet was subsequently washed twice with 300μl 
of lysis buffer before being resuspended in 40-60μl of 1x Lamelli sample 
buffer and boiled for 10 minutes. The resulting samples were then run on 
SDS-PAGE gels as explained below. 
 
2.5.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
• Four glass plates were prepared and assembled in two gel cassettes on a 
casting stand. Once assembled, ethanol was used to fill the space between 
the glass plates to test for leakages.  
• The system used to conduct SDS-PAGE in this study was an OmniPAGE 
VS10 vertical electrophoresis system (Cleaver Scientific Ltd., Rugby, 
Warwickshire, UK). The required percentage of resolving gel was 
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dependant on the protein size. A mixture of 15ml (enough for 2 mini gels) 
was prepared by adding all the constituents listed in the following: 
 
8% Resolving gel (protein size over 100 kDa) 
Distilled water 6.9ml 
30% acrylamide mix (Sigma-Aldrich, 
Poole, Dorset, UK) 
4.0ml 
1.5 M Tris (pH8.8) 3.8ml 
10% SDS 0.15ml 
10% Ammonium persulphate 0.15ml 
TEMED (Sigma-Aldrich, Poole, Dorset, UK) 0.009ml 
 
 
10% Resolving gel (protein size less than 100 kDa) 
Distilled water 5.9ml 
30% acrylamide mix (Sigma-Aldrich, 
Poole, Dorset, UK) 
5.0ml 
1.5 M Tris (pH8.8) 3.8ml 
10% SDS 0.15ml 
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10% Ammonium persulphate 0.15ml 
TEMED (Sigma-Aldrich, Poole, 
Dorset, UK) 
0.006ml 
• The resolving mixture was then added into space between the two glass 
plates carefully until it reaches a level about 1cm below the comb. In order 
to prevent gel oxidation, 1ml 2-propanol was added to cover the top of 
resolving gel. 
• The gels were then left to polymerise at room temperature for about 30 
minutes, or until set completely. The excess 2-propanol was poured off 
before a sufficient amount of stacking gel was added. The ingredients for 
staking gel are listed in the following: 
 
Component Stacking gel 
Distilled water 3.4ml 
30% acrylamide mix (Sigma-Aldrich, 
Poole, Dorset, UK) 
0.83ml 
1.0M Tris (PH 6.8) 0.63ml 
10% SDS 0.05ml 
10% Ammonium persulphate 0.05ml 
TEMED (Sigma-Aldrich, Poole, 
Dorset, UK) 
0.005ml 
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• A well forming Teflon comb was inserted immediately after adding the 
stacking gel, and the gel was left at room temperature for around 20 
minutes for polymerisation to occur. 
• After the gel was set, the loading cassette was transferred into an 
electrophoresis tank and covered with 1X running buffer before the well 
comb was removed. 10µl of Broad range markers (Santa Cruz 
Biotechnology, UK) were loaded into the first well of the gel, followed by 
10-15µl of the required protein samples.  
• The proteins were then separated at 100-120V, 50mA, and 50W for a 
period up to 3 hours depending on the degree of separation required for 
target proteins according to their molecular weight.  
 
2.5.6 Transferring proteins from gel to PVDF membrane 
• After SDS-PAGE, the gel containing protein samples was electrically 
transferred onto a PVDF membrane. Following SDS-PAGE separation, the 
electrophoresis cassettes were disassembled and the gels were taken out.  
The stacking gel on each gel was cut off and discarded. The resolving gel 
was then placed on the bottom graphite base electrode in a SD20 SemiDry 
Maxi System blotting unit (SemiDRY, Wolf Laboratories, York, UK) on top 
of 3 pieces of 1X transfer buffer pre-soaked filter paper (Whatman 
International Ltd., Maidstone, UK), and 1 sheet of PVDF membrane.  
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An additional 3 sheets of pre-soaked filter paper were placed on top of the 
gel to form a sandwich arrangement in an order as filter papers, gel, 
membrane, filter papers (from cathode to anode) (Figure 2.3). 
Electroblotting was then conducted at 15V, 500mA, and 8W for 40-60 
minutes according to the protein size. Once the proteins had been 
transferred sufficiently, the membranes were blocked with 10% milk 
solution (10% milk skimmed powder and 0.1% polyoxyethylene (20) 
sorbitan monolaurate (Tween 20) in TBS for at least one hour at room 
temperature. This step aims to reduce background, i.e. non-specific 
binding to the membrane and subsequently subject to a probing with 
antibodies.  
 
 
Figure 2.3: Diagram depicting process of western blotting; the transferring of 
proteins onto a PVDF membrane. 
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2.5.7 Protein detection using specific immuno-probing 
• Once blocking was completed, the membrane was transferred into 50ml 
falcon tubes (Nunc, Fisher-Scientific, Leicestershire, UK) with the 
membrane surface facing upwards. Then the membrane was incubated in 
10ml 3% milk solution (3% milk powder, 0.1% Tween 20 in TBS) with 
primary antibody diluted 1:500 overnight at 4oC. 
• After probing with primary antibody, the membrane was washed with 5ml 
TBST (TBS with 0.2% Tween 20) for three times (10 mins each) to remove 
remaining unbound antibodies. 
• The membrane was subsequently incubated with 5ml of 1:1000 horse 
radish peroxidase (HRP) conjugated secondary antibody diluted in 3% milk 
for one hour with continuous rotation. 
• The membrane was washed for three times (10 mins each) with 5ml TBST 
before undertaking chemiluminescent detection. 
 
2.5.8 Chemiluminescent protein detection 
Chemiluminescent protein detection was carried out using the Luminate Forta 
Western HRP substrate (Cat. No. WBLUF0500, Merk-Millipore, Hertfordshire, UK).  
This solution consists of a highly sensitive chemiluminescent substrate and is used 
to detect the HRP for visualising the probed protein bands. The protocol was 
undertaken as follows: 
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• 1ml reagent was added onto the membrane with a 5-minute incubation at 
room temperature with constant agitation. 
• Excessive solution on the membrane was removed before putting the 
membrane into a plastic tray. The chemiluminescent signal was detected 
using an UVITech Imager (UVITech Inc., Cambridge, UK) which contains 
both an illuminator and a camera linked to a computer. 
• The exposure time was adjusted as necessary until the protein bands were 
sufficiently visible and the image was captured and analysed using ImageJ 
for the protein band quantification.  
• In this study, β-actin was used as a loading control and ran alongside when 
detecting any other proteins for additional normalisation of the sample. β-
actin is used because of its high abundancy and conserved nature within 
eukaryotic cells and is one of the most widely employed and accepted 
internal controls in determining mRNA and protein expression.  
 
2.5.9 Immunohistochemical staining  
• After rehydration of the tissue section, the section was blocked with a 
blocking solution containing horse serum (Vector Laboratories Inc., 
Burlingame, USA) for 30 minutes at room temperature. The blocking 
solution was prepared by adding 1-2 drops of horse serum into 5ml of 1X 
OptiMax Wash Buffer (BioGenex, San Ramon, USA). 
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• After blocking, the slide was washed three times with wash buffer before 
being incubated for an hour at room temperature with primary antibody 
(the dilution may vary depending on a specific antibody used, but generally 
1:100 was used) diluted in blocking solution. 
• Any unbound antibody was subsequently washed off with wash buffer, this 
was repeated three times before incubating the samples for another 30 
minutes at room temperature, with the corresponding secondary antibody 
diluted 1:1000 in blocking solution.  
• After three washes with wash buffer, the sections were incubated with 
200μl of VECTASTAIN® Universal ABC complex (Vector Laboratories Inc., 
Burlingame, USA) for 30 minutes. The ABC complex was made up 30 
minutes before use by mixing 4 drops of the supplied reagent A, with 4 
drops of regent B.  
• The ABC solution was subsequently removed by washing three times with 
wash buffer before a few drops of 3,3’-Diaminobenzidine (DAB) 
chromogen (Vector Laboratories Inc., Burlingame, USA) were added onto 
the tissue followed by a 5-minute incubation in the dark to allow colour 
development. DAB was made up as follows; 2 drops of the provided buffer 
(pH 7.5), 4 drops of DAB, and 2 drops of hydrogen peroxide diluted in 5ml 
of distilled water. 
• Following DAB addition and development of a brown colouration, 
indicative of protein presence, the DAB was washed off using distilled 
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water before the sections were counterstained with Mayer’s haemotoxylin 
for approximately 5 minutes. 
• After three washes with distilled water, slides were dehydrated for 5 
minutes in each sequential solution; 50% ethanol, 70% ethanol, 90% 
ethanol, 100% ethanol, 50% ethanol/ 50% xylene, 100% xylene. 
• After dehydration, slides were mounted with DPX mountant and left to dry. 
• The intensity of IHC staining was quantified using Image J software 
(https://imagej.nih.gov/ij/). 
 
2.6 Targeting Kidins220 gene expression 
2.6.1 Knocking down Kidins220 using Ribozyme Transgenes 
Hammerhead ribozyme transgenes were used to knockdown the expression of 
Kidins220 by specifically targeting and cleaving the Kidins220 transcript. 
Hammerhead ribozymes targeting Kidins220 were designed using the mfold 
mRNA folding programme (http://unafold.rna.albany.edu/?q=mfold/RNA-
Folding-Form) based on the secondary structure of Kidins220 mRNA (Figure 2.4). 
The transgenes were synthesised using touchdown PCR and the products were 
then run on a 2% agarose gel to verify their presence and size before being cloned 
into the pEF6/His plasmid vector (Figure 2.5). Subsequently, the ribozymes 
obtained from the above procedure were cloned into the pEF6/V5-His-TOPO 
vector, and this was followed by transferring the reaction mixture to a vial of 
108 
TOP10 chemically competent E.coli. After 30 minutes on ice, the bacteria were 
subject to heat shock at 42oC for 30 seconds, before being placed on ice for 2 
minutes. The bacterial mixture was added to SOC media and placed on an orbital 
shaker for 1 hour, at a speed of 200rpm. The bacterial solution was plated on agar 
plates containing 100µg/ml amplicillin and allowed to grow overnight. As the pEF 
plasmid has antibiotic resistance genes to ampicillin and blasticidin, only the cells 
containing the plasmid were able to grow on the agar. Colonies of transformed 
E.coli, transgenes of Kidins220 cloned into pEF6/V5-His-TOPO plasmids (Invitrogen 
Inc., Paisley, UK) were analysed using RT-PCR with the T7F primer coupled either 
with RbBMR and RbTPF primers. After amplifying the correct colonies, the 
plasmids were extracted using the Sigma GenElute Plasmid MiniPrep Kit (Sigma-
Aldrich, Poole, Dorset, UK). Control plasmid and the plasmid containing the 
ribozyme transgene was used to transfect both Panc-1 and Mia paca-2 cell lines 
respectively. The transfected cells were cultured in selection media containing 
5μg/ml blasticidin for around 1-2 weeks so that only those cells containing the 
plasmid would survive. Following selection, the cells were transferred into 
maintenance media containing 0.5μg/ml blasticidin. To verify the knockdown of 
Kidins220, RT-PCR, QPCR and western blot procedures were carried out as 
previously described.  
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Figure 2.4: Secondary structure of Kidins220 mRNA, generated using the mfold 
(http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form ).   
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Figure 2.5: Schematic of the pEF6 plasmid (From pEF6/V5-His TOPO TA Expression 
Kit protocol). 
 
2.6.2 Knocking down gene expression using lentivirus shRNA 
RNA interference (RNAi) has been used as a research tool to regulate the 
expression of specific genes in several experimental organisms. Its role in 
controlling gene expression also contributes to therapeutic strategies targeting 
specific genes linked to onset or progression of a particular disorder. RNAi can be 
achieved through a vector-based shRNA. Lentiviral vectors are capable of 
delivering genetic material into cells (in vivo or in vitro) and can stably integrate 
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shRNAs into the genome of both dividing and non-dividing cells, resulting in long 
term expression of the transgene. 
The current study used the pLV lentivirus vector with a Kidins220 shRNA 
construct which comprises three selective markers, i.e. a green fluorescent protein 
and resistance genes to Ampicillin for prokaryotes and Neomycin/G418 for 
mammals (Figure 2.6).  
 
 
Figure 2.6: Schematic of the pLV lentivirus plasmid. The lentivirus plasmid 
containing shRNA was generated using the online vector designing tool. 
(https://www.Vectorbuilder.com). 
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2.6.3 Plasmid amplification and purification 
• shRNA was picked from the tube and inoculated in 10ml of LB broth with 
100μg/ml ampicillin and subsequently incubated at 37oC overnight with 
constant agitation. 
• The amplified E. coli were then pelleted by centrifugation at 4oC for 15 
minutes at 6,000rpm and then used for plasmid extraction. This was 
carried out using the Sigma GenElute Plasmid MiniPrep kit (Sigma-Aldrich, 
Poole, Dorset, UK) according to the provided protocol, outlined below. 
• The bacterial pellet was resuspended in 200μl of resuspension fluid 
(containing RNase A) before being mixed thoroughly and transferred into 
the 2ml collection tubes provided. 
• This was followed by the addition of 200μl lysis solution and gentle mixing 
by inverting the tubes 5-6 times. The resulting mixture was left at room 
temperature for 5 minutes before adding 350μl of neutralisation solution.  
• The tube was inverted several times, and centrifuged at 12,000rpm for 10 
minutes. The resulting supernatant was then transferred into a fresh 
collection tube containing a Mini Spin Column, which binds the plasmid 
DNA. This was centrifuged at 12,000rpm for 1 minute.  
• The flow through was discarded before the column was washed with 700μl 
of wash solution (containing ethanol) and centrifuged at 12,000rpm for 1 
minute. The flow through was discarded once more, before the column 
was dried by another centrifugation for one minute. 
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• The column was then transferred into a fresh collection tube for elution. 
This was carried out by adding 100μl of elution solution and centrifugation 
at 12,000rpm for 1 minute. The resulting flow through containing the 
purified plasmid was collected, and approximately 4μl was run on a 0.8% 
agarose gel in order to confirm the presence and purification of the 
plasmid. 
 
2.6.4 Production of lentivirus particles 
• For each plasmid to be transfected, 7 x 105 HEK-293T cells in 5ml of media 
was added into a 6cm2 tissue culture plate, and the cells were incubated at 
37oC, 5% CO2 until 50-80% confluent. 
• The transfection reagent (Santa Cruz Biotechnology, UK) was mixed and 
added in polypropylene microfuge tubes to 20μl serum-free OPTI-MEM as 
follows: 
 
 
  
1μg pLV shRNA plasmid 
750 ng psPAX2 packing plasmid 
250ng pMD2.G envelope plasmid 
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• The transfected reagent was added into HEK-293T cells and the cells were 
incubated at 37oC, 5% CO2 for 12-15 hours. 
• Following incubations, the medium containing transfection reagent was 
removed and replaced with 5ml fresh medium. The medium was pipetted 
onto the side of the plate so as not to disturb the transfected cells and the 
cells were incubated for an additional 24 hours.  
• The media was harvested from cells and transferred to a polypropylene 
tube. The medium containing lentiviral particles was stored at 4oC.  
• 5ml fresh medium was added to the cells and incubated at 37oC and 5% 
CO2 for another 24 hours. 
• The medium was harvested from the cells and pooled together with the 
previously collected medium. 
• The medium was centrifuged at 1,250 rpm for 5 minutes to pellet any HEK-
293T cells that were inadvertently collected during harvesting. The 
lentiviral particles were stored at -80oC for future use. 
 
2.6.5 Infecting target cells 
• Target cells were seeded in 6-well plates and grow at 37oC and 5% CO2 
overnight.  
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• When cells were approximately 70% confluent, fresh medium containing 
8µg/ml polybrene, used to increase the transfection efficiency, was added 
to the plate. 
• 0.05-0.1ml Lentiviral particle solution (add 0.5ml for a high multiplicity of 
infection (MOI), and 0.1ml for a low MOI) was added to the target plate 
and the cells were incubated at 37oC and 5% CO2 overnight. 
 
2.6.6 Establishment of stable expression in mammalian cell lines 
• Following infection, in order to obtain a stable cell line expressing shRNAs 
it is necessary to select culture cells. 
• The pLV vector contains a resistance sequence against neomycin/G418 and 
this can be used for selection in mammalian cells. Therefore, the cells were 
cultured in selection medium containing 500μg/ml G418 for around 1-2 
weeks which allowed only infected cells, containing the plasmid to survival.  
• After selection, the cells were cultured in maintenance medium containing 
100μg/ml G418. Verification of target gene knockdown was performed 
using RT-PCR and western blotting as outlined previously.  
• Once the cells had been verified to stably reduced expression of the 
desired molecule, they were subject to various in vitro assays to detect the 
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effect on the biological functions of the cells by altering expression of the 
target gene. 
 
2.7 In vitro cell function assay  
The hallmarks of cancer characterise the most essential phenotypic features of 
malignant transformation and progression (Menyhart et al., 2016). The basic 
aberration that lead to the development of cancer is the continual uncontrolled 
proliferation of cancer cells. Cancer cells grow and divide in an unregulated 
manner, invading to surrounding tissues and organs and finally spreading 
throughout the body (Lopez-Saez et al., 1998). In the current study, we used 
several in vitro function tests, such as cell proliferation assay, adhesion assay, 
trans-well invasion assay and migration assay to determine the impact of 
Kidins220 on cellular functions of cancer cells. 
 
2.7.1 In vitro cell growth assay (2D model) 
• The protocol by Hu et al. was followed (Hu et al., 2012). 200μl of media 
containing 3,000 cells was seeded into 96 well plates.  
• These plates were incubated at 37oC, with 5% CO2, for a period of 24, 48, 
72, and 120 hours respectively. 
117 
• After incubation, the media was aspirated, and the cells were fixed with 4% 
formaldehyde for 10-20 minutes before being stained with 0.5% crystal 
violet for 10 minutes. The plate was then rinsed with tap water and left to 
air dry. 
• The stain was then solubilised using 200μl of 10% acetic acid and the 
amount of cells was assessed by measuring the absorbance of the resulting 
solution at 540nm using a spectrophotometer (BIO-TEK, ELx800, UK). The 
growth rate was calculated as a percentage, using the absorbance from the 
corresponding plate collected at 24 hours as a baseline. 
 
2.7.2 Tumour spheroid growth assay (3D model) 
Three-dimensional (3D) in vitro models have been used in cancer research as an 
intermediate model between in vitro 2D models/assays and in vivo tumour models. 
Spherical cancer models represent major 3D in vitro models that have been 
described over the past 4 decades (Weiswald et al., 2015).  
• 200μl of media containing 1,000 cells was seeded into 96-well tumour 
spheroid plates.  
• These plates were incubated at 37oC, with 5% CO2, for a period of 15 days. 
• Images of the spheroid were captured using an EVOS automated 
microscope every 3 days. 
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• Spheroid size was calculated using ImageJ software. 
 
2.7.3. In vitro adhesion assay 
• 100μl of serum free media containing 5μg Matrigel® Basement Membrane 
Matrix (Corning Incorporated, Flintshire,UK) was coated in a 96-well plate. 
The Matrigel was then left to dry for 2 hours at 55oC. 
• 200μl of sterile water was added to each well and left for at least 45 
minutes at room temperature to rehydrate the Matrigel. 
• The media was aspirated and 20,000 cells, diluted in 200μl media, were 
seeded into each well and left to adhere at 37oC, with 5% CO2 for 40 
minutes. 
• After incubation, the media was discarded and the cells were washed with BSS 
to remove any non-adherent cells. The remaining adherent cells were then 
fixed with 4% formalin for 10-20 minutes, and then stained with 0.5% crystal 
violet for 10 minutes. Following substantial washes, the plates were left to dry 
before counting adherent cells and capturing images under the microscope. 
Due to the fluid dynamics within the small size wells of 96 well plate, the 
unevenly set Matrigel can lead to cell aggregation around the edges of the well. 
In order to avoid this issue, only the cells that adhered to the central area of 
the well were counted.   
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2.7.4 In vitro invasion assay 
• 8μm pore transwell inserts (FALCON®, pore size 8.0μm, 24 well format, 
Greiner Bio one, Germany) were placed into wells of a 24 well plate 
(NUNC™, Greiner Bio one, Germany), using sterile forceps in order to 
prevent contamination (Figure 2.7). 
• Each insert was coated with 100μl of serum free media containing 50μg 
Matrigel (stock concentration 0.5μg /μl) and left to dry for 2 hours at 55oC.  
• The Matrigel was then rehydrated with 200μl sterile water at room 
temperature for 45 minutes. 
• After the water was carefully discarded, 20,000 cells, in 200μl media, were 
seeded into each insert. 600μl media was then added to the bottom 
chamber of each well. The cells were incubated for 72 hours, with 5% CO2 
at 37oC. 
• After 72 hours incubation, the Matrigel layer and the non-invasive cells 
were then removed from the insert using a cotton bud. Both the Matrigel 
layer and the non-invasive cells were thoroughly removed as they can also 
be stained with crystal violet, impacting quantification of invasive cells that 
had invaded the Matrigel and porous membrane and established on the 
underside of the insert.  
  
120 
• The invasive cells were then fixed with 4% formalin for 10-20 minutes and 
then stained with 0.5% crystal violet for 10 minutes. The crystal violet was 
then washed off and the plate was left to airdry. The stained cells were 
subsequently counted and photographed under the microscope. 
 
 
Figure 2.7: Schematic diagram showing in vitro invasion assay.    
               
2.7.5 In vitro migration assay 
• 8μm pore transwell inserts (FALCON®, pore size 8.0μm, 24 well format, 
Greiner Bio one, Germany) were placed into wells of a 24 well plate 
(NUNC™, Greiner Bio one, Germany), using sterile forceps in order to 
prevent contamination (Figure 2.8). 
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• 20,000 cells, in 200μl media, were seeded into each insert. 600μl media 
was then added to the bottom chamber of each well. The cells were 
incubated for 72 hours, with 5% CO2 at 37oC. 
• After 24 hours incubation, non-invasive cells were then removed from the 
insert using a cotton bud.  
• Cells which had migrated through the insert were then fixed with 4% 
formalin for 10-20 minutes and then stained with 0.5% crystal violet for 10 
minutes. The crystal violet was then washed off and the plate was left to 
airdry. The stained cells were subsequently counted and photographed 
under the microscope. 
 
Figure 2.8: Schematic diagram showing in vitro migration assay. 
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2.7.6 In vivo peritoneal metastasis model 
Athymic nude mice (CD1) were purchased from Charles River Laboratories 
(Charles River Laboratories International, Inc., Kent, England, UK) and settled 
down for a week before use. The study was conducted under Home Office Project 
licence (PPL: PE944FC2). All mice were kept in filter-topped isolation cages and all 
the procedures were carried out in a class-II cabinet.   
Pancreatic cancer cells (scramble and shKidins220) were injected into the 
peritoneal cavity of athymic nude mice with a volume of 100µl which contained 
Matrigel at final concentration of 2.5mg/ml in PBS. The mice were then carefully 
monitored twice a week by measuring body weight. The mice were terminated 
after 4 weeks and intraperitoneal exploration was conducted to detect metastatic 
tumours of liver, stomach, pancreas, and duodenum to rectum. Metastatic 
nodules were photographed using a stero-microscrope (Olympus, Japan) and the 
volume of metastatic tumours was calculated by using the following formula: 
Tumour volume (mm3) = 0.5× Width2×length 
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2.8 Collection of clinical cohort 
In this study, the clinical cohort included pancreatic tumours (n=149) together 
with paired adjacent background tissues which were collected immediately after 
surgery and stored at -80 ºC until use, with written consent from patients at Peking 
University Cancer Hospital. All protocol and procedures were approved by Peking 
University Cancer Hospital Research Ethics Committee (Appendix1). The frozen 
tissues were first sectioned using a Leica CM1900 Cryostat (Leica Microsystems 
Ltd, Bristol, UK) at 8-10μm thickness. These sections (>50) were divided into three 
portions: 
1. Immediately mounted on glass slides and fixed for routine histology assessment; 
2. Mounted on slides and fixed using Superfrost®Plus microscopic slides for 
subsequent immunohistochemical analysis. These slides were stored at -20oC. 
3. The remaining sections were pooled and homogenised to extract RNA for 
molecular based analysis. 
 
2.9 Statistical analysis 
Following a normality check, t-test and One-way ANOVA were employed for 
normally distributed data whilst non-normally distributed data was analysed using 
a Mann-Whitney test. Differences were considered to be statistically significant 
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when p<0.05. Graphs were constructed using GraphPad Prism Software (Version6, 
GraphPad Software). Kaplan-Meier survival analysis was carried out using SPSS 
software (SPSS Standard version 13.0; SPSS Inc., Chicago, IL, USA). 
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Chapter 3 
Expression of Kidins220 in 
pancreatic cancer and the clinical 
relevance 
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3.1 Introduction 
Kidins220/ARMS is a transmembrane protein with predominant expression in 
nervous and neuroectodermic tissues (Iglesias et al., 2000). Several in vivo studies 
have strongly demonstrated that aberrant expression and function of this 
molecule is associated with occurrences of certain diseases. 
Like the findings in animal models, mutation of Kidins220 has also been 
evident in human diseases. For instance, heterozygous mutations of Kidins220 has 
been reported to be a cause of spastic paraplegia, intellectual disability, 
nystagmus, obesity, and homozygosity (Josifova et al., 2016). Expression of non-
functional variants of Kidins220 is associated with enlarged cerebral ventricles and 
limb contracture in foetuses (Mero et al., 2017, Josifova et al., 2016). In 
Alzheimer’s disease (AD), necropsies for AD patients in different progression 
stages presented an increased expression level of Kidins220 in the brain which is 
due to an increased resistance to calpain cleavage upon hyperphosphorylation of 
Kidins220 (Lopez-Menendez et al., 2013). Furthermore, Kidins220 has a role in the 
regulation of neurotrophin signalling pathways; mutations of Kidins220 such as 
A557V, H1085R and A1299G exhibit a potential link with an increasing risk of 
schizophrenia and psychosis (Kranz et al., 2015).  
Involvement of Kidins220 has also been found in HIV-associated neuro-
cognitive disorders (HAND) (Singh et al., 2015). HAND is caused by mild to severe 
neurocognitive impairment due to the long-lasting Human Immunodeficiency 
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Virus Type-1 (HIV) in the central nervous system (CNS). Kidin220 is expressed in 
microglia, a kind of resident immune cell that can be infected with HIV directly. 
Microglia cells subsequently secrete proinflammatory molecules that contribute 
to HIV-induced neuroinflammation. It was found that knockdown of Kidins220 
reduced the HIV Tat-induced proinflammatory response, which was associated 
with the loss of tumor necrosis factor alpha production and NF-κB activation (Singh 
et al., 2015). In addition to this, Kidins220 has also been shown to be involved in 
the immune-inflammation of asthma through the NGF-mediated signalling 
pathway (Ni et al., 2010). Anti-NGF treatment resulted in a down-regulation of 
Kidins220/ARMS, IL-1β and IL-4 in a mouse model (Li et al., 2013).  
In recent years, emerging evidence has also revealed an altered expression of 
Kidins220 in different malignancies including melanoma and neuroblastoma (Jung 
et al., 2014, Liao et al., 2007, Rogers and Schor, 2013b, Liao et al., 2011a). An 
elevated expression of Kidins220 was also observed in castration-resistant 
prostate cancer (CRPC) as a direct target of miR-4638-5p (Wang et al., 2016). 
Kidins220 knockdown or overexpressing miR-4638-5p can reduce proliferation 
and growth of CRPC cells in vitro and in vivo.  
Taken together, Kidins220 appears to play a positive role in certain 
malignancies by promoting proliferation and coordinating signal transductions to 
assist growth and metastasis of tumour cells. To date, little is known about the 
function of Kidins220 in the digestive system and its involvement in malignancies 
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of the digestive system. The present study aimed to examine the role of this 
molecule in pancreatic cancer. The very first objective was set to determine its 
expression at both mRNA and protein levels in pancreatic cancers using QPCR and 
IHC, respectively. Implication of Kidins220 expression in the development and 
disease progression of pancreatic cancer was to be analysed to evaluate the 
clinical relevance before further investigation of cellular and molecular machinery 
underlying its implication in pancreatic cancer.  
The current section of the study aims to explore the expression and 
association of this molecule at both transcript and protein level using QPCR and 
IHC and to associate such expression with the clinical pathological patient 
information. 
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3.2 Materials and methods 
3.2.1 Pancreatic cancer tissues 
Pancreatic tumours (n=149) together with paired adjacent background tissues 
were collected immediately after surgery and stored at -80°C until use, with 
written consent from the patients at Peking University Cancer Hospital. All 
protocols and procedures were approved by Peking University Cancer Hospital 
Research Ethics Committee. RNA was extracted and converted to complementary 
DNA for subsequent quantification using real time quantitative PCR (QPCR).  
 
3.2.2 Primers and antibody 
Polyclonal rabbit anti-Kidins220 antibody (sc-48738) was obtained from Santa 
Cruz Biotechnology. All the primers used were synthesised and provided by 
Invitrogen (Paisley, UK). Primer sequences are shown in Table 2.4. 
 
3.2.3 RNA extraction, reverse transcription, PCR and QPCR 
Total RNA was isolated using TRI Reagent (Sigma-Aldrich, Poole, Dorset, UK), first 
strand cDNA was then synthesis using the GoScriptTM Reverse Transcription 
System kit as described in section 2.4. QPCR was performed using the iCycler IQ5 
system (Bio-Rad, Hemmel, Hempstead, UK) to examine the Kidins220 transcripts, 
whilst GAPDH was also determined as a house-keeping gene.  
130 
3.2.4 Immunohistochemistry for pancreatic tissue microarray  
Immunohistochemical staining was conducted on a pancreatic adenocarcinoma 
tissue microarray (TMA) (PA2081a, Biomax, Maryland, US). The primary antibody 
used was an anti-Kidins220 rabbit monoclonal antibody (SC-48738) at 1:50 
concentration (Santa Cruz Biotechnology, UK). The secondary antibody solution 
consisted of 100µl biotinylated antibody stock at 5ml dilution (Vectastain 
Universal Elite ABC Kit, PK-6200, Vector Laboratories, Peterborough,UK). Presence 
of cancerous cells and assessment were performed by two pathologists (Professor 
Paul Griffiths (PG) and Dr Nadine Burke (NB), Morriston Hospital, ABM University 
Health Board, Swansea, UK) by determining the intensity and distribution of 
Kidins220 staining. Intensity of Kidins220 staining was also determined using 
ImageJ (https://imagej.nih.gov/ij/) by two researchers (Shuo Cai and Ping-Hui Sun) 
at the host lab. Briefly, the IHC intensity was determined in 10-20 cancerous cells 
by a subtraction of background of empty area on the slide for each core on the 
TMA. Average intensity was calculated for each core with duplicates of samples 
from each tissue, followed by statistical analyses.  
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3.2.5 Statistical analysis 
Kaplan-Meier survival analysis was performed with SPSS software (SPSS Standard 
version 13.0; SPSS Inc., Chicago, IL, USA). One-way ANOVA, t-test, paired t-test, 
Mann-Whitney test were employed to analyse Kidins220 transcript levels in 
tumours regarding different clinic-pathologic characteristics. T-test was used for 
normally distributed data whilst the Mann-Whitney test was used for non-
normally distributed data. Differences were considered to be statistically 
significant when p<0.05. 
 
3.3 Results 
3.3.1 Expression of Kidins220 in pancreatic cancer 
The expression of Kidins220 in pancreatic cancer was first evaluated by 
determining the transcript levels of Kidins220 in a clinical cohort comprising 
pancreatic tumours (n=149) and the paired adjacent normal pancreatic tissues 
(n=145) using QPCR. Clinical and pathological information together with average 
Kidins220 transcript levels are shown in the Table 3.1. Kidins220 was significantly 
reduced in pancreatic tumours in comparison with adjacent normal tissues 
(p=0.029) (Table 3.1 and Figure 3.2A). Although a relatively lower expression of 
Kidins220 was observed in tumours from female patients, statistical analyses did 
not show a significant association. Similarly, variable levels of Kidins220 transcripts 
were seen in tumours regarding their differentiation but lacked statistical 
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significance. Variable transcription levels of Kidins220 were also observed in 
tumours of different histological types, pancreatic adenocarcinoma presented the 
highest Kidins220 gene expression compared with pancreatic ductal carcinoma 
and other types of pancreatic carcinoma such as islet cell carcinoma, 
neuroendocrine carcinoma, and solid pseudopapillary tumour of the pancreas. 
However, statistical analyses did not shown any significant correlation between 
Kidins220 transcript levels and the histological types (Table 3.1). 
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Table3.1: Clinical cohort of Kidins220 in pancreatic cancer. 
 
 
N 
Mean±SEMean 
(copies/50ng RNA) 
p-value 
Tumour 149 75150± 576945 0.029 
Normal 145 2.13 E+12 ± 9.62 E+11  
Gender    
Male 89 114106±96478 0.32 
Female 60 17365±6882  
Node status    
Node negative 56 168646± 1530096 0.28 
Node positive 3 986± 9861  
Differentiation    
High 9 1305± 1299  
High-Med 10 17158+118016  
Medium 53 12778± 5732 0.056（Medium&High） 
Med-low 59 168403±1454345  
Low 10 1767± 1226 0.8（Low&High） 
Histology    
Adeno 61 82114± 65598  
Ductal 6 22796± 22739 0.39 
Others 10 26053± 24104 0.42 
TNM staging    
1-2 114 20490± 6680 0.0034 
3-4 19 519± 226  
Clinical outcomes    
Dead 108 99489±795413 0.28 
Alive 33 13124±73627  
Metastasis    
Yes 10 614±338 0.2 
No 139 80512±61835  
Note: There are 223 pairs of tumours and adjacent normal pancreatic tissues in the cohort of pancreatic 
tissues from Beijing Cancer Hospital. The quantitative analysis of Kidins220 transcripts in those tissues is 
shown above. The number of samples in each category is different subject to availability of both 
corresponding clinicopathological information and valid Kidins220 quantification. For example, the node 
status, 89 patients in the collection did not have lymph node involvement, but only 56 patients had valid data. 
On the other hand, 6 patients had lymph node involvement, but only 3 patients presented valid data. For 
histology, 192 patients were diagnosed with adenocarcinoma, but only 61 samples had valid data; 8 patients 
had ductal carcinoma, and 6 samples presented with valid data. For other histological types, 10 of the 21 
samples presented valid data. 
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To examine the protein expression of Kidins220, immunohistochemical 
staining was performed on a pancreatic adenocarcinoma tissue microarray which 
has dual cores for each sample including primary tumours, adjacent normal 
pancreatic tissues, metastases, benign tumours, pancreatic tissues of 
inflammatory diseases and normal pancreatic tissues. Summative information of 
this TMA can be seen in the Table 3.2. Presence of cancerous cells was verified by 
the pathologists (PG and NB) on the TMA slide with a reference of corresponding 
H&E staining (Appendix 2). The IHC scoring did not show a significant difference of 
Kidins220 staining in pancreatic tumours compared with adjacent normal tissues 
and normal pancreatic tissues (Figure 3.1). Nevertheless, further analysis assessing 
intensity of the staining, using semi-quantification, demonstrated malignant 
tumours exhibited weaker immunointensity of Kidins220 in comparison with 
adjacent normal pancreatic tissues (p<0.001) and normal pancreas (p<0.01) 
(Figure 3.2 B). Representative images of each group can be seen in Figure 3.2 C. 
Furthermore, in a tumour tissue under a magnification of X400, as a 
transmembrane protein Kidins220 exhibited an immunoreactivity which was more 
condensed on joining borders between cells rather than in the intracellular area 
particularly the nuclei (Figure 3.3).  
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Table3.2: Summative information of pathology diagnosis of TMA. 
 
Histological characteristic Number of samples 
Normal pancreatic tissue 10 
Adjacent normal pancreatic tissue 21 
Pancreatic ductal adenocarcinoma 42 
Pancreatic adeno squamous 
carcinoma 
3 
Pancreatic islet cell carcinoma, 1 
Pancreatic metastatic carcinoma 6 
Pancreatic islet cell tumour 10 
Pancreatic inflammation 11 
 
 
 
 
 
 
 
 
 
 
 
 
  
136 
 
Figure 3.1: Scoring assessment of Kidins220 IHC. Shown is the IHC scoring of 
Kidins220 in pancreatic tumour tissues, adjacent normal tissues, and normal 
tissues on the TMA (PA2081a, Biomax, Maryland, US). The IHC scoring was 
calculated based on the assessment of both distribution and intensity of Kidins220 
staining by two pathologists (PG and NB). IHC score = intensity score (0-3) × 
distribution score (0-5).  
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Figure 3.2: Transcript and protein Expression of Kidins220 in pancreatic tumour 
tissues and normal tissues at mRNA and protein levels. (A) The levels of Kidins220 
transcripts were reduced in pancreatic tumours compared with the adjacent 
normal tissues. Shown are average transcript levels of Kidins220 per 50ng RNA and 
error bars represent standard error of mean. (B) The expression of Kidins220 
protein in pancreatic cancer was assessed in a tissue microarray (PA2081a, Biomax) 
using IHC. Kidins220 protein showed decreased expression level in pancreatic 
tumour tissues compared with adjacent normal control and normal pancreatic 
tissues (pancreatic tumour versus adjacent normal control, ***p<0.001; 
pancreatic tumour versus normal tissue, **p<0.01.  (C) Representative images of 
IHC staining in the TMA; a-b are normal pancreatic tissues; c-d are adjacent 
pancreatic tissues; e-f are malignant tumour tissues; g is the negative control using 
an endogenous peroxidase H2O2. Images were captured at x200 objective 
magnification. 
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Figure3.3: Representative images of detection of Kidins220 expression in 
malignant tumour. (A) Expression of Kidins220 in tumour X200 magnification. (B) 
Corresponding magnification at X400, indicating that Kidins220 immunoreactivity 
is more concentrated on the membranes with a stronger staining at the joint 
borders between cells. 
 
3.3.2 Kidins220 expression and tumorigenesis of pancreatic cancer 
The initial assessment showed a reduced expression of Kidins220 in pancreatic 
cancer. This led to a question of whether this molecule is involved in the 
tumorigenesis of pancreatic cancer. To answer this, an analysis of Kidins220 
expression in benign lesions proceeding onto cancerous lesions and invasive 
adenocarcinomas was performed, using gene expression array data (GDS3836) 
(Hiraoka et al., 2011). It included normal pancreatic tissues (n=7), intraductal 
papillary-mucinous adenoma (IPMA, n=6), intraductal papillary-mucinous 
carcinoma (IPMC, n=6) and Invasive cancer originating in intraductal papillary-
mucinous neoplasm (IPMN, n=3). As shown in Figure 3.4A, a trend of reduced 
expression of Kidins220 was observed in lesions which occurred during the 
tumorigenesis of pancreatic cancer from IPMA, IPMC, and invasive cancer 
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originating in IPMN compared with normal pancreas. Among which, a decreased 
Kidins220 expression was seen in invasive cancer originating in IPMN compared 
with normal pancreatic tissues (p<0.001). There was also a significantly reduced 
expression of Kidins220 in invasive cancer originating in IPMN compared with 
IPMC (p<0.01). The lowest expression was seen invasive cancer originating in 
IPMN samples. Another individual comparison between invasive cancer 
originating in IPMN and IPMA did not show statistical significance in difference 
between them. Furthermore, the semi-quantification of Kidins220 IHC staining on 
the TMA showed that malignant tumours had the lowest expression of Kidins220 
compared with normal pancreas, inflammation pancreas, and benign tumour 
(Figure 3.4B). Lower expression of Kidins220 was also seen in benign tumours 
compared with inflammation, however, this result was not found to be statistically 
significant. The representative images are shown in Figure 3.4C. Interestingly, a 
much stronger staining of Kidins220 was observed in pancreatic tissues with 
inflammatory disorders compared with normal pancreatic tissue, benign tumours 
and malignant tumours. Normal pancreas also presented a stronger staining of 
Kidins220 compared with benign tumours and malignant tumours (Figure 3.4B). 
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Figure 3.4: Implication of Kidins220 in development of pancreatic cancer. (A) 
Aberrant expression of Kidins220 can be seen in different lesions during 
development of pancreatic cancer. The lowest expression of Kidins220 was shown 
in invasive cancer originating in IPMN (Invasive IPMN) compared with normal 
pancreas, IPMA, IPMC in a cohort of 145 primary pancreatic ductal 
adenocarcinomas and 46 pancreas tissues (GDS3836). The classification of 
different types of neoplasia used in the study was an older system of pathological 
classification of pancreatic neoplasms. (B) IHC of Kidins220 on the pancreatic TMA 
(PA2081a, Biomax) showed reduced protein expression in pancreatic cancers 
compared with normal pancreas (**p<0.01), Inflammation (**p<0.01), and benign 
tumours (*p<0.05). (C) Representative images of IHC in TMA from different 
pathological types.  a-b: Normal pancreas; c-d: Inflammation; e-f: benign tumour; 
g-h: malignant tumour. Images were captured at x200 objective magnification. 
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3.3.3 Kidins220 and disease progression 
Further exploration was carried out on the involvement of Kidins220 in disease 
progression of pancreatic cancer. In terms of TNM staging, more advanced 
tumours which developed lymph node and/or distant metastases including TNM3 
and TNM4 exhibited lower transcript levels of Kidins220 compared with tumours 
at earlier stages including TNM stage 1 and 2 (p=0.0034) (Figure 3.5A). It indicated 
a link between reduced expression of Kidins220 and distant metastasis. After a 
search of gene expression array data, a dataset comprising primary tumours 
(n=146) and distant metastases (n=62) was chosen for analysis. The distant 
metastases showed a decreased expression of Kidins220 compared with the 
primary tumours (p<0.05) (GSE71729) (Figure 3.5B). The IHC results also presented 
that primary tumours with distant metastasis exhibited a decreased level of 
Kidins220 protein expression compared to those without metastasis. Since only 
two such samples were available on the TMA, statistical comparison did not show 
a significant link (Figure 3.5C). The same trend was also seen in IHC scoring, which 
showed a lower score in primary tumours with metastasis compared to tumours 
without metastasis (Figure 3.6). The representative slides chosen from the TMA 
presented a stronger staining in primary tumours without metastasis compared 
with pancreatic tumours with metastasis (Figure 3.5D). Moreover, whether the 
deregulated expression of Kidins220 in pancreatic cancer played a role in 
prognosis was then investigated. A Kaplan Meier survival analysis was performed 
using a gene expression array dataset (GSE71729) which has follow up data. The 
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analysis showed that the reduced expression of Kidins220 was associated with 
shorter overall survival (p=0.02) (Figure 3.7).  
 
Figure 3.5: Kidins220 and disease progression of pancreatic cancer. (A) The levels 
of Kidins220 transcripts were determined in a cohort of pancreatic cancer using 
QPCR. Shown are Kidins220 transcript levels (mean ± standard error of mean) in 
pancreatic tumours of early stages (TNM1 and TNM2) compared with advanced 
stages (TNM3 and TNM4) according to TNM staging. ** represent p<0.01. (B) 
Kidins220 transcript levels in distant metastases of pancreatic cancer compared 
with primary tumours were also analysed using a gene expression array data 
(GSE71729). * represents p<0.05. (C) Protein expression of Kidins220 in primary 
tumours at the most advanced stage, i.e. with distant metastases was also 
analysed in the pancreatic TMA (PA2081a, Biomax). Shown are intensity of 
Kidins220 IHC.  (D) Representative images of the IHC staining of Kidins220; a and 
b: primary tumours without metastases; c and d are primary tumours with 
metastases. Images were captured at x200 objective magnification. 
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Figure 3.6: IHC scoring of Kidins220 staining in the development of pancreatic 
cancer. The scores were determined depending the distribution and staining 
intensity of Kidins220. Primary tumours with metastases had a lower IHC score in 
comparison with primary tumours without distance metastases (p=0.1828). 
However, the difference was not statistically significant. 
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Figure 3.7: Kidins220 expression and overall survival of patients with pancreatic 
cancer. Correlation between Kidins220 expression (mRNA) and overall survival of 
patients with pancreatic cancer was analysed in the gene expression array data 
(GSE71729) using Kaplan-Meier survival analysis (SPSS version 23). Median of 
Kidins220 expression value was used as a cut-off value. 
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3.4 Discussion 
Despite recent studies demonstrating the role of Kidins220 in neurotrophin 
response, emerging evidence has suggested the importance of Kidins220 in neural 
diseases and human cancer which was recently reviewed (Cai et al., 2017). An 
overexpression of Kidins220 was initially detected in primary malignant 
melanomas compared with benign tumours (Liao et al., 2007). The expression of 
Kidins220 in a panel of different malignancies (The Cancer Genome Atlas, 
https://cancergenome.nih.gov/) was initially analysed using an online analysis tool 
(Firebrowse Gene Expression Viewer, http://firebrowse.org/). An altered 
expression level of Kidins220 was present in different cancer types compared with 
relevant normal controls (Figure 3.8A), and details of aberrant expression in 
malignancies are listed in Table 3.3. However, no obvious change of Kidins220 
expression was noticed in this TCGA cohort which might be due to the small 
number of normal tissues (n=4) (Figure 3.8B). In our current study, reduced levels 
of Kidins220 transcripts were observed in pancreatic tumours (n=149) compared 
with paired adjacent normal pancreatic tissues (n=145) in a pancreatic cancer 
clinical cohort collected at the Beijing Cancer Hospital. Its protein expression in 
pancreatic cancer was then examined using immunohistochemical staining of 
Kidins220 in a pancreatic TMA (PA2081a, Biomax).  
The IHC scoring conducted by pathologists did not show any significant change 
of Kidins220 staining in malignant tumours in comparison with normal pancreas. 
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Furthermore, we determined the intensity of Kidins220 staining in cancerous cells 
by a subtraction of background from empty area on the same image, and we found 
there was a significant decreased expression of Kidins220 in malignant tumours 
compared with adjacent normal tissue and normal pancreases. Taken together, 
the results suggested that a contrasting role might be played by Kidins220 in 
pancreatic cancer compared with the previously identified functions of this 
molecule in melanomas. However, further investigation should be performed to 
validate this finding, particularly for its protein expression assessment. An 
improvement should be made in optimising the Kidins220 antibodies and 
enhancing the accuracy for IHC assessment. Validation of the altered expression 
of Kidins220 in pancreatic cancer should also be performed in a larger clinical 
cohort of pancreatic cancer patients. 
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Figure 3.8: mRNA sequence expression level of Kidins220. (A): overview of 
Kidins220 expression in different types of cancer compared with normal control.  
(B): The total numbers and median of tumour and normal sample in pancreatic 
adenocarcinoma. Cancer types are: adrenocortical carcinoma (ACC), bladder 
urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous 
cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma 
(CHOL), colon adenocarcinoma (COAD), colorectal adenocarcinoma (COADREAD), 
lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), oesophageal carcinoma 
(ESCA), glioblastoma multiforme (GBM), glioma (GBMLGG), head and neck 
squamous cell carcinoma (HNSC), kidney chromophobe (KICH), pan kidney cohort 
(KIPAN, including KICH, KIRC and KIRP), kidney renal clear cell carcinoma (KIRC), 
kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain 
lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung 
adenocarcinoma (LUAD), mesothelioma (MESO), ovarian serous 
cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), 
pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), 
rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma 
(SKCM), stomach adenocarcinoma (STAD), stomach and oesophageal carcinoma 
(STES), testicular germ cell tumour (TGCT), thyroid carcinoma (THCA), thymoma 
(THYM), uterine corpus endometrial carcinoma (UCEC) and uveal melanoma 
(UVM). 
 
 
  
148 
Table 3.3: Aberrant expression of Kidins220 in malignancies. 
 
 
Note: Summative information is prepared from an analysis of TCGA data using the 
Firebrowse (http://firebrowse.org/). 
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In order to determine whether the expression of Kidins220 is related to the 
tumorigenesis of pancreatic cancer, analysis of its expression in different lesions 
during tumorigenesis was performed which included the normal pancreas, IPMA, 
IPMC, and invasive cancer originating in IPMN. IPMN is one of the morphologically 
distant precursors of pancreatic adenocarcinoma (Patra et al., 2017). Based on the 
gene array data, the lowest expression of Kidins220 was seen in the invasive 
cancer originating in IPMN when compared with IPMC and normal pancreas. 
Kidins220 has been shown to be involved in the differentiation of neuroblastoma 
through maintaining the morphology of N-type cells, the phenotype with invasive 
characteristics (Rogers and Schor, 2013a). Several types of cancer have been 
related to inflammatory origins, such as colorectal cancer, gastric cancer, and 
bladder cancer (Farrow and Evers, 2002). Patients with hereditary pancreatitis and 
chronic pancreatitis have 53 times risk and 17 times for developing pancreatic 
cancer respectively compared with patients without pancreatitis (Lowenfels et al., 
1993, Whitcomb et al., 1999). In the current study, the semi-quantification of 
Kidins220 IHC did not show any change of its protein expression in the pancreatic 
tissues of inflammatory disorders compared with normal tissues. However, due to 
the size of the cohort, the observation should be validated in a large cohort of 
pancreatic tissues collection. K-ras mutations, loss of p53 and SMAD are important 
factors during tumorigenesis of pancreatic cancer, and mutations of K-ras and 
SMAD have been found in chronic pancreatitis (Rozenblum et al., 1997) (Popovic 
Hadzija et al., 2007). The correlation between Kidins220 and these factors 
150 
contributes to the tumorigenesis of pancreatic cancer and needs to be further 
investigated.  
Kidins220 expression was upregulated in metastatic melanoma in comparison 
with benign tumours (Liao et al., 2007). In the current study, we found primary 
tumours with distant metastasis exhibited a reduced immunointensity of 
Kidins220 rather than those without metastasis, and a decreased expression level 
of Kidins220 in the distant metastases of pancreatic cancer compared with 
primary tumours according to the analysis of the gene array data (GSE71729). 
Furthermore, by contrast, melanoma tissues with nodal metastasis had a stronger 
expression of Kidins220 in comparison with those without nodal metastasis, and 
also the stronger expression of Kidin220 was also present in melanoma when 
tumour thickness was more than 1.0mm (Liao et al., 2011a). The different 
expression pattern of Kidins220 in melanoma and pancreatic cancer may be a 
result of different signalling pathways involved. Since pancreatic cancer patients 
are always diagnosed at late stage where cancer cells are often locally invasive or 
spreading to other parts of the body, pancreatic cancer commonly have a poor 
prognosis and lower survival rate (Ryan et al., 2014). TNM is used for classifying 
the extent of cancer spread and helps to evaluate the prognosis of cancer patients 
(Sobin and Fleming, 1997). The association between Kidins220 and disease 
progression was determined in the Beijing clinical cohort by analysing its 
expression in pancreatic cancer tumours according to their TNM staging. This 
showed that more advanced tumours in the late stage (TNM3 and TNM4) had a 
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decreased Kidins220 expression in comparison with tumours at early stages of the 
disease (TNM1 and TNM2).  Moreover, the reduced Kidins220 expression is also 
related to a shorter overall survival of patients with pancreatic cancer, indicating 
an important role played by Kidins220 in the prognosis of pancreatic cancer.  
Taken together, the results show that the expression of Kidins220 is reduced 
in pancreatic cancer. The reduced expression may occur during the tumorigenic 
process of pancreatic cancer. This is associated with the disease progression and 
poor prognosis, i.e. a shorter overall survival. Current findings suggest that 
Kidins220 has prognostic potential for pancreatic cancer. Furthermore, the 
findings from our initial analyses of Kidins220’s expression in pancreatic cancer led 
to a further investigation for its function in pancreatic cancer cells. This will help 
to answer the questions; ‘why is Kidins220 downregulated in pancreatic cancer?’ 
and ‘How does it elicit a protective effect during the development and progression 
of pancreatic cancer?’. 
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Chapter 4 
Influence of Kidins220 
knockdown on cellular functions 
of pancreatic cancer cell lines  
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4.1 Introduction 
In the initial investigation, reduced expression of both Kidins220 transcript and 
protein was evident in human pancreatic cancer. The down-regulation of 
Kidins220 may occur at an early stage during the tumorigenesis as such a trend 
was observed in IPMA, IPMC and Invasive cancer originating in IPMN. Furthermore, 
pancreatic cancer patients with lower expression of Kidins220 have a shorter 
overall survival, suggesting its implication in the prognosis of the disease. However, 
previous studies of Kidins220 in other malignancies revealed an oncogenic effect, 
such as in melanoma and neuroblastoma (Jung et al., 2014, Liao et al., 2007, Liao 
et al., 2011a, Rogers and Schor, 2013b). The different expression pattern of 
Kidins220 in pancreatic cancer suggest that it may have different functions in the 
pancreas and pancreatic cancer which is yet to be investigated. 
The fundamental abnormality that contributes to cancer development is 
caused by the continual unregulated proliferation of cancer cells. Normal cells 
respond to internal and external signals appropriately. The balance between 
proliferation and senescence/apoptosis ensures the homeostasis of tissues and 
organs. However, cancer cells exhibit aberrations in these signals, growing and 
dividing in an uncontrolled manner (Hanahan and Weinberg, 2011).  
Cancer cells can also metastasise from the primary site to spread throughout 
the body and progressively colonise distant organs (Steeg, 2016). The tumour cells 
broadly undergo three main processes in a metastatic cascade; invasion, 
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intravasation and extravasation. The process of invasion occurs when tumour cells 
dissociate from the primary tumour mass and invade the surrounding tissue 
through an alteration of cell-matrix interaction and degradation of extracellular 
matrix. The tumours cells may subsequently disseminate through blood or lymph 
vessels to distant organs (Tracey A. Martin, 2013). Cancer metastasis remains the 
major cause of cancer-related death (Guan, 2015). Therefore, the cellular and 
molecular machinery underlying cancer metastasis has been a pivotal part of 
cancer research. Metastasis is a multiple-step procedure that requires 
proliferation, adhesion, invasion, and migration of cancer cells, orchestrated 
through various molecules and pathways. Study of the cellular and molecular 
aberrations occurring in cancer cells could permit identification of new markers 
and targets for diagnosis and treatment.  
The present study revealed a reduced expression of Kidins220 in pancreatic 
cancer, indicating that it may act as a tumour suppressor in disease progression of 
pancreatic cancer. Considering the different expression pattern of Kidins220 in 
other types of cancer in comparison with our findings in pancreatic cancer, 
together with its role in the regulation of cellular function in other malignancies, 
we aimed to examine whether Kidins220 has a very different function in 
pancreatic cancer cells, thus contributing to the development of pancreatic cancer. 
A Kidins220 knockdown cell model was employed to examine the corresponding 
effect on cellular functions of pancreatic cancer cells, including cell proliferation 
(2D&3D culture), adhesion, invasion, and migration using various in vitro assays.  
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4.2 Materials and methods 
4.2.1 Cell lines 
Panc-1, Mia paca-2, and ASPC-1 pancreatic cancer cell lines were used in the 
current study. All these cancer cell lines were cultured in DMEM medium with 10% 
FBS and antibiotics and described in Chapter2.  
 
4.2.2 Silencing of Kidins220 using ribozyme transgene 
Anti-Kidins220 ribozyme transgenes have been constructed and tested in a pilot 
study. After plasmid amplification and extraction, the ribozyme plasmids were 
transfected into pancreatic cancer cells using electroporation. The transfected 
cells were selected with 5µg/ml blasticidin and maintained with 0.5µg/ml 
blasticidin. Knockdown of Kidins220 in the transfected cells was determined using 
both RT-PCR and western blot. 
 
4.2.3 Generation of Kidins220 lentivirus shRNA transgenes 
Lentivirus shRNA (shRNA2, shRNA3 and shRNA6) targeting Kidins220 was obtained 
from Cyagen Biosciences (CA, USA). After amplification and purification, plasmids 
containing lentiviral shRNA or scramble control, together with lentiviral packaging 
plasmids (psPAX2) and envelope plasmid (pMD2.G) were transfected into HEK-
293T cells respectively, to generate lentiviral particles.  The lentiviral particles 
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carrying either Kidins220 shRNA or scramble shRNA were then used to infect 
target cells, respectively. The scramble shRNA was employed as a control for the 
following experiments. After a selection using 500ng/ml G418, knockdown of 
Kidins220 was verified using both RT-PCR and western blot. Full details of the 
cloning process have been provided in section 2.6. The stable Panc-1 and Mia 
paca-2 sublines and corresponding scramble control cells were maintained in the 
same medium and supplemented with 100μg/ml G418. 
 
4.2.4 RNA isolation, cDNA synthesis, RT-PCR, and QPCR 
RNA was extracted using a Tri Reagent kit (Sigma-Aldrich, Poole, Dorset, UK), and 
cDNA was then converted using the the GoScriptTM Reverse Transcription System 
kit as described in section 2.4. RT-PCR was carried out using the following 
conditions; 94˚C for 5 minutes, followed by 94˚C for 30 seconds (30 to 42 cycles), 
56˚C for 30 seconds, and 72˚C for 1 minute and a final extension of 7 minutes at 
72˚C. The PCR products were separated on an agarose gel and stained using 
SYBR®Safe DNA gel stain (Invitrogen, Paisley, UK). 
 
4.2.5 Protein extraction, SDS-PAGE, and western blot analysis 
Proteins were extracted using lysis buffer and then quantified using the Bio-Rad 
DC Protein Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK). Proteins were 
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transferred onto PVDF membranes after separation in the SDS-PAGE gel, and 
subsequently blocked and probed with anti-Kidins220 primary antibody and a 
corresponding peroxidise-conjugated secondary antibody. Information on the 
antibodies used in this study is provided in Table 2.5. The protein bands were 
eventually visualised using the chemiluminescence detection kit (Luminata, 
Millipore). 
 
4.2.6 In vitro cell growth assay 
3,000 cells were seeded into 200μl medium in three 96-well plates, and incubated 
for 1, 3, and 5 days respectively. Following incubation, the cells were fixed and 
stained with crystal violet. The absorbance was measured after dissolving the 
crystal violet with acetic acid (10% v/v) and the absorbance was determined at a 
wave length of 540nm using a spectrophotometer (BIO-TEK, Elx800, UK). 
 
4.2.7 In vitro cell adhesion assay 
The cells were seeded into a 96-well plate pre-coated with Matrigel (5μg/well) as 
described in section 2.7.2. The cells were left to adhere over a period of 40 minutes, 
before being fixed and stained with crystal violet. The adhered cells were then 
counted. 
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4.2.8 In vitro cell invasion assay 
20,000 cells were seeded into transwell inserts (pore size, 8μm) coated with 50μg 
Matrigel followed by an incubation of three days. After the incubation, cells that 
had invaded through the Matrigel and migrated on to the other side of the insert 
were fixed and stained with crystal violet, and then counted. 
 
4.2.9 In vitro transwell migration assay 
20,000 cells were seeded into transwell inserts (pore size, 8μm) in a 24-well plate.  
After 24-hour incubation, the cells that had migrated through and moved onto the 
other side of the insert were fixed with 4% formaldehyde and stained with crystal 
violet. Cells which had migrated were then counted. 
 
4.2.10 In vitro tumour spheroid assay 
1,000 cells were seeded into 200μl DMEM medium into 96-well non-coated U-
shape bottom 3D culture plate (Greiner Bio-One, Ltd. Stonehouse, UK). The cells 
were incubated for a period up to two weeks. Images were taken every three days 
to monitor tumour growth. Culture media was topped up every two or three days. 
Size of the spheroids was measured using ImageJ software.  
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4.2.11 In vivo peritoneal metastasis assay 
Athymic nude mice (CD1) were purchased from Charles River Laboratories 
(Charles River Laboratories International, Inc., Kent, UK). All the mice were kept in 
filter-topped isolation cages and all the procedures were carried out in a class-II 
cabinet. The study was conducted under the Home Office Project licence (PPL: 
PE944FC2). After the mice were settled for a week in the designated laboratory, 
Panc-1 scramble and Kidins220 knockdown cells were injected into the peritoneal 
cavity of the mice at a volume of 100µl which contained Matrigel at final 
concentration of 2.5mg/ml in PBS. The mice were then carefully monitored twice 
a week by measuring body weight. The intraperitoneal exploration was conducted 
after 4 weeks. Metastatic nodules were photographed using a stero-microscrope 
(Olympus, Japan) and the volume of metastatic tumours were calculated by using 
the following formula:  
Tumour volume (mm3)= 0.5× Width2×Length.  
 
4.3 Results 
4.3.1 Kidins220 expression and the knockdown of Kidins220 in pancreatic cancer 
cell lines 
The expression of Kidins220 was detected in three pancreatic cancer cell lines 
originated from human carcinoma including Panc-1, Mia paca-2, and ASPC-1. 
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Panc-1 was derived from an epithelioid carcinoma of the pancreas while Mia paca-
2 was isolated from a pancreatic carcinoma, and ASPC-1 was derived from 
metastatic ascites of a pancreatic adenocarcinoma. Kidins220 transcripts in the 
three pancreatic cancer cell lines were determined using RT-PCR. Overall, 
Kidins220 is generally expressed in all three cancer cell lines, although the 
expression levels displayed differences between the cell lines. A higher expression 
of Kidins220 was seen in Panc-1 and ASPC-1 cancer cells compared with Mia paca-
2 (Figure 4.1A). All these three cell lines were included in preliminary experiments 
for knockdown of Kidins220.  
Initially, anti-Kidins220 ribozyme transgenes were used to knockdown 
Kidins220. However, due to the low transfection efficiency and the difficulties in 
the selection with blasticidin, a satisfactory knockdown of Kidins220 was not 
achieved in pancreatic cancer cell lines. Ribozyme transfection relies on the 
electroporation and lipo transfection and the structure of cell membrane can be 
impacted during these processes. The cells became very sensitive to the selective 
antibiotics and this resulted in poor rates of survival. Afterwards, knockdown of 
Kidins220 using lentiviral Kidins220 shRNA (shRNA2, shRNA3 and shRNA6) was 
conducted in Panc-1, Mia paca-2, and ASPC-1 pancreatic cancer cell lines. Initial 
tests showed that a knockdown of Kidins220 in Panc-1 and Mia-paca-2 but not in 
ASPC1. The knockdown of Kidins220 in both Panc-1 and Mia-paca-2 cell lines was 
then verified using both RT-PCR (Figure 4.1 B) and Western bolt (Figure 4.1 C).  
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Figure 4.1: Kidins220 expression in pancreatic cancer cell lines and knockdown 
of Kidins220 in Panc-1 and Mia-paca-2. (A) The mRNA expression of Kidins220 in 
pancreatic cancer cell lines (Panc-1, ASPC-1, and Mia paca-2) was examined using 
conventional PCR. PCR water was used as a negative control to exclude any 
contamination in the PCR reactions, and GAPDH was employed as a house-keeping 
control. (B) Expression of Kidins220 mRNA in Panc-1 and Mia pca-2 pancreatic 
cancer cells infected with Kidins220 lentiviral shRNA particles were determined 
using RT-PCR. (C) The verification of Kidins220 knockdown at protein level in the 
Panc-1 and Mia paca-2 pancreatic cancer cells was performed using western bolt. 
β-actin was employed as a loading control.   
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4.3.2 Effect of Kidins220 on proliferation of pancreatic cancer cells  
Deregulated and un-controlled cellular proliferation is an important trait of cancer 
cells. The impact of Kidins220 knockdown on proliferation of these two pancreatic 
cell lines was first evaluated using the in vitro growth assay. The knockdown of 
Kidins220 resulted in an increasing proliferation in both cell lines but to variable 
levels (Figure 4.2). A marginal increase of proliferation was seen in the Panc-1 cells 
following the Knockdown of Kidins220 at Day 5 compared with the scramble 
control with the difference statistically significant (p<0.05) (Figure 4.2A). Similarly, 
in the Mia paca-2 cells, the cells with Kidins220 knockdown exhibited a significant 
increase of cell proliferation compared to control as seen in Figure 4.2B.  
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Figure 4.2: Knockdown of Kidins220 has a significant increase in the growth of 
the Panc-1 and Mia paca-2 cells. Cells were incubated for 1, 3, and 5 days 
respectively. Six repeats were included for each cell lines on each plate. Growth 
rate (%) was calculated using the following formula; growth rate (%) = Absorbance 
(Day X) / Absorbance (Day 1) × 100. Shown are representative results of one 
experiment out of three performed. Error bars represent standard deviation. * 
represents p<0.05 and ** represent p<0.01, respectively. 
 
  
164 
4.3.3 Effect of Kidins220 on adhesion of pancreatic cancer cells 
Adhesion mediated by adhesion molecules, such as integrins is a critical cellular 
event for cancer cells to interact with the local environment and also for their 
migration and invasion during the local invasion and distant dissemination. As 
aforementioned, the association between reduced expression of Kidins220 in 
pancreatic cancer and disease progression suggests a possible role of this protein 
in the regulation of adhesion, migration and invasion. Following the in vitro 
proliferation test, the influence on cell-matrix adhesion was assessed using a 
Matrigel, comprising collagen 4 and laminin being similar to the major 
components of the basal membrane underlying epithelial cells, adhesion assay. 
The Kidins220 knockdown cell lines including both Panc-1 and Mia paca-2 
exhibited enhanced adhesion to the Matrigel in comparison with their 
corresponding scramble controls (Figure 4.3). The increase in adhesiveness was 
approximately 2-4 folds in both cell lines compared with the control. 
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Figure 4.3: Impact on adhesion of Panc-1 and Mia paca-2 pancreatic cancer cells 
by the knockdown of Kidins220. (A) There was a significant increase in cell 
adhesion in the Kidins220 knockdown cells compared with scramble control in 
Panc-1 cells (*** p<0.001). (B) Adhesion of Mia paca-2 cancer cells was also 
enhanced following the knockdown of Kidins220 compared with the scramble 
control (*** p<0.001). Six repeats were included for each cell line in the 
experiment. Three experiments were carried out to validate the observations. 
Error bars are standard deviations. Representative images of each cell line are 
shown above the bar graph. 
 
 
 
 
 
 
 
 
 
 
 
 
  
166 
4.3.4 Influence of the Kidins220 knockdown on cell invasion of pancreatic cancer 
cell lines  
Cancer cells invading into surrounding tissue and the vasculature is an initial step 
during cancer metastasis (Yamaguchi et al., 2005). In order to investigate whether 
Kidins220 is involved in regulation of invasiveness of pancreatic cancer cells, an in 
vitro trans-well invasion assay was performed. The invasive ability of cells was 
determined by measuring the number of cells that invaded through the Matrigel 
and also the membrane onto the bottom of the insert. Figure 4.4A shows that 
Panc-1 cells with knockdown of Kidins220 significantly increased in invasiveness 
compared with scramble control (**p<0.01) (Figure 4.4A). Meanwhile, knockdown 
of Kidins220 also promoted the invasive capacity of Mia paca-2 cancer cells in 
comparison with scramble cells (**p<0.01) (Figure 4.4 B).  
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Figure 4.4: Knockdown of Kidins220 increases the invasive capacity of both Panc-
1 and Mia paca-2 cell lines. (A) Representative images of Panc-1 cells after staining 
(upper panel) and the absorbance measured by dissolving the crystal violet stained 
invaded cells (bar graph). ** represent p<0.01. (B)  Representative images of Mia 
paca-2 invaded cells (upper panel) and bar graph shows the measurement of 
absorbance of stained cells.  ** represent p<0.01. Three experiments were 
performed. Error bars represent standard deviation. 
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4.3.5 Effect of Kidins220 on the migration of pancreatic cancer cells 
During cancer metastasis, cancer cells migrate and spread to distant organs and 
form a new mass. In the current study, a trans-well migration assay was used to 
assess the impact of Kidins220 knockdown on the migration of pancreatic cancer 
cells. This assay is similar to the transwell invasion but with a lack of Matrigel 
coating in the insert. The ability of cell migration was determined by measuring 
the number of cells which had migrated to the bottom of the insert from the upper 
culture chamber over a period of 24 hours. The result showed that there was 
significantly enhanced cell migration in Panc-1 and Mia paca-2 pancreatic cancer 
cells as a result of the Kidins220 knockdown. After 24 hours incubation, Kidins220 
knockdown Panc-1 cells exhibited an increased migration in comparison with the 
scramble control (p<0.001) (Figure 4.5 A). This result was also in accordance with 
a measurement of cell migration using wound (scratch) assay in Panc-1 cells using 
the IncuCyte Live-Cell Analysis System (Essen Bioscience, UK). The migration of 
cells was monitored over a period of 2 days following the wounding. It was shown 
that Panc-1 cells with knockdown of Kidins220 migrated faster compared with the 
scramble control cells (Figure 4.5B and Figure 4.5 C). Furthermore, an increase in 
migration was also seen in the Mia paca-2 Kidins220 knockdown cells compared 
with the scramble control (p<0.01) (Figure 4.6).  
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Figure 4.5: Influence of Kidins220 knockdown on the migration of Panc-1 cells. 
(A) Migration of Panc-1 cells was determined using a transwell migration assay, 
representative images of migrated cells are shown above the bar graph.  *** 
represent p<0.001. Error bars are standard deviation. (B) A wound assay was also 
performed using the IncuCyte live cell analysis system. Four repeats were 
evaluated for each cell line in each experiment. Shown are the average percentage 
of the closure of the wounds, the migration was measured in wound density. Error 
bars represent standard deviation. (C) The representative images were taken by 
the IncuCyte live cell analysis system over the first 48 hours following the 
wounding. 
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Figure 4.6: Influence of Kidins220 knockdown on migration of Mia paca-2 cells. 
The migration of Mia paca-2 cells was determined using the transwell migration 
assay. ** represent p<0.01. Error bars are standard deviation.  
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4.3.6 Effect of Kidins220 on tumour spheroid  
Tumour spheroids usually contain a high concentration of stem-like cancer cells 
(Nath and Devi, 2016). This is the reason that the sphere formation is closely 
related with cancer recurrence and metastasis. 3D culture mimics a sphere 
formation procedure, which results in enrichment of the cancer cells expressing 
stem –like markers. In order to monitor the impact of Kidins220 in the growth of 
tumour spheroids, the solidity and circularity was determined. Figure 4.7 shows 
representative optical images of spheroids in Panc-1 cells with knockdown of 
Kidins220 and scramble control. The images were captured every 3 days. The 
morphological changes involved several stages during spheroid formation. Initially, 
single suspending cells assembled themselves to form cell aggregates in each well 
(day 1). Subsequently, tumour spheroid in Panc-1 cells with knockdown of 
Kidins220 presented bigger spheroids compared with the scramble control cells at 
the fourth day. At the final stage, the spheroids formed by Kidins220 knockdown 
cells became irregular in comparison with the scramble cells (day10-day13). In a 
similar way, the single and suspended Mia paca-2 cancer cells started to assemble 
themselves and form cell aggregates (day 1). The difference of spheroid solidity 
can be observed from Day4. Mia paca-2 cells with knockdown of Kidins220 
presented bigger spheroids in comparison with scramble control. From Day 7, the 
spheroid became circular in the Kidins220 knockdown cells. At the end of the two 
weeks experiment, the Kidins220 knockdown Mia paca-2 cells grew into much 
bigger spheroids compared with the scramble control (p<0.001) (Figure 4.8).   
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Figure 4.7: Growth of Kidins220 knockdown Panc-1 cells was examined using a 
3D spheroid model. 1,000 Panc-1 cells were seeded in the 96-well U-bottom 
plates. Representative images of Panc-1 spheroids were photographed using the 
EVOS Auto imaging system (Thermo Fisher Scientific, Waltham, MA USA) at the 
indicated time over a period of two weeks. Size of the spheroids was measured 
using Image J software. Each cell line was tested in triplicate. Three experiments 
were performed. Shown are representative images and results. Error bars are 
standard deviations. * represents p<0.05 and ** represent p<0.01. 
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Figure 4.8: Growth of the Kidins220 knockdown Mia paca-2 cells was also 
examined using the 3D spheroid model. Representative images of Mia-paca-2 
spheroids were photographed using the EVOS Auto imaging system (Thermo 
Fisher Scientific, Waltham, MA USA) at the indicated time over a period of two 
weeks. Size of the spheroids was measured using Image J software. Each cell line 
was tested in triplicate. Three experiments were performed. Shown are 
representative images and results. Error bars are standard deviations. *** 
represents p<0.001. 
 
 
 
 
 
  
174 
4.3.7 Knockdown of Kidins220 promoted peritoneal metastasis in vivo 
Panc-1 pancreatic cancer cells (scramble and shKidins220) were injected into the 
peritoneal cavity of athymic nude mice (n = 6 mice per group). The mice were 
terminated after 4 weeks and intraperitoneal exploration was conducted to detect 
the metastatic tumours in the liver, stomach, pancreas, and duodenum to rectum. 
In the current study, all the metastatic tumours were found in intestine and the 
nodule numbers, total and average tumour volume, body weight, and tumour 
burden of the mice are listed in table 4.1. Knockdown of Kidins220 resulted in an 
increased number of nodules but this lacked statistical significance. Interestingly, 
tumour burden of the mice injected with Kidins220 knockdown Panc-1 cells was 
significantly increased in comparison with scramble control (Figure 4.9). 
Furthermore, there is a significant increase in total tumour volume and average 
tumour volume (Figure 4.10) in mice injected with Kidins220 knockdown cells 
when compared with the control group (p=0.032 and p=0.009 respectively).  
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Table 4.1: The analysis of peritoneal metastatic tumours in mice injected with 
Panc-1 scramble cells and Kidins220 knockdown cells. 
 
 
Scramble 
(mean±SD) 
shKidins220 
(mean±SD) 
P value 
Number of 
nodules 
 
4.17±0.98 
(Median: 4) 
5.33±2.94 
(Median: 5) 
P=0.394* 
Total tumour 
volume 
(mm3/mouse) 
7.68±2.00 20.66±10.86 P=0.032* 
Average tumour 
volume 
(mm3) 
1.87±0.43 4.43±1.58 P=0.009* 
Body weight 22.97±1.07 22.38±0.55 P=0.262# 
Tumour burden 
(mm3/g) 
0.33±0.086 0.92±0.48 P=0.032* 
Note: Different statistical methods were employed; * for which t-test with Welch’s 
correction was used whilst t-test was used for the # labelled data. All data are 
normally distributed. The t-test with Welch’s correction was used for data with 
unequal variation.  
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Figure 4.9: The impact of Kidins220 knockdown on peritoneal metastasis of Panc-
1 cells in a mouse peritoneal metastatic model. Shown are tumour burden of the 
peritoneal metastasis nodules developed in each mouse. The tumour burden was 
determined based on the total tumour volume (mm3) of each mouse against the 
corresponding body weight (g).  *represent p<0.05. 
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Figure 4.10: The influence of Kidins220 knockdown on the average tumour 
volume of peritoneal metastatic nodules developed by Panc-1 cells in the nude 
mouse model. The metastatic tumours volume (mm3) were determined according 
to the equation (length × width2)/2. The length and width of the tumour were 
measured using imageJ. ** represents p<0.01.  
 
 
 
 
 
 
 
 
 
 
  
178 
4.4 Discussion 
Initial investigation demonstrated a reduced expression of Kidins220 in human 
pancreatic cancer tissue samples. The reduced expression is associated with 
disease progression and poor prognosis. This is very different from the 
overexpression of Kidins220 seen in melanoma (Liao et al., 2011a). The 
downregulation of Kidins220 observed in human pancreatic cancer suggests that 
this molecule acts as a negative regulator for the cellular functions that are 
acquired by cancer cells during the disease progression. This could be tissue 
specific or disease specific which is yet to be investigated. Kidins220 has been 
shown to promote proliferation and survival of melanoma cell lines. As seen in a 
mouse xenograft model, knockdown of Kidins220 resulted in an increasing 
population of apoptotic cells compared with control group. Overexpression of 
Kidins220 was able to protect cells from stress-induced apoptosis, whilst 
melanoma cells with Kidins220 knockdown resulted in a decrease in anchorage-
independent growth in soft agar and an extended cell death following an UVB-
induced apoptosis (Liao et al., 2007). Similar to the findings in melanoma, a study 
of Kidins220 in neuroblastoma also showed a positive role played by this molecule 
in the regulation of cell proliferation. Knockdown of Kidins220 in neuroblastoma 
cells induced a decrease of proliferation through an inhibition of cell cycle in which 
an arrest at G1 phase was observed. The inhibitory effect on cell cycle is 
accompanied with decreased expression of cyclin D1 and cyclin-dependent kinase 
4 (CDK4) and inhibition of hyperphosphorylated pRb to which an upregulation of 
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p21 may contribute (Jung et al., 2014). In the current study, three pancreatic 
cancer cell lines were examined for their expression of Kidins220. All three cell 
lines examined expressed this gene but to variable levels. A knockdown model was 
successfully established using Kidins220 shRNA in two of the three cell lines, i.e. 
Panc-1 and Mia paca-2. Due to the lack of an appropriate cDNA library for use in 
the amplification of the Kidins220 coding sequence, consisting of multiple variants 
which are generally expressed, combined with the high cost for synthesis of such 
a long DNA sequence (5316 bps for one of Kidins220 isoforms), the overexpression 
model was not employed in the current study. An increase was seen in the 
proliferation of both Panc-1 and Mia paca-2 cell lines following the knockdown of 
Kidins220. This is in line with the reduced expression of Kidins220 observed in 
pancreatic cancer tumour tissues, this suggests that Kidins220 is a negative 
regulator of proliferation of pancreatic cancer cells although the increase was just 
marginal. Regulation of other cellular functions could be more remarkable and has 
been shown in the following functional tests.  
The unique hallmark of cancer cells is their acquired capability to metastasise. 
The spread of cancer to distant locations is a major complication and commonly 
associated with the death of patients with cancer. It also indicates disease 
progression to a more advanced stage. Metastasis begins when individual cancer 
cell breaks away from the tumour and invade nearby blood vessels and migrate 
through bloodstream, lymphatic system, or through body cavity spaces. Once the 
metastatic cancer cells arrive at a new site, they can begin a process forming a new 
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tumour by leaving the blood vessel, and begin to colonisation and form a 
secondary tumour (Klein, 2008).  
Cellular and molecular mechanisms of cancer metastasis have been 
investigated for several decades. Scaffold proteins has been shown to play an 
important role in cancer development and metastasis due to their critical role in 
maintaining the cell structure through regulation of the cytoskeleton, adhesion 
and migration of cells, and also interactions with certain signalling pathways 
(Bompard et al., 2005, Lin et al., 2005, Yamagishi et al., 2004, Mattila et al., 2003). 
Also, there is a growing amount of evidence supporting the importance of 
Kidins220 in cancer development apart from its function in neuronal activity. The 
aberration of Kidins220 was involved in affecting cell proliferation, invasion, 
migration, and apoptosis, which play an important role in tumour formation and 
metastasis (Cai et al., 2017).  
In melanoma, Kidins220-knockdown reduced migratory and invasive abilities 
of melanoma cells in vitro and in vivo (Liao et al., 2011a). However, the present 
study detected a contrasting role played by Kidins220 in pancreatic cancer. The 
effect of Kidins220 on the adhesion of Panc-1 and Mia paca-2 cells showed a 
significant difference compared with scramble control. With regard to the impact 
of Kidins220 on the motility of pancreatic cancer cells, trans-well migration assay 
was performed and the result showed that Kidins220 negatively regulated the 
motility of both Panc-1 and Mia paca-2 cancer cells. In Panc-1 cells, knockdown of 
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Kidins220 significantly increased migratory ability compared with scramble control. 
Similarly, knockdown of Kidins220 also increased migration significantly in Mia 
paca-2 cancer cells. In line with the findings of the previous clinical study 
(Chapter3), knockdown of Kidins220 is associated with increased migration and 
invasiveness of pancreatic cancer cells. It suggests that Kidins220 is a negative 
regulator of these cellular functions in pancreatic cancer cells. 
We also used 3D culture to verify the effect of Kidins220 in regulating cell 
growth by tumour spheroid assay. It was shown that knockdown of Kidins220 
increased the solidity of tumour spheroid in Mia paca-2 cells significantly, and the 
increase of tumour spheroid was also seen in Panc-1 cells with Kidins220 
knockdown compared with scramble control. The 3D spheroid model has been 
shown as an appropriate in vitro model to evaluate tumorigenic and stemness of 
cancer cells (Nath and Devi, 2016). Indeed, the current finding in the 3D model 
together with the reduced expression of Kidins220 seen in the early cancerous 
lesions preceding pancreatic cancer, suggest loss or reduced expression of this 
gene is implicated in the development and also disease progression of pancreatic 
cancer. Further investigation will help to shed light on what molecules, such as 
stem cell markers and epithelial mesenchymal transition markers are affected.  
As involvement of Kidins220 in distant metastases of pancreatic cancer was 
observed in corresponding clinical tissue samples, a peritoneal metastatic model 
was employed to evaluate the corresponding impact using the Kidins220 
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knockdown Panc-1 cells. The loss of Kidins220 resulted in an increased tumour 
burden and increased average tumour volume of metastatic nodules developed 
by the Panc-1 cells in the peritoneal metastasis model but did not significantly 
impact the number of nodules formed which remained relatively stable. This result 
indicated that Kidins220 may not be involve in peritoneal seeding but plays a 
significant role in growth and invasion of the metastatic tumours following the 
initial colonisation. A further experiment using more mice per group will increase 
the statistical power to clarify this finding. Possible targets for corresponding 
treatment will also be investigated in the following experiments. 
In conclusion, the reduced expression of Kidins220 is associated with 
pancreatic cancer proliferation and hallmarks of disease progression. Knockdown 
of Kidins220 promoted in vitro growth, migration and invasion of pancreatic 
cancer cells, and peritoneal metastasis in vivo.  The current study suggests that 
Kidins220 may act as a tumour suppressor in the development and disease 
progression of pancreatic cancer thus contributing to the poor prognosis and 
shorter survival. Further investigation will aim to dissect the signalling pathway 
and molecules underlying these aberrant cellular functions as a result of loss of 
Kidins220 in pancreatic cancer cells. 
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Chapter 5  
Molecular machinery underlying 
the reduced Kidins220 expression 
in pancreatic cancer 
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5.1 Introduction 
The previous chapter has shown that the knockdown of Kidins220 increased 
proliferation, adhesion, invasion, and migration of pancreatic cancer cell lines. All 
these cellular functions are crucial for cancer progression. These findings are in 
line with the reduced expression of Kidins220 in pancreatic cancer tumour 
samples and its association with disease progression. This suggests that Kidins220 
is a putative tumour suppressor in pancreatic cancer which is opposite to its role 
evident in some other malignancies, such as melanoma and neuroblastoma (Jung 
et al., 2014, Liao et al., 2007, Liao et al., 2011a). Molecules and pathways involved 
in this different role played by Kidins220 in pancreatic cancer are likely to be organ 
specific but are yet to be investigated. 
In a parallel study carried out in the host lab, the implication of Kidins220 in 
gastric cancer has been examined. Our unpublished data showed that Kidins220 
was up-regulated in the gastric cancer compared with normal gastric tissues or 
adjacent normal gastric tissues. However, in vitro experiments showed similar 
effects on cellular functions of gastric cancer cell lines as seen in the current study 
of pancreatic cancer. A screening of proteins and protein phosphorylation affected 
by the Kidins220 knockdown in gastric cancer using a protein microarray (KinexTM 
antibody microarray, Kinexus, British Columbia, Canada) identified EGFR to be one 
of the most affected receptors in a gastric cancer cell line (HGC27). The microarray 
contains over 850 antibodies that recognise both total protein and phospho-
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proteins. An increased level of tyrosine phosphorylation was seen for EGFR 
including tyr1068, tyr1110, tyr1148, try1197, tyr998 following the knockdown of 
Kidins220 with ribozyme transgene compared with pEF control (Figure 5.1 A). 
Meanwhile, the protein level of total EGFR was also increased in the HGC27 
Kidins220 knockdown cells compared with the corresponding pEF empty plasmid 
vector control. Knockdown of Kidins220 enhanced cell invasion in gastric cancer 
cells, which is in accordance with its role observed in the pancreatic cancer cell 
lines. We hypothesised that EGFR signalling might be involved in Kidins220-
coordinated cellular functions thus contributing to the disease progression of 
pancreatic cancer. Corresponding alteration of downstream intracellular signalling 
pathways such as ERK and AKT pathways was also observed in the Kidins220 
knockdown cell line. This suggests that EGFR/ERK and AKT pathways are affected 
or involved in the reduced Kidins220 expression associated cellular events and are 
implicated in the disease progression. 
Epithelial-mesenchymal transition (EMT) occurs when tumour cells lose their 
epithelial features such as loss of polarity, down regulation of E-cadherin, and 
spread to distant sites (Thiery et al., 2009). When cells developed a mesenchymal 
phenotype with elevated expression of mesenchymal markers including N-
cadherin and vimentin, they would acquire the ability to disseminate (Acloque et 
al., 2009). In the past decades, several studies regarding patients with pancreatic 
cancers have provided evidence for the EMT involvement in the disease 
progression (Hotz et al., 2007, Rasheed et al., 2010). In human pancreatic tumour 
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samples, fibronectin and vimentin are increased in high-grade (poorly 
differentiated) tumours and at foci of poorly differentiated cancer cells in low-
grade tumours, with a corresponding decrease in E-cadherin expression. Patients 
with tumour exhibiting EMT have worse survival than those patients whose 
tumours demonstrate less evidence of EMT. In a study based on a rapid autopsy 
program for patients with pancreatic cancer, 75% of the primary tumours with 
mesenchymal features developed metastatic lesions to liver and lung (Rasheed et 
al., 2010). 
In the previous chapter, it has been shown that Kidins220 knockdown is 
associated with increased proliferation, adhesion, invasion, and migration in 
pancreatic cancer cell lines. The following experiments will focus on the EGFR 
signalling and EMT occurrence in the pancreatic cancer cell lines following the 
knockdown of Kidins220. 
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Figure 5.1: Expression and activation of EGFR in Kidins220 Knockdown gastric 
cancer cell line (HGC27). (A) Tyrosine phosphorylation status of EGFR in HGC27 
Kidins220 knockdown cells was determined using the KinexTM antibody microarray. 
Y1068: EGFR-pY1068 phosphosite-specific antibody Y1110: EGFR-pY1110 
phosphosite-specific antibody Y1148: EGFR-pY1148 phosphosite-specific 
antibody Y1197: EGFR-pY1197 phosphosite-specific antibody. Y998: EGFR-pY998 
phosphosite-specific antibody (B) Expression of total EGFR in the HGC27 
Kidins220 knockdown cells was also determined using the same array. Shown are 
changes as percentage against the HGC27 control cell line which were transfected 
using the empty plasmid vector. Pan-specific: EGFR-specific antibody.  
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5.2 Materials and methods 
5.2.1 Materials 
The primers used in this chapter are shown in Table 2.4, including EGFR, E-cadherin, 
vimentin, snail, slug, and twist. Details of antibodies for detection of EGFR, ERK, 
AKT, E-cadherin, vimentin, snail, slug, and phosphor-tyrosine are shown in Table 
2.5. Recombinant human EGF was purchased from Santa Cruz Biotechnology, UK 
(sc-4552). 
 
5.2.2 Protein array in Kidins220 knockdown gastric cancer cells.  
Protein samples were collected from HGC27 gastric cancer cells of PEF control and 
Kidins220 knockdown using anti-Kidins220 ribozyme transgene, respectively. After 
protein extraction and subsequent quantification, 300μl lysis (4mg/ml) was 
prepared and being stored at -20°C before sending for an analysis using the 
KinexusTM antibody microarray (Kinexus Bioinformatics, Vancouver, British 
Columbia, Canada). 
 
5.2.3 Determining the expression of EGFR-related signalling molecules and EMT 
markers using PCR and Western blot. 
Both RNA and protein were extracted from stable pancreatic cancer cell lines 
infected with lentiviral Kidins220 shRNA. The samples were used in either western 
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blot analysis or PCR to detect the expression level of these molecules involved in 
cell function. The methods were carried out as per the previous description in 
section 2.4 and 2.5. 
 
5.2.4 Immunoprecipitation and detection of EGFR with tyrosine phosphorylation 
Protein was extracted from Panc-1 and Mia paca-1 cells. Following 
immunoprecipition with anti-EGFR, immunoprecipitated protein samples were 
separated on an SDS-PAGE and blotted for detection of EGFR with tyrosine 
phosphorylation using an antibody (PY-99, Santa Cruz Biotechnology). The details 
of immunoprecipitation and western blot are provided in section 2.5.4 and 2.5.5. 
 
5.2.5 Statistical analysis 
Correlation between Kidins220 and other genes in pancreatic cancer tissue 
samples was assessed based on gene expression array dataset (GSE71729) and 
TCGA pancreatic cancer cohort using Spearman correlation test and the statistical 
analysis software (Sigma Plot version 11). GSE71729 is a validation cohort 
including 46 normal pancreatic sample, 145 primary pancreatic tumour samples, 
and 61 metastatic tumour sample. TCGA pancreatic cancer cohort containing 178 
primary pancreatic tumour samples. 
  
190 
5.3 Results 
5.3.1 Possible link between Kidins220 and EGFR in pancreatic cancer 
The possible correlation between Kidins220 and EGFR and other HER family 
members was evaluated in a gene expression array dataset (GSE71729) using the 
Spearman correlation test. A positive correlation was seen between Kidins220 
transcript and EGFR, whilst an inverse correlation was shown between Kidins220 
and HER3 (Table 5.1). To validate this discovery, a similar correlation analysis was 
performed in the TCGA pancreatic cancer cohort. The positive correlation 
between Kidins220 and EGFR was also observed in the TCGA pancreatic cancer 
cohort. A positive correlation was also seen between Kidins220 and HER4 in this 
TCGA cohort. More interestingly, an inverse correlation was seen between 
Kidins220 and HER2, but not HER3 (Table 5.2). The inconsistence in the correlation 
between Kidins220 and Her2 observed in the two cohort of pancreatic cancer gene 
array data might be due to the variation in the number of the Her2 positive tumour 
and also the expression of the Her2. The possible link between Kidins220 and Her2 
could be explored in the future study.  
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Table 5.1: Correlation between Kidins220 and HERs in pancreatic cancer 
(GSE71729). 
 EGFR HER2 HER3 HER4 
Kidins220 Cor=0.326 
p<0.001 
n=145 
Cor=-0.001 
P=0.989 
n=145 
Cor=-0.187 
p=0.024 
n=145 
Cor=-0.016 
p=0.849 
n=145 
Note: Cor = correlation coefficient. 
Table 5.2: Correlation between Kidins220 and HERs in pancreatic cancer 
(TCGA_PAAD). 
 
 EGFR HER2 HER3 HER4 
Kidins220 Cor=0.451 
p<0.001 
n=178 
Cor=-0.317 
p<0.001 
n=178 
Cor=-0.096 
p=0.203 
n=178 
Cor=0.317 
p<0.001 
n=178 
Note: Cor = correlation coefficient. 
 
5.3.2 Kidins220 knockdown and EGFR signalling 
Positive correlation between Kidins220 and EGFR was observed in both cohorts of 
pancreatic cancer though there were inconsistences for other HERS. However, the 
positive correlation was not seen in the gastric cancer cell line following 
knockdown of Kidins220. Instead, an increased total protein level and tyrosine 
phosphorylation were evident in the Kidins220 knockdown cells. The inconsistency 
in findings for the correlation between Kidins220 and EGFR at mRNA and protein 
levels led to the following investigations.  
The expression and tyrosine phosphorylation of EGFR were first determined 
using western blot. An increased protein level of EGFR was seen in both Panc-1 
and Mia paca-2 cancer cell lines following the knockdown of Kidins220. Meanwhile, 
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levels of phosphorylated EGFR were analysed using immunoprecipitation and 
western blotting. A marked increase of p-EGFR (Tyr) was seen in the Kidins220 
knockdown cells in comparison with the scramble control, suggesting that 
knockdown of Kidins220 affected EGFR signalling and also the total protein level 
of EGFR (Figure 5.2A). To detect whether knockdown of Kidins220 affects the 
expression of EGFR at mRNA level, we examined the expression of EGFR using RT-
PCR. The results showed that there was no difference seen at the mRNA level in 
the expression of EGFR in Kidins220 knockdown cells compared with 
corresponding scramble control, which indicated that Kidins220 did not affect 
EGFR expression at the transcript level (Figure 5.2B).  
 
 
 
 
 
 
 
 
  
193 
 
Figure 5.2: The expression and activation of EGFR in the Kidins220 knockdown 
pancreatic cancer cell lines. (A) The expression of total protein and tyrosine 
phosphorylation of EGFR were determined using immunoprecipitation and 
Western blot. p-EGFR: EGFR phosphorylation; p-try: tyrosine phosphorylation. (B) 
EGFR transcripts expressed by both Panc-1 and Mia paca-2 were determined using 
conventional RT-PCR. Images of the corresponding Western blots and RT-PCR are 
provided in Appendix 3.  
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5.3.3 MAPK and AKT pathway 
Deregulation of EGFR can induce an activation of pro-oncogenic signalling 
pathways such as the MAPK and AKT signalling pathways, consequently leading to 
various biological activities involved in development and progression of certain 
malignancies (Oliveira-Cunha et al., 2011). The knockdown of Kidins220 in the two 
pancreatic cancer cell lines resulted in a promotion of cell migration, invasion and 
proliferation, and consistently upregulation and activation of EGFR in those cells. 
This provoked an investigation of the intracellular signalling pathways 
downstream of the EGFR, i.e. ERK and AKT pathways. 
The western blots showed a similar total protein level of these proteins in 
both cell lines which appeared not be affected by the Kidins220 knockdown. 
Interestingly, but not surprisingly, corresponding activation of both ERK and AKT 
were seen in both Panc-1 and Mia paca-2 Kidins220 knockdown cell lines.  Levels 
of phosphorylated ERK and AKT were increased in the Kidins220 knockdown 
sublines of both cell lines compared with their respective scramble control, and 
there was no difference seen in the expression of total ERK and AKT protein levels 
in Kidins220 knockdown cells compared with corresponding scramble control 
(Figure 5.3). 
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Figure 5.3: Activation of ERK and AKT in Kidins220 knockdown cell lines was 
determined using western blot analysis. Expression of total protein and protein 
phosphorylation were determined using corresponding antibodies. Details of the 
antibodies are provided in the general method. The same experiments were 
performed three times and shown are representative results of the western blots. 
Phos-ERK: ERK phosphorylation; ERK: total ERK protein; Phos-AKT: AKT 
phosphorylation; AKT: total ERK protein. 
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5.3.4 Kidins220 and EMT 
5.3.4.1 EMT markers 
Epithelial-mesenchymal transition (EMT) occurs when tumour cells lose their 
epithelial features such as loss of polarity and spread to distant sites with down 
regulation of E-cadherin (Thiery et al., 2009). When cells develop a mesenchymal 
phenotype, they acquire the ability to metastasise expressing mesenchymal 
markers such as N-cadherin and vimentin (Acloque et al., 2009). To determine 
whether Kidins220 affects the EMT in pancreatic cancer cells, the expression of 
EMT markers E-cadherin and vimentin was detected using western bolt. In the 
Panc-1 cancer cells, knockdown of Kidins220 resulted in a decreased expression of 
E-cadherin, whilst vimentin was increased. However, E-cadherin did not express in 
Mia paca-2 cancer cells, and vimentin presented a reduced expression in the cells 
when Kidins220 was knocked down (Figure 5.4A). 
In terms of the mRNA levels of these genes, we examined the expression of E-
cadherin and vimentin using RT-PCR for both cell lines. As shown in Figure 5.5B, 
down-regulation of E-cadherin and up-regulation of vimentin were seen in the 
Panc-1 cells with Kidins220 knockdown compared scramble control. E-cadherin 
was undetectable in Mia paca-2 cell lines and reduced expression of vimentin was 
observed in the Kidins220 knockdown cells compared the scramble control (Figure 
5.4B). 
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5.3.4.2 EMT regulatory transcription factors; snail, slug and twist 
The expression and activity of transcription factors (TFs) such as snail, slug, zeb, 
and twist mediate transcriptional regulation of the aforementioned EMT markers. 
To determine the involvement of these transcription factors in the Kidins220 
knockdown induced EMT, RT-PCR and western blot were employed to examine 
their expression in the Kidins220 knockdown cell lines.  
The results from RT-PCR indicated that there was an increased expression of 
snail and twist in panc-1 cancer cells with knockdown of Kidins220 in comparison 
with scramble control, and the expression of slug was undetectable in panc-1 
cancer cells. Furthermore, knockdown of Kidins220 enhanced expression of snail 
and slug in Mia paca-2 cancer cells when compared with the scramble control, 
however, the expression of twist was not showed at the transcript level (Figure 
5.5A).  
Expression of these proteins was subsequently determined using western 
bloting. An elevated expression of snail and slug was seen in Panc-1 Kidins220 
knockdown cells. Increased expression of snail was also observed in Mia paca-2 
Kidins220 knockdown cells while the slug was undetectable (Figure 5.5B). 
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Figure 5.4: Expression of EMT markers in the Kidins220 knockdown cell lines. (A) 
Protein expression of these EMT markers was determined using western blot. (B) 
Corresponding impact of the EMT markers at mRNA level was examined using RT-
PCR. 
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Figure 5.5: EMT related transcriptional factors was determined in the Kidins220 
knockdown pancreatic cancer cell lines using RT-PCR and western blot, 
respectively. (A) The mRNA expression was examined using RT-PCR. (B) The 
impact of Kidins220 Knockdown on the protein expression of these transcriptional 
factors was then evaluated using Western blot.  
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5.3.4.3 Kidins220 and EGF/EGFR induced EMT 
Following experiments aimed to dissect the role of Kidins220 in EGFR and its 
downstream signalling, and also the corresponding changes in EMT markers. EGF, 
a ligand of EGFR, was employed to treat the Panc-1 cancer cells. The increased 
expression and activation of EGFR protein in Kidins220 knockdown cells were 
enhanced upon treatment with recombinant human EGF in comparison with the 
control group. Moreover, both scramble control and Kidins220 knockdown cells 
showed increased expression of phosphorylated-ERK and total ERK in exposure to 
EGF. Panc-1 cells with knockdown of Kidins220 showed reduced expression of E-
cadherin and increased vimentin expression when they were treated with EGF but 
to a further level. In terms of the EMT transcriptional factors, the expression of 
snail was increased in the scramble control cells when treated with EGF, whilst the 
Kidins220 knockdown cells did not present a greater difference under the 
treatment of EGF (Figure 5.6).  
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Figure 5.6: The correlation of Kidins220 and EGF-induced EGFR, ERK, and EMT 
activation in Panc-1 cancer cell lines. Panc-1 scramble and Kidins220 knockdown 
cells were Serum-starved for 1 h before stimulation with vehicle control (-) and 
rhEGF (200ng/ml) for 5 min. Protein extracts were analysed using western blot 
analysis with corresponding antibodies. Actin was included as a loading control. P-
EGFR: EGFR phosphorylation. 
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5.4 Discussion 
During cancer metastasis, malignant cells acquire the ability to invade surrounding 
tissue and spread to a distant site. These malignant traits are orchestrated by 
several aberrant cellular signalling pathways (Tracey A. Martin, 2013). An 
important finding from our parallel study of Kidins220 in gastric cancer showed 
that Kidins220 knockdown increased the protein level of EGFR and also its 
phosphorylation in gastric cancer cells. Overexpression of EGFR and alterations in 
its downstream signalling pathways such as MAPK and AKT signalling, are 
associated with more aggressive behaviours of various human malignancies and 
poor prognosis (Mendelsohn and Baselga, 2003). The present study was aimed to 
investigate the role of EGFR and its downstream signalling in the pancreatic cancer 
cell lines with Kidins220 knockdown. In an initial analysis of mRNA expression in 
two cohort of pancreatic cancer (GSE71729 and TCGA_PAAD), a positive 
correlation between Kidins220 transcripts and EGFR transcripts is observed in both 
cohorts. This suggested that a possible crosstalk may occur between Kidins220 and 
EGFR which could contribute to disease progression in pancreatic cancer. The 
experiments in this current study showed an increase of both protein expression 
of EGFR and phosphorylated EGFR in the Kidins220 knockdown pancreatic cancer 
cell lines. No change was seen in the mRNA expression of EGFR in the Kidins220 
knockdown cell lines compared to their corresponding scramble control. It 
suggests that Kidins220 is not involved in the transcriptional regulation of EGFR 
though there is a positive correlation between the transcript levels of these two 
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genes in the pancreatic cancers. In the Kidins220 knockdown cell lines an 
upregulation of EGFR was evident for both total protein expression and activation, 
indicating that reduced expression of Kidins220 in pancreatic cancer may 
strengthen EGFR signalling and the corresponding implication in the disease 
progression which is yet to be investigated. For instance, correlation between 
Kidins220 expression and protein expression/activation of EGFR in human 
pancreatic cancer should be further examined using immunochemical or other 
protein analysis techniques. Molecular machinery underlying the Kidins220 
regulated protein expression/activation of EGFR is also yet to be explored, for 
example, the involvement of protein degradation. 
Several studies have demonstrated the role of Kidins220 correlated with 
MAPK signalling in malignancies (Rogers and Schor, 2013b, Liao et al., 2007). 
Downregulation of Kidins220 resulted in the attenuation of NGF- induced, but not 
BDNF- induced MAPK signalling in neuroblastoma cells (Rogers and Schor, 2013b). 
In melanoma cells, Kidins220 -mediated cells migration and invasion is related to 
kinase (ERK) kinase (MEK)/ERK signalling (Liao et al., 2011a). Kidins220 was also 
involved in the angiogenesis of castration resistant prostate cancer, which is 
regulated by miR-4638-5p through the activity of VEGF and PI3K/AKT pathway 
(Wang et al., 2016). In the present study, the reduction of Kidins220 expression in 
Panc-1 and Mia paca-2 cells showed a promotion in ERK and AKT signalling 
pathway. The tyrosine phosphorylation of ERK and AKT were increased in 
Kidins220 knockdown cells in comparison with the scramble control. Both ERK and 
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AKT pathways are essential signalling pathways that mediate intracellular signal 
transduction for EGFR (Oliveira-Cunha et al., 2011). However, whether the 
enhanced activation of both ERK and AKT is dependent on the Kidins220 regulated 
EGFR expression and activation is yet to be elucidated. 
Furthermore, our study also found that knockdown of Kidins220 was 
accompanied with a change of EMT in Panc-1 cancer cell lines. To date, the 
correlation between Kidins220 and EMT in cancers remains largely unknown. Loss 
of E-cadherin and increase of vimentin are considered as important markers of 
EMT (Prieto-Garcia et al., 2017). E-cadherin restrains the mobility of tumour cell 
during tumour dissemination, as it has a role in maintaining cell-cell interaction 
and cytoskeleton stabilisation. Therefore, the breakdown of adherens junctions 
caused by the down-regulation of E-cadherin expression, lead to loss of cell 
polarity and acquisition of a mesenchymal phenotype with migratory abilities 
(Wijnhoven et al., 2000, Ghahhari and Babashah, 2015). In panc-1 cancer cells, 
knockdown of Kidins220 decreased the expression of E-cadherin as well as 
increased vimentin expression. The altered expression pattern of E-cadherin and 
vimentin was further enhanced by EGF. When cells were treated with EGF, the 
expression of E-cadherin was reduced in comparison with the untreated group, 
whereas vimentin caused an increased expression. EMT-inducing transcription 
factors (EMT-TFs) not only play a role in the regulation of cell progression, invasion, 
and migration, but are also involved in protecting cells from senescence and 
apoptosis. Their role in resistance to chemotherapy and radiotherapy has been 
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identified (Nieto, 2011, Ansieau et al., 2008, Mejlvang et al., 2007). As TFs, snail, 
slug, are involved in promoting EMT (De Craene and Berx, 2013). Snail, slug and 
zeb are reported as direct repressors of E-cadherin since they bind to conserved 
E-box sequences in the promoter of E-cadherin and repress its transcription 
(Prieto-Garcia et al., 2017). Furthermore, loss of E-cadherin can also trigger certain 
epithelial cells switching to a mesenchymal state (Onder et al., 2008). In panc-1 
cancer cells, knockdown of Kidins220 enhanced the expression of snail and slug. 
These findings indicate that Kidins220 might play a significant role in EGF/EGFR-
induced EMT in pancreatic cancer cells. Further investigation will shed light on the 
involvement of EGFR, ERK and AKT signalling in the reduced expression of 
Kidins220 related EMT. 
Taken together, the current study showed an increased protein expression 
and phosphorylation of EGFR in panc-1 Kidins220 knockdown cells which may 
contribute to the promotion of cell proliferation and migration, although this 
needs to be further investigated. Among downstream pathways of the receptor 
tyrosine kinase, ERK1/2 signalling pathway also exhibited increased activation. In 
addition to these, involvement of EMT markers may also contribute to the 
metastasis of pancreatic cancer in line with Kidins220. The employment of EGFR 
and ERK inhibitors will help to clarify the involvement of these signalling in 
downregulation of Kidins220 related cellular events and corresponding 
implication in disease progression of pancreatic cancer.  
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General Discussion 
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Increased evidence suggests that scaffold proteins are crucial regulators of many 
key signalling pathways and also engaged in maintaining the cell structure through 
the regulation of the cytoskeleton, adhesion and migration of the cells (Bompard 
et al., 2005, Lin et al., 2005, Yamagishi et al., 2004, Mattila et al., 2003). Kidins220 
is a scaffold protein and was first identified as a substrate of protein Kinase D 
(Iglesias et al., 2000). Several studies have indicated its role in mediating neuronal 
activities such as neuronal differentiation, survival, and cytoskeleton remodelling 
by interacting with a variety of binding partners (Scholz-Starke and Cesca, 2016). 
Elevated expression of Kidins220 has been observed in melanoma and 
neuroblastoma which is associated with disease progression (Jung et al., 2014, 
Liao et al., 2007, Liao et al., 2011a). In contrast to the increased expression of 
Kidins220 in melanoma and neuroblastoma, our initial analyses of Kidins220’s in 
pancreatic cancer showed a reduced in pancreatic carcinomas. We hypothesised 
that aberrant expression of Kidins220 is involved in the development and disease 
progression of pancreatic cancer being different from its role in the melanoma and 
neuroblastoma. In the current study, we evaluated the role played by Kidins220 in 
human pancreatic cancer by analysing its expression of both mRNA and protein in 
different pancreatic cancer cohorts. Following the analyses of clinical relevance, 
we determined the influence of Kidins220 on cellular functions of pancreatic 
cancer cell lines. Finally, molecular machinery was dissected according to the 
regulation of cellular functions. 
  
208 
6.1 Reduced expression in pancreatic cancer is associated with tumorigenesis 
and disease progression. 
A significantly reduced expression of Kidins220 transcripts was revealed in 
pancreatic cancers compared with adjacent normal pancreatic tissues. This is 
supported by the findings from IHC staining of Kidins220 conducted on a 
pancreatic tumour tissue microarray which presented a reduced expression of 
kidins220 in pancreatic cancers compared with adjacent normal pancreatic tissues 
and normal pancreas. The analysis of Kidins220 transcript levels in the cohort of 
pancreatic cancer tissue samples showed more advanced pancreatic tumours 
(TNM3 and TNM4) had lower expression of Kidins220 compared with those of 
early stages (TNM1 and TNM2). Kidins220 expression was also reduced in primary 
tumours which developed metastases and also distant metastatic tumours of 
pancreatic cancer. The reduced expression of Kidins220 is also associated with 
poorer survival of patients with pancreatic cancer. Our following experiments 
showed that knockdown of Kidins220 in pancreatic cell lines resulted in an 
increase of cell proliferation, migration and invasion. Furthermore, Knockdown of 
Kidins220 also promoted peritoneal metastasis of pancreatic cancer cells in a 
murine peritoneal metastatic model. More interestingly, the Knockdown of 
Kidins220 resulted in bigger metastatic tumours in the peritoneal metastatic 
model leading to a remarkedly increased tumour burden but with little effect on 
number of nodules formed. The effect of Kidins220 Knockdown on proliferation, 
migration and invasion may contribute to the increased tumour size and tumour 
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burden in the peritoneal metastatic model, while its influence on attachment of 
suspending pancreatic cancer cells to the peritoneum was little though it 
promotes adhesion of pancreatic cancer cells to extracellular matrix. Hyaluronic 
acid (HA) forms a fluid film which coats on top of mesothelial cells of peritoneum. 
The specific binding partner to HA such as CD44 and RAHMM may play more in 
mediating the adhesion and initial seeding of pancreatic cancer during the 
peritoneal metastasis(Wang et al., 1998, Zhang et al., 1998, Maxwell et al., 2008). 
The exact cellular and molecular mechanism underlying the enhanced peritoneal 
metastases following the loss of Kidins220 are yet to elucidated. Collectively, our 
findings suggest that Kidins220 is an inhibitory factor in the disease progression of 
pancreatic cancer through a regulation of proliferation, migration and invasion of 
pancreatic cancer cells. 
 In contrast to the down-regulation of Kidins220 discovered in pancreatic 
cancer, an upregulation of Kidins220 was observed in melanoma cancer cells lines 
and human melanoma tissues. In melanoma, stronger immunointensity of 
Kidins220 was observed mostly in melanomas with Breslow tumour 
thickness >1.0mm, or with nodal metastasis, and was correlated with a worse 
overall survival in melanoma patients (Liao et al., 2011a). Findings of the present 
study have demonstrated that Kidins220 may act as tumour suppressor in 
pancreatic cancer in comparison with melanoma and neuroblastoma. Our study 
showed that the reduced Kidins220 promoted proliferation, migration and 
invasion of pancreatic cancer cells through an up-regulation of EGFR. This suggests 
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that Kidins220 plays different roles in different malignancies which can be tissue 
specific or cancer specific depending on signal pathway involved.  
The present study has also indicated that Kidins220 might be involved in the 
tumorigenesis of pancreatic cancer. Our study was based on the analysis of a gene 
expression array data (GSE71729). The reduction of Kidins220 expression in 
invasive cancer originating in IPMN appeared to be significant compared with 
normal pancreas. Furthermore, according to the IHC staining, there was a 
significant decrease of Kidins220 expression in malignant tumour compared with 
normal pancreas, inflammation pancreas, and benign tumour. In line with the 
findings from the human pancreatic cancers, an enhanced tumorigenic capacity 
was also observed in the pancreatic cancer cells following the knockdown of 
Kidins220 in an in vitro 3D tumour spheroid experimental model. This suggests 
that the downregulation of Kidins220 may occur early during the tumorigenesis of 
pancreatic cancer. Certain molecular and biological changes have been observed 
in IPMN of pancreas, such as the activation of oncogenic pathways including K-ras 
and AKT, and downregulation of tumor suppressors such as p16, p53, and SMAD4 
(Hayashi et al., 2010). However, the exact molecular and cellular events associated 
with the reduced expression of Kidins220 in pancreatic cancer are yet to be 
explored. Furthermore, the reduced expression of Kidins220 in pancreatic cancer 
was associated with shorter overall survival, which implicated Kidins220 as a 
potential biomarker for the evaluation of prognosis of pancreatic cancer.   
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6.2 Knockdown of Kidins220 promoted proliferation, migration and invasion of 
pancreatic cancer cells 
To understand how the reduced expression of Kidins220 in pancreatic cancer is 
associated with tumorigenesis, disease progression and poor prognosis, the 
impact on cellular function of pancreatic cancer cells was examined in the current 
study. To date, 14 splicing variants have identified which encode 11 Kidins220 
protein isoforms. The coding sequence for Kidins220 isoform 1 is approximately 
5300bps. It is difficult to amplify the coding sequence due to mixture of different 
variants in the available cDNA libraries. Cost of synthesising such long sequence is 
unaffordable to the current study. Due to these technical difficulties and the 
limitations on time required to generate a Kidins220 overexpression cell model, 
the Kidins220 knockdown cell model was established using lentivirus shRNA. 
Knockdown of Kidins220 in Panc-1 and Mia paca-2 resulted in an increased 
proliferation of these two cancer cell lines. In neuroblastoma, knockdown of 
Kidins220 reduced cell proliferation because of the arrest of cell cycle at G1 phase 
(Jung et al., 2014). The different signalling pathways regulated by Kidins220 might 
be involved in the proliferation of pancreatic cancer cells.  
Adhesion of cells to the ECM is key to the regulation of cellular morphology, 
migration, proliferation, survival, and differentiation (Nagano et al., 2012). 
Following the knockdown, an increase was seen in cell-matrix adhesion of the two 
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pancreatic cancer cell lines, which adhesion molecules are involved is yet to be 
determined.   
Apart from the impact of Kidins220 on cell growth and adhesion, we also 
examined the influence of Kidins220 on cell invasion and migration, the two 
essential cellular functions for cancer metastasis. The results showed that 
knockdown of Kidins220 increased invasion and migration in pancreatic cancer 
cells. This is different from the findings in melanoma, in which kidins220 
knockdown decreased migratory and invasive abilities of melanoma cells (Liao et 
al., 2011a). Migration and invasion of melanoma cell regulated by Kidins220 was 
through the activation of MEK/ERK signalling pathway, but its upstream regulator 
is still unknown. Our investigations in pancreatic cancer showed that knockdown 
of Kidins220 increased phosphorylation of ERK and AKT, potentially through the 
EGFR signalling pathway. FAM120A knockdown abolished liver colonization in a 
mouse model, which presented its role in liver metastasis of colorectal cancer 
(Bartolome et al., 2015). In the current study, knockdown of Kidins220 resulted in 
an increased number of nodules in an in vivo mouse model but this lacked 
statistical significance. However, there was a significant increase in tumour burden, 
total tumour volume and average tumour volume of the mice injected with 
Kidins220 knockdown Panc-1 cells compared with scramble control group. These 
results provide evidence that Kidins220 might be involved in peritoneal metastasis 
of pancreatic cancer for metastatic cells invasion and proliferation.   
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6.3 Loss of Kidins220 is accompanied with an enhanced EMT in pancreatic cancer 
EMT is a highly conserved process that allows cells to lose epithelial features, such 
as loss of polarity, and down regulation of E-cadherin. During this process, the cells 
also gain mesenchymal phenotype, acquiring the capability of motility and 
invasion, and start expressing mesenchymal markers such as N-cadherin and 
vimentin (Yeung and Yang, 2017, Thiery et al., 2009). EMT enables cancer cells  to 
disseminate from a primary tumour to a distant site and finally develop a 
secondary tumour (Thiery, 2002). 
In human pancreatic tumour samples, a decreased expression of E-cadherin 
along with an increased expression of vimentin were detected in high-grade 
tumours and also poorly differentiated areas of low-grade tumours. Interestingly, 
the patients with better survival presented less evidence of EMT (Dangi-Garimella 
et al., 2012). An autopsy program performed on pancreatic cancer patients 
showed that 75% of the primary tumours with metastases to liver and lung 
presented mesenchymal features (Rasheed et al., 2010). In pancreatic cancer cells, 
snail, a key regulator of EMT, exhibited a higher level of expression together with 
a reduced expression of E-cadherin in poorly differentiated cell lines compared 
with their expression in moderately differentiated cell lines (Hotz et al., 2007). 
Our current study indicated that knockdown of Kidins220 decreased the 
expression of E-cadherin and increased vimentin expression in Panc-1 cells. 
Knockdown of Kidins220 also increased the protein expression of snail and slug in 
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panc-1 cells. Further study will shed light on the Kidins220 coordinated EMT in 
pancreatic cancer using clinical sample, for example, the correlation between 
Kidins220 expression and EMT markers in pancreatic cancer particularly in EGFR 
positive pancreatic tumours. 
 
6.4 Reduced Kidins220 is associated with an enhanced EGFR signalling through 
an upregulation of its protein expression  
Overexpression of EGFR has been indicated in several studies in pancreatic cancer 
and may be related to disease progression and poor survival of pancreatic cancer 
patients (Oliveira-Cunha et al., 2011). The two major intracellular pathways 
activated by EGFR are the PI3K/AKT and MAPK/ERK pathways, which have been 
implicated in the development of pancreatic cancer and are also being evaluated 
as target therapies (Roy et al., 2010, Williams et al., 2012).   
Knockdown of Kidins220 increased the phosphorylation of EGFR and total 
EGFR in pancreatic cancer cell lines, without a notable change of Kidins220 
transcripts. Corresponding changes of ERK and AKT were also seen in the Kidins220 
knockdown cell lines, by which knockdown of Kidins220 increased 
phosphorylation of ERK and AKT. After treatment with EGF, the Kidins220 
knockdown cells showed enhanced activation of EGFR and ERK in comparison with 
the control group. The altered expression pattern of E-cadherin and vimentin was 
also further enhanced by the EGF treatment. The expression of E-cadherin was 
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reduced, whilst vimentin was increased in the EGF treated cells. However, no 
obvious change was found for snail expression. Involvement of EGFR/ERK and/or 
AKT in the Kidins220 knockdown resulted in promotion of EMT. Invasion is yet to 
be elucidated, for example using a small inhibitor, such as Gefitinib. On the other 
hand, other HER family members, such as HER2, HER3 and HER4 will be 
investigated for their link with EGFR signalling and involvement in malignancies 
(Seshacharyulu et al., 2012). Reduced expression of Kidins220 in EGFR 
overexpressing pancreatic cancer may act as a biomarker for the corresponding 
target therapy which is yet to be evaluated in human pancreatic tissue samples. 
 
6.5 Conclusion and perspectives 
In this present study, a reduced expression of Kidins220 was observed in 
pancreatic cancer which is associated with disease progression, distant metastases 
and poor prognosis. In vitro cellular function tests have shown that Kidins220 
knockdown promotes proliferation, migration and invasion of pancreatic cancer 
cells. The Kidins220 knockdown Panc-1 cells also exhibited an enhanced 
metastatic capability in an in vivo peritoneal metastatic mouse model. This 
suggests that Kidins220 is a putative tumour suppressor in pancreatic cancer. 
Enhanced EMT was also observed in the pancreatic cancer cell lines following the 
knockdown of Kidins220. Further examination showed that the Kidins220 
knockdown resulted in an elevated expression and activation of EGFR and 
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consequent activations of its downstream signalling pathways including ERK and 
AKT pathways. As a transmembrane scaffold protein, Kidins220 plays an important 
role in the regulation of cell signalling by recruiting external and internal stimuli to 
various cellular outputs. Kidins220 exhibited a regulation of EGFR and EGFR 
signalling in pancreatic cancer cells. These results provoke further investigation for 
the remaining question and gaps in knowledge. For instance, it would be 
interesting to discover the molecular mechanism utilised by the Kidins220 to 
regulate the protein level of EGFR, in which protein degradation cascades may be 
affected. Molecules that related to protein degradation might be examined using 
western blot. In term of the impact on cellular function, the involvement of EGFR 
and its downstream signalling should be further examined in the Kindins220 
knockdown cell lines using specific inhibitor or a Kidins220 overexpression model 
for a validation. More importantly, the exact implication of the reduced expression 
of Kidins220 in EGFR positive pancreatic cancer should be elucidated with 
investigation of other HER family members also be included. As for its clinical 
relevance, the role of Kidins220 in the evaluation of prognosis of pancreatic cancer 
patients needs to be future investigated using a larger clinical cohort.  
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Appendix 1: Peking University Cancer Hospital Patients in Consent Information 
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Appendix 2: H&E staining of PA2081a, Biomax. 
 
This image was downloaded from 
https://www.biomax.us/index.php?route=product/zoomify&park=29872. High 
resolution image is available from this website.  
 
 
 
 
 
 
 
 
 
  
244 
Appendix 3: Original images used in RT-PCR and western blot. 
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Original images of gel (RT-PCR) and blot (western blot) of Figure 4.1. The highlighted bands in the boxes are the cropped bands presented 
in Figure4.1 
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Original images of gel (RT-PCR) and blot (western blot) of Figure 5.2. The highlighted bands in the boxes are the cropped bands presented 
in Figure5.2. 
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Original images of blot of Figure 5.3 The highlighted bands in the boxes are the cropped bands presented in Figure5.3 
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Original images of blot of Figure 5.4. The highlighted bands in the boxes are the cropped bands presented in Figure5.4. 
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Original images of blot of Figure 5.5. The highlighted bands in the boxes are the cropped bands presented in Figure5.5. 
250 
 
Original images of blot of Figure 5.6. The highlighted bands in the boxes are the cropped bands presented in Figure5.6. 
 
